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ABSTRACT
Alterations in the expression of vital proteins of the cellular signalling pathways are at the forefront of 
molecular abnormalities established in cancer. Therefore, to understand the fundamental mechanisms of 
cancer initiation and progression, characterisation of tumour markers, such as key proteins like MUC1/Y 
that are highly expressed in malignant cells, is crucially important.
Rapid drug discovery is a pressing need in the pharmaceutical industry. Agents that are able to bind 
tightly and selectively to the surface of diseased cells would greatly benefit both disease diagnosis and 
treatment. An aptamer is a functional oligonucleotide that has the appropriate sequence and structure to 
form a complex, possessing great affinity and selectivity for its target.
Aptamers of high affinity and specificity have been successfully generated against the MUC1/Y splice 
variant from a non-conventional single round SELEX system termed SimpLex. The 72 base long 
aptamers were truncated to an ideal therapeutic length of 25 bases long via two different means. The first 
entails eliminating the primers and leaving only the central variable region and the second involves 
truncation of the aptamers based on their predicted secondary structure. Thus, three aptamer versions 
were taken for further investigation, the complete and two truncated ones.
However, as is it often the case, aptamers lack in vivo stability and are prone to rapid renal filtration and 
therefore require modification to achieve their full potential in vivo as therapeutic agents. Thus, the 
MUC1/Y selected aptamers were conjugated with a 32 kDa polyethylene glycol (PEG) polymer to 
increase their molecular weight to ca. 40 kDa, an appropriate size to avoid rapid renal clearance.
The truncated aptamers, the pegylated aptamers and the full length aptamers were characterised 
employing qualitative techniques which include EMSA, affinity column chromatography and DNA 
thermal denaturation studies. The aptamers were further assessed for their binding, specificity and 
internalisation by FACs and fluorescence microscopy. The characterisation studies have shown that the 
anti-MUCl/Y aptamers possess affinity and specificity for the MUC1/Y protein and the conjugation of 
the aptamers to PEG has further enhanced their binding and internalisation potential. These encouraging 
results display potential future prospects as therapeutic agents for the pegylated aptamers and warrants 
their further future evaluation in in vivo studies.
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INTRODUCTION
1.0 INTRODUCTION
Over the course of many decades, malignancy of different organs has become increasingly prevalent. In 
many cases, this fatal disease eludes detection, leaving the diagnosed insufficient or no time at all to 
respond effectively to the therapy administered. It is estimated that 12 million individuals are being 
diagnosed with this devastating disease, causing mortality in 7.6 million cases every year, equating to 
approximately one in eight deaths worldwide only from cancer. There are 26 types of cancers of which, 
cancers of the lung, breast, bowel, stomach, and prostate approximately account for half of all the cancers 
diagnosed globally. The most common causes of cancer death are cancers of the lung, stomach and liver, 
whereas breast cancer remains the most prevalent cancer worldwide 1,2.
With cancer on the increase and continuing to be a global public health dilemma, there is a pressing need 
for the development of novel anticancer therapeutics and effective diagnostic agents. This being the main 
focus, scientists are evermore researching, following a path of exploration of different methodologies to 
result in the discovery of innovative and advanced anticancer agents. In order to achieve the design of 
effective anticancer agents, it is essential to understand the fundamental mechanisms of cancer initiation, 
progression and characterisation of tumour markers. There are many proteins, growth factors, hormones, 
antibodies and small molecules which are involved either at the cancer development stage of these 
processes or during the progression of the malignancy. However, involvement of any of these molecules 
indicates their potential as tumour biomarkers, such as molecules involved in cell proliferation, initiation 
of excessive cellular division, and those responsible for cell signalling. Molecules involved in cell 
signalling are vital as, through mutations, the normal function is bypassed, allowing cell proliferation to 
occur indefinitely and inhibit apoptosis, which in turn can result in greater expression of particular 
proteins. Hence, over-expression of proteins in malignant tissues, as opposed to the expression of the 
proteins found in normal tissues of the same organ, are crucially important and of great interest as 
potential molecular tumour targeting biomarkers. Following this rationale, a novel target protein, 
MUC1/Y, a splice variant of the MUC1 glycoprotein, was selected as a potential therapeutic target and as 
a tumour biomarker for diagnosis in many tumour models.
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The therapeutic applications currently available in the market for the treatment of cancer include 
radiotherapy, chemotherapy and immunotherapy, which employ small chemical molecules, antibodies, 
peptides, or oligonucleotides. The continuing research into novel anticancer reagents has led to the 
discovery of a class of nucleic acid-based agents referred to as aptamers. Aptamers are compounds with 
great potential to bind selectively and with high affinity to their targets, thus possessing the remarkable 
ability to distinguish between normal and malignant tissues effectively. This, in turn, provides a 
measureable method for determination of target expression levels within the malignant form. Aptamers 
are considered to be a rival to antibodies in numerous ways, especially as they pose limited drawbacks 
with respect to their applications in in vivo and in vitro studies. Most importantly, the relevance of their 
use in therapeutics is their ability to reduce or inhibit cell proliferation of cancerous cells or initiate 
apoptosis via mechanisms of affecting the cellular signalling pathways 3. Although the MUC 1 AT protein 
has yet not been as widely researched as the native form, MUC1, this isoform has been studied more than 
many of the other splice variants of MUC1. Hence, the aptamers selected specifically against the 
MUC1/Y protein can also be used as tools in understanding in greater detail the nature and 
characteristics of the protein, alongside their use in therapeutic or diagnostic applications.
The major drawback of all aptamers for in vivo applications is their degradation by nucleases present in 
serum and cells, in addition to their rapid elimination from the body. Nevertheless, numerous approaches 
are available to improve the efficacy of aptamers, which include chemical modifications on the 
backbone, the sugar or the base moieties of the nucleotide, to prevent nuclease degradation. 
Modifications which include conjugation of aptamers with high molecular weight polymers, attachment 
to the phospholipid lamellae and linkage of a multiple number of aptamers of the same sequence to each 
other, or a combination of these techniques, have a dual functionality of inhibiting nuclease degradation 
and significantly reducing the swift elimination of aptamers from the body, thus improving their 
pharmacological properties.
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l .l .Q  MUCINS
The cells of epithelial organs within the body, such as mammary and salivary glands, respiratory, 
gastrointestinal, reproductive tracts, kidney and bladder 4, have their luminal surfaces protected by a 
significantly viscous and slimy secretion, referred to as mucus. Mucus comprises a mixture of 
components which include water, salts, secreted proteins, mucins and immunoglobulins. Goblet or mucus 
cells are epithelial cells present on the surface of organs responsible for the secretion of mucus, which 
serves the purpose of providing a protective layer between the cellular surface and the extracellular 
environment. Although the mucus mainly operates as a physical selective barrier, the second function is 
to maintain the cells in their hydrated form via lubrication. From the mixture of components present in 
the mucus, the main constituents are mucins, which are vastly glycosylated proteins5.
Mucins are viscous, high molecular weight glycoproteins, appearing in structure to be similar to an 
elongated rod which can vary significantly in size, resulting in a sequence length from several hundred to 
a few thousand residues. However, frequently found in most mucins, are regions that are mainly 
generated from tandem repeat sequences which differ from mucin to mucin with respect to the number, 
length and amino acid sequence. Nonetheless, despite the differences in size, the majority of the mucin 
polypeptide chains contain a high ratio of amino acids threonine and serine, whereby the hydroxyl groups 
of these residues are altered via O-glycosidic bonding with oligosaccharides 6,7. The amino acid residues 
can also be linked to oligosaccharides via N-glycosylation, and with the entire carbohydrate composition 
present on a mucin, this can constitute for up to 90 % of its total molecular weight. From the studies 
performed on mucins it can be derived that these highly structured glycoproteins have been precisely 
situated on the cells’ surface in order to perform many functions simultaneously. These include guarding 
the cells from micro-organisms which possess the ability to cause infections via their ability to keep the 
organisms at a mere distance and capturing them via the carbohydrates’ elaborate binding mechanisms. 
Furthermore, under the umbrella of protective mechanisms, mucins prevent cellular dehydration, shield 
the cells against physical or chemical injury, whilst allowing particular substances to enter the cell and 
aiding the passage of various matter along the tracts mentioned earlier7’8.
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There are two categories which mucins are divided into, the secretory and the membrane bound forms. A 
well founded characteristic of the secreted mucins is their ability to form considerably bulky oligomers 
resulting from the linking of protein monomers via disulphide bonds. The secreted mucins lack the 
transmembrane region within the protein and are secreted from the cells into the extracellular space, 
where they remain at the apical surface of the epithelial cells forming the viscous mucus. Thus, these 
proteins serve as the first line of defence (Figure 1.0). However, they have not appeared to be associated 
to any form of tumour initiation or progression9. In contrast to the secreted mucins, the membrane bound 
mucins possess a hydrophobic transmembrane region and a cytoplasmic domain which varies in length. 
In addition, the membrane bound proteins also maintain their protective function, by extending from the 
apical surface through their extracellular domain and are incorporated in the formation of the mucus gel. 
Thus, they operate as the second line of defence and operate as sensors, detecting any external 
disturbances in the environment. Any alterations in the external environment, such as pH and ionic 
composition or interaction of any foreign substances binding to the extracellular domain can lead to 
conformational changes, promoting a signalling cascade within the cell10.
From the family of mucins, the glycoproteins identified under the two categories include eight secreted 
mucins (MUC2, MUC5AC, MUC5B, MUC6, MUC7, MUC8, MUC9 and MUC 19) 11 and ten membrane 
bound mucins (MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, and 
MUC20)10.
1.2.Q MBC1
Of the many membrane bound proteins, the protein commonly referred to as MUC1 is the first mucin 
from the many to be cloned and have its full cDNA and genomic clones identified for both human and 
mouse. Hence, the in depth study of this protein has unveiled its numerous properties and functions, 
which are crucial for many precise biological roles. The entire cDNA sequence of the human MUC1 
gene encodes the full protein consisting of three distinctive domains, the extracellular domain, 
transmembrane and cytoplasmic domains6.
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■o
■o Transmembrane 
domain
MUC1 and other mucins within gel
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Actin
cytoskeleton
Extracellular
domain
Proteolytic 
cleavage site
Figure 1.0. Illustration of a mucosal cell surface and membrane protected by mucins. (A)
First line of defence: the mucus gel, consisting of secreted or shed mucins. (B) Second line of defence: 
MUC1 is present on the apical surface of cells as a heterodimer that can be released by shedding or 
proteolysis at the proteolytic cleavage site shown. The release can potentially initiate signalling within 
the cell due to changes in the extracellular environment. Adapted from re f9,12
= O-linked carbohydrate, O  = N-linked carbohydrate.
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1.2.1 MUC1 GENE <1 PROTEIN STRUCTURE
The MUC1 gene produces many MUC1 protein variants, of which the major product that has been 
studied in considerable depth is the MUC 1 mucin, a polymorphic transmembrane glycoprotein. The 
MUC1 gene consists of 7 exons with a region of an estimated length of 4 to 7kb of DNA, although this 
can vary with respect to the number of 60bp tandem repeat units present within the variable number of 
tandem repeats (VNTR) domain situated in the exon 2 13,14.
The MUC1 protein is comprised of three domains: a substantial proportion of the protein is encompassed 
by the extracellular domain, followed by a transmembrane domain and a short cytoplasmic domain (Fig. 
1.0). The extracellular domain is a major part of the core protein as a result o f20-125  tandem repeats of 
20 amino acid sequences, whereby each 20 amino acid repeat is rich in serine, threonine, proline, alanine 
and glycine residues. The serine and threonine resides within the tandem repeat sequence, provide five 
potential O-glycosylation sites, hence attributing up to 50% of the molecular mass to the carbohydrates 
present on the protein. Amino acids alanines and glycines are considered to aid the action of 
glycosylation enzymes in close proximity. The proline residues are precisely situated between the 
glycosylation sites, separating the regions of the attached carbohydrates providing an inflexible 
construction to the extended protein. This large domain protrudes 200 to 500 nm above the membrane, 
extending out far beyond the cell surface in comparison to the other membrane-bound proteins. Due to 
the large distance spanning of the domain, along with the high number of proline residues, this has 
encouraged the likely formation of polyproline (3-turn helixes, which are stabilised by the attached 
oligosaccharides 15,16. A hydrophobic transmembrane domain, connected to the extracellular domain, is a 
stretch of 31 amino acids, which links to the phosphorylated cytoplasmic tail consisting of 72 amino 
acids 17. The cytoplasmic domain has appeared to be networked with the actin cytoskeleton and is 
proposed to be involved in signalling pathways 6’18. The three domains of the core protein has an 
approximate mass of 120 -  225 kDa, however, the glycosylated mature form of the protein can have an 
increased weight in the range of 240 -  450 kDa 13.
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MUC1 has also been referred to as MUC1/REP, MUC1/TM, Episialin, H23Ag, CA15-3, ETA (Epithelial 
Tumour Antigen), PEM (Polymorphic Epithelial Mucin), EMA (Epithelial Membrane Antigen), MCA 
(Mammary Carcinoma Antigen) 17, Epitectin, PAS-0, DF3 and NCRC11. Many of these MUC1 
designations have evolved from antibody and antigen classifications, though PAS refers to a positive 
indication when utilising a stain, periodic acid-Schiff s reagent for carbohydrates, whereas episialin 
signifies the high presence of sialic acid on epithelial glycoproteins 12.
1.2.2 PROTEOLYTIC CLEAVAGE & SOLUBLE MUC1
Although MUC1 is typically a transmembrane protein, a soluble form of MUC1 has been detected in 
tissue culture supernatants and bodily fluids. This has suggested shedding of the extracellular domain 
from the MUC 1/REP or a direct secretion of a MUC1 variant, MUC 1/SEC, within the soluble form. The 
soluble form of MUC 1 lacks both the transmembrane domain and the cytoplasmic tail proposing that the 
soluble form is released from the membrane by proteases via two potential mechanisms. Upon translation 
of the MUC1 protein, a proteolytic cleavage of the extracellular domain occurs within the endoplasmic 
reticulum resulting in two subunits, which then progresses to the cell surface as a heterodimer complex 
19,2°. The two subunits generated, N-terminal and C-terminal, also referred to as a  and |3 21 respectively, 
interact with each other specifically via strong non-covalent binding, although the bonds are susceptible 
to sodium dodecyl sulphate (SDS). The stability of this interaction has been demonstrated by the 
heterodimer remaining intact despite the several recycling steps of the protein re-entering the cell to the 
Golgi apparatus for further glycosylation and proceeding back to the cell surface 19,22. The potential 
proteolytic cleavage site appears to be within a sequence of 18 amino acids, in between 71 to 53 amino 
acids upstream of the transmembrane domain, where the N-terminal subunit is the product consisting of 
the larger part of the extracellular domain, including the variable number of tandem repeats (VNTR). The 
smaller segment (20-30kDa) of the extracellular domain consists of the remaining 58 amino acids, along 
with the transmembrane and cytoplasmic domain is positioned at the C-terminal 14,19. It has been 
suggested from various studies that the larger portion of the extracellular domain is released from the 
heterodimeric complex via possible mechanisms not yet clearly identified, although two possibilities
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have been proposed; dissociation of the N-terminal subunit from the C-terminal subunit or a second 
proteolytic cleavage. This release of the N-terminal may be a possible means to signal to the cell interior 
of an external change in the environment 19,23. Research has also led to the understanding that the 
proteolytic cleavage site remains unaffected by any number of tandem repeats which are subjected to 
heavy glycosylation. Furthermore, it has been observed from experimental results that proteolytic 
cleavage and arrangement of the heterodimeric complex not only occurs in normal epithelial cells but 
also within malignant cells 20. In addition, similar to the MUC1 soluble forms, MUC 1 /SEC also lacks the 
transmembrane and the cytoplasmic domain. However, MUC 1/SEC can be differentiated as this splice 
variant possess the potential to be secreted directly from the cell14.
1 .2.3 PROPERTIES & FUNCTION OF MUC1
MUC1 possess many properties that serve its numerous functionalities, which include preventing 
dehydration and protection of the cell surface from foreign material. Additionally, it possesses a dual 
functionality of performing as an adhesive and an anti-adhesive molecule. The oligosaccharides present 
on the protein prevent moisture from escaping by binding to water molecules, thus keeping the moisture 
in close vicinity of the cell surface and permitting the cells to remain hydrated. Furthermore, they play a 
significant role in the formation of the mucus gel and provide lubrication. The extended extracellular 
domain of MUC1, with a network of oligosaccharides, aids in protecting the cell surface from direct 
contact with the external environment via utilisation of two main pathways. Oligosaccharides either 
provide a steric obstruction, by blocking the entry of any unrecognised material, or capture bacterial 
organisms through some form of interaction. Upon any interaction of foreign materials with the protein, 
cellular changes are promoted by means of activating greater tyrosine phosphorylation on the 
cytoplasmic tail, indicating to the interior of the cell, the presence of abnormal activities in its external 
environment. In order to terminate the extension of each carbohydrate chain, the chain is either capped at 
the end with sialic acid, fucose or sulphate, attributing a negative charge on the molecule. There are 
several functionalities associated with the presence of sialic acids which determine, depending on the 
expression of the sialic acid, the fate of cell-cell interactions and cell-matrix formation24.
CHAPTER ONE 9
INTRODUCTION
A change in cell-cell and cell-matrix interactions is observed through a greater expression of sialic acids 
causing steric hindrance brought about from the negative charge. As the number of tandem repeats is 
reduced, so is the O-glycosylation, leading to increased levels of sialyl transferases prompting greater 
sialylation. The presence of sialic acid (Figure 1.1) in normal, non-cancerous cells, demonstrates two 
functions. Firstly, sialic acid allows the lumens of the vessels to remain open through strong repulsion 
generated from the negative charge. Secondly, they have the capability to bind to foreign microorganisms 
preventing them from reaching the cell surface and causing any damage 12. The degree of sialylation 
appears to increase each time with the recycling process of the MUC 1 protein. However, this can result 
in the down regulation of the immune response, as access of antibodies binding to their corresponding 
peptide regions is limited through either steric hindrance or masking of the antigen present on the 
tumour-associated MUC1. With greater expression of sialic acid, MUC1 performs as an anti-adhesive 
molecule, preventing cell-cell interactions and cell-matrix formation due to the negative charge repulsion, 
as well as providing rigidity to the protein. As MUC1 is typically expressed only on the apical surface, it 
is unable to interfere with the adhesion molecules situated on the basolateral side. MUC1 however, is 
able to inhibit interaction with proteins present on the opposite side of the cells, preventing non-essential 
adhesive interactions. Furthermore, in the presence of lectin molecules, which are sugar binding proteins, 
cell-cell interactions can take place by interacting with the oligosaccharides on the extended extracellular 
domain 16,25.
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Figure 1.1. Structure of the two major sialic acid derivatives. Neu5Ac is the most abundant 
sialic acid in all living systems. Neu5Gc is commonly disseminated in the mammalian system, excluding 
healthy humans. However, the presence of Neu5Gc can be found on malignant cells. Adapted from re f26.
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As the number of tandem repeats decrease, resulting in a considerable reduction of O-glycosylation, 
carbohydrates such as sialyl Lewisx and sialyl Lewisa (Figure 1.2) are significantly increased on MUC1 
expressed by tumour cells. Sialyl Lewisx and sialyl Lewisa extensively promote the anti-adhesive 
properties of the protein and have an important role in advancing metastasis. Alternatively, sialyl Lewis 
carbohydrates can also interact with adhesion molecules like P- and E-selectin. These selectin molecules 
which bind to leukocytes and endothelial cells, forms a complex with the sialyl Lewis carbohydrates 
present on tumour cells and leukocytes, whereby this interaction can lead to extravasation. Further aiding 
the metastatic process is the presence of the soluble MUC1 expressed with excessive sialyl Lewis 
carbohydrates, thus upon binding to the selectin molecules, the leukocytes are distracted away from the 
tumour site 24'2\
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Figure 1.2. Structure of Sialyl Lewis carbohydrates. (A) Structure of sialyl Lewis3 and (B)
sialyl Lewis*. Adapted from re f27.
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Other than the adhesive and non-adhesive, glycosylated and under glycosylated properties, MUC1 is also 
associated with immune regulation and/or immune suppression, which is further explained in the 
following section, 1.2.4.
1.2 .4  EXPRESSION OF MUC1
Quantitatively, the expression of each type of mucin is typically varied to some degree across the 
numerous different organs and tissues. However, aside from the fluctuating levels of mucin expression, 
the MUC1 protein also possess the ability to be expressed in different morphological structures as a 
result of differing VNTR regions and glycosylation patterns. The variations may possibly be dependent 
upon the functional role required to perform a biological process 12. Expression of the MUC1 mucin, 
under normal conditions, is restricted to the apical surface on most epithelial membranes. However, 
beyond the last decade, expression of MUC 1 on hematopoietic stem cells, which are stem cells that give 
rise to all varying type of blood cells, has also been discovered 9,28. This appears to suggest that MUC1 
may have an immunomodulatory role in the functioning of the immune system 29,3°. In particular, in 
organs dependent upon steroidal hormones for the regulation of cell proliferation, for example in the 
mammary gland where alternating cycles of active and inactive periods take place, the expression of 
MUC1 is seemingly elevated during the cell multiplication phase 12. Within the endometrium, the mucous 
membrane lining the uterus, a similar trend is also observed, whereby during a particular phase of the 
menstrual cycle, which is progesterone dominated, greater expression of MUC1 is observed. This 
progesterone regulated expression of the protein has resulted in either a reduced or inhibited T-cell 
stimulation within the reproductive tract, which has been found to permit the implantation of the foetus. 
Aside from the fluctuating levels in the expression of MUC1 within the endometrium, the degree of 
glycosylation on the protein appears to be much varied. As it appears, MUC1 on normal epithelial 
surfaces is more densely glycosylated in comparison to the protein found in the endometrium and the 
serum of expectant mothers, where the sugar chains are significantly truncated 14. The abnormal form of 
glycosylation has been found to initiate an immune system response, by activating the production of anti- 
MUC1 T cells. Thus, it has been proposed that this in-built mechanism performing as a natural 
immuniser may act as a barrier against the formation of breast cancer during the pregnancy period29,3!.
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From the results and observations obtained through numerous investigations performed on the expression 
of MUC 1, it can be postulated that under the normal biological organisation, MUC1 can operate as a 
regulator of the immune system or an immune suppressor depending upon the role that is required by the 
protein. However, the precise mechanism of how MUC1 operates in the immune regulatory system is yet 
to be determined29.
1.2.5 ROLE OF MUC1 IN SIGNAL TRANSDUCTION
The MUC1 transmembrane protein has not been designated to a particular function, though the protein 
appears to be responsible for numerous activities, as previously mentioned, including detecting changes 
within the extracellular environment, protection of cells, cellular adhesion and signal transduction. It has 
been demonstrated that multiple functional properties of MUC 1 can come into action simultaneously via 
the protein’s elaborate structure. The extracellular domain of MUC 1 responds to any external change in 
the environment and this is communicated to the interior of the cell by the means of heterodimer 
dissociation or by alteration of the domain through some form of binding. The intracellular region of 
MUC1 provides a platform to interact with different kinds of signalling proteins 11 (GRB2 / Sos / Ras 32, 
ErbB receptors 33, (3-Catenin34, c-Src tyrosine kinase35), whereby upon initiation of the external stimuli, 
signals appear to be carried to the nucleus via the interaction between the cytoplasmic tail (CT) of MUC 1 
and signal transducing agents. The cytoplasmic region of MUC1 possesses seven tyrosine residues, 
which provide several moieties that represent varying degree of binding potential to different forms of 
signal transducing agents. The MUC1 CT is composed of 72 amino acids of which seven are tyrosine 
residues, where phosphorylation of these residues has first been demonstrated by Zrihan-Licht et al 17 
who has strongly suggested that the MUC1 CT is involved in signal transduction. Amongst the seven 
tyrosine residues, four tyrosines are positioned in an eloquent manner within the entire amino acid 
sequence, whereby upon phosphorylation they are projected as signalling receptors and have been noted 
to allow MUC1 to function in a similar fashion to that of cytokine receptors. Evidence from extensive 
studies has established that these four tyrosine residues are phosphorylated in response to extracellular 
stimuli and each of them is able to interact with the Src homology (SH2) domain belonging to different
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protein kinases. The SH2 domain is a protein domain which is structurally conserved, found within many 
signal transducing proteins, which assist proteins in locating other proteins by recognising 
phosphotyrosine residues. This suggests that each phosphotyrosine residue contributes to a particular 
functional role and each maybe be accountable for responding differently to the extracellular stimuli36.
The phosphorylated tyrosine residues of the MUC1 CT have been shown to interact with adaptor proteins 
such as growth factor receptor-bound protein 2 (GRB2). GRB2 is associated with growth factor receptors 
involved in signalling pathways 37. Pandey et a l 32 has also shown the binding between the cytoplasmic 
tail and GRB2 in breast cancer cells. However, results have also shown that upon formation of this 
complex a further interaction takes place with the son of sevenless homology 1 (Sos) protein. The GRB2, 
whilst in complex with the MUC1 CT, is also able to bind via the SH3 domain to the Sos, forming a 
MUCl-GRB2-Sos complex. This, in turn, interacts with the Ras protein and is responsible for 
communicating signals from the exterior of the cell to the nucleus.
Another interaction between the intracellular region of MUC1 and p -catenin has also been observed 34. 
However, in this case a protein kinase referred to as c-Src has been found to phosphorylate the tyrosine 
residues present in a particular place within the entire sequence. Subsequent to phosphorylation, the SH2 
domain of Src is able to directly interact with that particular phosphotyrosine residue to prevent the 
binding of MUC 1 with glycogen synthase kinase 3p  (GSK3/?) and instead promote the interaction with p- 
catenin. Upon the formation of MUC 1- ^-catenin complex, the complex is transported to the nucleus, 
where /?-catenin is responsible for the increase in the expression of cell cycle progression genes 38. 
Through this mechanism, MUC1 is able to increase the levels of p -catenin present in the cytoplasm and 
nucleus, resulting in a continuation of the inhibition of phosphorylation by GSK3/?. However, the 
formation of the MUC1- GSK3/? complex can inhibit the MUC1- p~catenin formation, affecting cell 
adhesion and resulting in decreased MUC 1-associated tumorigenicity10,35>38.
A further participation of MUC 1 in signal transduction has been demonstrated by MUC1 expressed on 
malignant cells, through its ability to interact with carbohydrate-binding proteins via the carboxy
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terminal. The complex formed upon the interaction between the carbohydrate binding protein known as 
epidermal growth factor receptor (EGFR) and MUC1 mediates signalling pathways that have been shown 
to contribute in cancer cell growth, promoting tumour growth formation and metastasis 33’39’40. The 
prevention of the MUC1 and EGFR interaction has resulted in a decrease in proliferation, migration and 
invasion 40,41. The inhibition of this type of interaction can take place via the natural regulatory system, 
whereby other proteins are able to phosphorylate and bind to the phosphotyrosine residues in the CT. On 
the other hand, if the protein responsible for phosphorylating the residues does not bind to the CT, then 
the protein can mediate the binding with further relevant proteins 40.
In addition to the importance of the cytoplasmic tail present in MUC1 for signal transduction, Kohlgraf 
et al 42 have also demonstrated the impact of the presence of the tandem repeats. The lack of either the 
tandem repeats or the cytoplasmic tail has resulted in the over expression of MUC1 and the cells have 
had an amplified tendency to invade lymph vessels and metastasise. If the primary functions of MUC1 
such as sensory, intracellular signalling and adhesion properties are dependent upon the tandem repeats 
and the CT, then the absence of either of the two domains, which leads to aggressive characteristics of 
the overexpressed MUC1, could support the hypothesis that the normal properties and function of the 
protein are not maintained. This has been demonstrated by the altered form of MUC 1 expressed in cancer 
cells. Following on from this, it has been demonstrated that excessive expression of the full length 
MUC1 protein has influenced the expression levels of other proteins, thus effecting the invasion and 
degradation of the extracellular matrix. However, this cannot be achieved in the absence of either the 
tandem repeats or the cytoplasmic tail. Furthermore, the signals initiated are dependent upon the different 
types of interaction MUC1 would have. This mainly relies on where the expression of MUC 1 has taken 
place on the cell surface and if the appropriate ligands are present within close proximity of MUC 1 for 
an interaction to take place.
In brief, only a few selected possible signalling pathways involving the extracellular and intracellular 
regions of the MUC1 protein and interacting proteins have been described above. From this it can be 
concluded that the intracellular processes and signalling pathways involve an extremely complex
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organisation. MUC1 is considered to possess versatile attributes through its involvement in many 
different physiological roles such as cell growth and differentiation, cell-cell and cell-matrix adhesion, 
oncogenesis, and immunity. However, MUC1 also functions in signal transduction through the presence 
of a variety of binding motifs on the cytoplasmic tail. This increases the availability and possibility of 
interaction with signalling proteins, permitting the formation of a comprehensive network' of molecular 
interactions.
1.2.6 QLVCOSVlLATlON
The core of the MUC1 protein, once processed in the endoplasmic reticulum (ER) undergoes proteolytic 
cleavage within the ectodomain region, which initially comes from the transmembrane domain and these 
two portions remain intact, forming a heterodimeric complex. At the extracellular portion of MUC 1, the 
tandem repeats are the main feature of the protein core. This domain accommodates particular amino 
acids which are appropriately positioned for the potential attachment of glycans. The oligosaccharide 
constructs present on the protein core are found to be in an array of diverse forms, which is determined 
by the type of tissue the protein is expressed upon and how the glycosyltransferases are expressed within 
that particular tissue 9’43. The glycosylation process is a post-translational development which involves 
two types of glycosylation, the N- linked and the O- linked glycosylation. The section within the MUC1 
extracellular domain between the beginning of the transmembrane domain and the VNTR region includes 
five potential sites for TV-glycosylation and within the VNTR each tandem repeat is bearing five potential 
O-glycosylation sites 44.
A considerable amount of carbohydrate content on the extracellular portion of the protein is owing to the 
attachment of the O-glycans through covalent links with the hydroxyl groups of serine and threonine 
residues within the tandem repeats. In 0-glycosylation, the process of adding the sugars, N- 
acetlylgalactosamines (GalNAc), occurs by attaching each one individually and in sequential order as the 
protein passes through the Golgi, with each addition being catalysed by glycosyltransferases. Once the 
GalNAc residues have been attached along the core of the extracellular domain, the basis for the addition 
of numerous other sugars has been created. Hence, from each of these core sugars an extension can be
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generated by further attaching N-acetylglucosamine (GlcNAc) and galactose in an alternating fashion, 
resulting in the formation of side chains which can be either straight or branched. The actual composition 
of the oligosaccharide chains can vary with individual protein cores even if the protein is expressed on 
the same tissue. This closely depends on the level of activity of the specific glycosyltransferases 
available and the position of the protein as it passes through the Golgi with relation to other enzymes that 
are present in the vicinity that can also compete for the same substrate. The cessation of the chain 
extension procedure is achieved by the addition of terminal sugars, such as GalNAc, GlcNAc, galactose, 
fucose, sialic acid or by sulphation. The availability of the number of enzymes responsible for adding 
sialic acid can significantly influence the length of each 0-glycan chain, as addition of the sialic acid 
during the early stages of O-glycosylation can inhibit the chain extension process and affect the final 
carbohydrate structure 45,46. Although the final termination of the chain extension by adding sialic acid 
residues is performed in the Golgi, the process is not complete through the first round, as at the end of 
the first round, the form that is exposed on the plasma membrane is not the mature form. Subsequent to 
the exposure of the protein to the plasma membrane, MUC1 is reintemalised via endocytosis for greater 
sialylation in the Golgi and finally the recycled mature form of the protein is brought to the cell surface. 
A number of recycling rounds are required in order to fully sialylate MUC1, whilst the shorter lengths of 
the O-glycan present allow internalisation at a faster pace than the mucin bearing considerably longer 
lengths of the 0-glycans 25,44,47.
The other form of glycosylation which is significantly different and has not been studied as extensively 
as the O-glycosylation is the iV-glycosylation. Unlike the 0-glycans, which are moderately small residues 
that can be attached to adjacent amino acids on the protein core, TV-glycosylation cannot occur in this 
manner. The A-glycans are large oligosaccharides which cannot be packed closely, hence are required to 
be situated in a spacious manner 48. The addition of TV-glycans also appears to contribute towards the 
functional properties of MUC1 and is particularly important for the stability, folding, transport, 
membrane trafficking and secretion for these type of glycoproteins. 7V-glycosylation also contributes 
significantly to the particular role of MUC 1 in the apical expression and sorting of glycoproteins present 
amongst polarised cells. For example, if the addition of (9-glycan remains incomplete and an early onset
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of sialylation has occurred, this would result in modification and perhaps greater polarisation in the 
protein, as opposed to the normal form. Thus, it would generate two forms of the protein, consequently 
leading to the sorting of the two forms. For 7V-glycosylation to come about, the iV-glycans are attached to 
the asparagine residues present in the protein core. This type of attachment takes place in the ER 
subsequent to protein synthesis. The oligosaccharides, which are bound to the asparagine residue, are a 
mannose rich 7V-glycans, Glc3Man9GlcAc2, which are initially trimmed by mannosidases in the Golgi, 
followed by further enzymatic addition of other saccharides. Furthermore, the procedure of recycling the 
protein through the Golgi permits the continuation of processing the high mannose glycans, which is 
observed through the different profiles of the TV-glycosylation 47,49.
Both forms of glycosylation on the MUC1 protein contribute towards the overall properties and function 
of the protein. The highly glycosylated extracellular domain plays a role in bulking up the weight of the 
glycoprotein, with the addition of providing stiffness to its overall structure. The O-glycosylation also 
takes part in cell protection and cell adhesion, whilst the iV-glycosylation is involved in further intricate 
biological roles such as transport, secretion and membrane trafficking.
1.8 .0  CANCER ASSOCIATED MUC1
The epithelial mucin MUC1 is a functional protein with important roles in the survival of the cell. 
However, MUC1 is also distinctly associated with many malignancies, where several of the original 
characteristics of the protein have been lost. As opposed to the typical expression, which is restricted to 
the apical surface of normal epithelial cells, MUC1 has notably been observed to be overexpressed in 
many adenocarcinomas such as those of the breast, lung, ovary, pancreas, prostate and numerous other 
epithelial organs. Other cancers also expressing MUC1 to a substantial degree include multiple myeloma, 
lymphoma and particular leukaemias 8. Greater expression is due to the loss of polarisation. However, 
MUC1 on tumour cells displays many different features compared to the native protein, such as 
significantly reduced glycosylation due to the lessening in the number of tandem repeats present in the 
extracellular domain, combined with the extra addition of sialic acids which also distorts the cellular 
adhesion properties.
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On malignant cells, it has been clearly demonstrated that the carbohydrates are unevenly distributed 
along the domain and branches of the oligosaccharides are drastically truncated (Figure 1.3), with chain 
lengths composed of only one to six sugar units. As a consequence of this, although the polarised 
composition from the oligosaccharides has been lost, allowing the expression of MUC1 to take place all 
over the cells surface, larger portions of the malignant MUC1 is exposed in the extracellular environment
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Figure 1.3. Illustration of the glycosylation arrangement on MUC1. (A) Distribution of 
carbohydrates on normal MUC1, (B) Distribution of carbohydrates on malignant MUC1, (C) The core 
peptide consisting of a tandem repeat of a 20 amino acid sequence. Adapted from ref 29.
Due to the over expression of MUC1 in carcinoma cells, which also includes the presence of the protein 
in the same location as adhesion molecules, and the unique length of the extracellular domain extending 
far beyond the cell surface, MUC1 masks such adhesion molecules in carcinoma cells. This shielding of 
the adhesion molecules prevents any cell-cell aggregation and cell-matrix interactions from forming. 
Therefore, in such situations, metastasis is encouraged as the adhesive properties are lost, permitting the 
separation of the tumour cells from the neighbouring cells and the cell matrix at the primary site. As the 
tumour cells become unattached from the primary site, the cells are capable of invading the surrounding
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tissues, metastasising to form secondary tumours at varying organs around the body. To accompany this, 
MUC1 may also protect cancer cells from detection and removal of these cells by the body’s immune 
system. This may occur through the combination of the presence of soluble MUC1 from the tumour in 
the serum, which can inhibit adhesive interactions of migrating cells with endothelial cells, and the 
ability of MUC1 to shed itself from the transmembrane core. The release of the heterodimer and the 
soluble MUC1 could reduce the intensity of inflammatory cells at the tumour site, allowing tumour to 
escape from immune surveillance29.
Interestingly, MUC1 can also operate as an adhesive molecule, due to the attached carbohydrate 
structures such as sialyl Lewis3 and sialyl Lewisx, in cancers of the pancreas and the colon 24. These 
carbohydrates are proposed to be ligands for molecules such as P-selectin. Such interactions are able to 
imitate the typical mechanism utilised for trafficking leukocytes and in this case to aid in the spread of 
metastasis. The conventional method of leukocyte trafficking entails a weak binding between the sialyl 
Lewis carbohydrates present on the leukocytes and the selectins expressed on the surface of epithelial 
cells. This weak interaction allows a gradual movement of the leukocytes along the cell surface. This 
motion is mimicked by tumour cells expressing MUC1 containing these carbohydrate structures, also 
referred to as blood group antigens. Blood group antigens interact with the P-selectin in the same manner 
allowing migration to take place into other tissues. On the other hand, using the same mechanism, the 
blood group antigens present on the soluble form are able to bind with the selectin adhesion molecules on 
the leukocytes, distracting the leukocytes from the tumour. Furthermore, these carbohydrates on the 
soluble form are able to generate a mucous gel which acts as a barrier and further limits the immune 
system from gaining access to the malignant tissue9’24.
Although the general consensus is that greater expression of MUC1 is found on cancerous cells 
compared to that on normal cells of the same organs or tissue, this does not seem to be the case for all 
types of cancers. As an example, using monoclonal antibodies (mAb’s) against an epitope present on the 
protein backbone, it was observed that more protein was expressed on colon carcinoma cells compared to 
normal cells. However, contrary to these findings, when cell lines from both tissues were analysed using
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in situ hybridisation, the same levels of MUC1 expression were observed. This strongly suggests that the 
difference in these results is due to the varying glycosylation patterns on the protein of both types of 
cells. The carbohydrates present on the normal cells are potentially much greater and longer relative to 
that on cancer cells, thus masking the mAb from reaching the epitope on the protein, whilst on cancer 
cells the epitope is more exposed due to the truncated oligosaccharides 16.
The MUC1 protein plays a significant role in malignant cells to evade the immune system and with that 
advantage to further invade and infiltrate into neighbouring tissues and organs rapidly.
1.4.0 ALTERNATIVE SPLICED VARIANTS OF MUC1
Although MUC1 is one of the main mucins, continual research in the area of mucins has led to the 
discovery of many MUC1 isoforms generated through alternative splicing, that are often found expressed 
within the same type of cells or tissues. The different alternative spliced variants vary in structure from 
the native MUC1 protein in either lacking the transmembrane domain, cytoplasmic domain or the tandem 
repeat regions. Hence, each of the isoforms also differs in their functional properties. It has also been 
observed across numerous cell lines that most of the isoforms are overexpressed in cancer cells compared 
to cells obtained from benign tumours or normal epithelial cells. Whilst the existence of various MUC1 
isoforms has been established, there is very little characteristic information relating to any of the known 
spliced variants available. However, the main reason which contributes towards the lack of information 
on the functional properties of any isoform has been due to the lack of available antibodies which are 
capable of reacting specifically and selectively with the individual MUC1 isoforms.
1.4.1 MUC1/SEC
Of the many alternative splice variants, MUC1/SEC is a splice variant which possesses the extracellular 
domain, including the tandem repeat sequence, of the original MUC1 protein. However, as MUC1/SEC 
is devoid of the transmembrane domain and the cytoplasmic tail, it is suggested that MUC1/SEC is an 
original secreted form of MUC1. As MUC1/SEC is secreted directly from the cell surface, it contributes
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to the soluble form observed in serum, which also consists of the cleaved product of MUC1. However, 
this secreted form appears to be copious in comparison to the cleaved product. The secreted form of 
MUC1 can be differentiated from the cleaved MUC1 by identifying an amino acid sequence that is 
present at the C-terminal exclusively on MUC1/SEC 20. Obermair et al 50 demonstrated with primary 
ovarian cancer cases an interesting expression pattern of MUC1/SEC in benign and malignant ovarian 
tumour tissue samples. Amongst other MUC1 splice variants, which tested positive, MUC1/SEC has 
been the single splice variant which displayed negative in all the malignant samples, yet positive in the 
benign samples though not as intensively expressed as the other splice variants. Data also demonstrated 
that in ovarian cancers, MUC1/SEC is co-expressed with MUC1/Y in benign tumours, yet in malignant 
tumours the expression of MUC1/SEC is no longer observed whilst the MUC1/Y remains present. 
Although the expression of MUC1/SEC is non-existent in ovarian cancers, this does not seem to be the 
case in cancers of the breast and endometrial carcinoma, where the expression of this secreted form has 
been clearly detected in malignant tissues 14. Furthermore, evidence suggests that in breast cancer the 
MUC1/SEC has the capability to efficiently bind to another splice variant, MUC1/Y, with profound 
effects on the biological functions 51. From the investigations performed it seems that expression of the 
alternative splice variant MUC1/SEC is much dependent upon the type of tissue and the differentiation 
stage at which the cells are at. Hence, findings from cells or tissue samples from a particular organ are 
not necessarily observed using a tissue sample from a different organ.
1.4.2 HUC1/V
Another alternatively spliced variant, MUC1/Y, appears to be expressed significantly in many cell lines 
and in many cases more than the MUC1. The MUC1/Y protein is identical to the MUC1 with regards to 
the transmembrane domain and the cytoplasmic tail. However, the splice variant is devoid of the tandem 
repeat region and the flanking region. The tandem repeat region is a unique characteristic feature of the 
MUC1 protein and the lack of this feature in the MUC1/Y protein not only has an effect on the overall 
structure of the protein but also suggests the protein may not portray the typical mucin like characteristics 
and hence may also possess a different functionality to the MUC1. With the missing tandem repeat 
domain, the molecular weight of the mature MUC1/Y protein after recycling, appears to be in the range
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of 42 -  45kDa 15. On the other hand, experiments conducted have shown the mature MUC1/Y is able to 
form a complex with other cell surface molecules, bringing the overall molecular weight to 60kDa. 
Formation of the MUC1/Y complex shows mediation potentially occurring through the cysteine residues, 
which are capable of forming disulfide bridges. This splice variant, like MUC1, possesses sequences 
which are also observed in cytokine receptors, suggesting that MUC1/Y can perform as a cytokine 
receptor and can possibly be involved in similar ligand interactions. Although MUC1/Y shares 
similarities with MUC1, the splice variant does not have a heterodimeric component upon where 
cleavage of the protein can occur 17. Furthermore, this membrane bound cell protein goes through 
transphosphorylation within the cell on the tyrosine and serine residues, which are part of the 
cytoplasmic domain, and in breast malignancy this has been found to occur upon binding to the 
MUC1/SEC protein. The interaction between MUC1/Y and MUC1/SEC, which occurs at the 
extracellular domain, has not only thought to induce phosphorylation but has been responsible for 
instigation of many biological processes such as changes to the cell morphology and prompting of the 
signalling cascade. Triggers to initiate the signalling cascade are believed to occur from the evidence 
obtained via the interaction of the cytoplasmic phosphorylated residues to the GRB2 protein, a similar 
mechanism to that observed with MUC1. One of the many effects of the signal transduction produced 
through the MUC1/Y protein is the enhancement of tumour progression. Interestingly, in cancers of the 
breast, the expression of this splice variant is seemingly advantageous as MUC1/Y is apparently found to 
be present in the malignant tissue, yet undetectable in neighbouring normal tissue of the same organ. 
However, this is not the case in malignancies of many other organs, where the expression of MUC1/Y is 
also detected in neighbouring normal tissue of other malignant organs, though in significantly lower 
levels. In addition, the overall levels of expression of not only MUC1/Y but also MUC1 are likely to 
show discrepancy in the various breast cancer tissue samples obtained from different patients 15,51.
From the few cell lines studied, the expression levels of the protein MUC1/Y is less variable in 
comparison to MUC1 in malignant tissues. The presence of MUC1/Y is significantly greater in cancerous 
tissue and barely detectable in normal tissue, as opposed to MUC1, where the expression ranges from 
significant to detectable or undetectable levels within tissue samples of the same organ from different
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patients. As an example, in observing the expression levels in HeLa cervical carcinoma cells, MUC1/Y 
was present to a large extent, whereas MUC1 was remotely detectable. It has emerged that in breast 
cancer tissue and HeLa cervical carcinoma cells to a substantial degree, the expression is limited to only 
this isoform, suggesting that MUC1/Y could potentially be a promising marker for identifying 
malignancy. This demonstrates that as MUC1/Y expression levels increase, the level of tumourgenicity 
also intensifies. However, the opposite is observed with the normal MUC1, lower the levels of MUC1, 
the greater the association of cells with the malignancy37. To further support this evidence Obermair et al 
52 have demonstrated the extensive expression of MUC1/Y after screening eight different cervical cancer 
cell lines, whereby it was found that seven out of eight were expressing this splice variant. Also evident 
from these studies is that MUC1/Y is frequently expressed with other MUC1 isoforms such as MUC1/X 
and MUC1/Z.
Similarly, when investigating primary ovarian tumour samples, it was observed that MUC1/Y is much 
more frequently expressed in malignant than in benign tumours. From the 55 ovarian cancer samples that 
were analysed, 54 of those samples expressed MUC1/Y, proposing that MUC1/Y is a strong candidate 
for indicating the presence of malignancy. Furthermore, MUC1/Y splice variant is co-expressed with the 
splice variant MUC1/SEC in benign tumours. However, this is not the case in malignant tumours 50. 
Although this may not be the case with other malignancies, the absence of MUC1/SEC and the presence 
of MUC1/Y can potentially be a better and more definitive approach in distinguishing the stage of the 
tumour from benign to malignant for diagnostic purposes and in confirming ovarian malignancy.
The results obtained from the different tissue organs or cell lines explored have shown that the 
expression of MUC1/Y splice variant is variable in the different cell lines or tissue samples. Thus, 
although there are many variables with regards to the expression of MUC1 and other splice variants, it is 
evident that MUC1/Y is associated with many malignancies.
CHAPTER ONE 24
intro d u ctio n
1.4 .3  MUC1/X AND MUC1/Z
There is very limited literature discussing the other splice variants, MUC1/X and MUC1/Z, often co­
expressed with MUC1/Y. However, though the significance of the role of these splice variants is not 
exactly known, the structure of these proteins has been established. Similar to MUC1/Y, MUC1/X and 
MUC1/Z both lack the VNTR region, a distinctive feature of the core MUC1 protein. Furthermore, 
MUC1/X and MUC1/Z are also found to be recurrent in malignant tumours rather than in benign tumours 
as in the case of ovarian cancers 50. Analogous to this is the expression of these short isoforms 
determined in the cervical carcinoma cell lines, where from the eight cell lines investigated seven 
expressed MUC1/X and six expressed MUC1/Z. Also from the eight cell lines, the C-3A cell line did not 
express either of the splice variants including MUC1/Y and MUC1/SEC, yet expression of MUC1 was 
clearly observed. Furthermore, often found across the cell lines studied, isoforms MUC1/X/Y and Z are 
expressed in differing combinations together rather than any one of them individually52.
Between MUC1/X and MUC1/Z, the MUC1/X isoform has been the most examined. Unlike MUC1/Y, 
the MUC1/X protein does undergo proteolytic cleavage and this takes place in the SEA module within 
the extracellular domain. The name SEA was derived from the original place where the SEA module was 
identified in Sperm protein, Enterokinase and in Agrin. Other than the SEA module, which consists of 
120 aa, adjacent to the 30 aa N-terminal, the extracellular domain also contains an additional 18 aa, 
hence overall proving to be a much shorter isoform than the MUC1 protein. From research findings, 
proteolytic cleavage occurs in MUC1/X at a site that is equivalently present in the tandem repeat region 
within the MUC1 protein, indicating that the sequence composing the SEA module is the minimum 
number of amino acids required for proteolytic cleavage to take place 21. Using cervical HeLa and 
ovarian carcinoma cells, from preliminary results it has been presumed that MUC1/X may be 2 kDa 
larger than MUC1 /Y, nevertheless further investigations are required to confirm this37.
Although MUC1/Z is devoid of the tandem repeat, like MUC1/X but unlike MUC1/Y, it has 18 more 
amino acids within the extracellular region. However, any other structural feature or molecular weight 
has not yet been established. Schut et a l53 investigated the expression of MUC1 and the splice variants of
CHAPTER ONE 25
INTRODUCTION
MUC1, in particular MUC1/Y and MUC1/Z, on benign prostatic hyperplasia (BPH) and malignant 
prostate tissue. The findings showed that no significant expression specificity of MUC1/Z was displayed 
for the malignant tissue over the BPH. However, it has been suggested that BPH could eventually 
develop into cancer as, like MUC1/Y, MUC1/Z is also preferentially expressed by tumours. In another 
investigation involving the screening of serous effusions, through the detection of cancer cells in these 
fluids, it has been found that MUC1/Z along with MUC1/Y are greatly over-expressed in primary breast 
tumours and ovarian cancer in comparison to the MUC1 protein. Also ascertained is the co-expression of 
these two splice variants which are rarely detected in benign tissue54.
It still remains unclear the exact role of the MUC1 splice variants MUC1/X, MUC1/Y and MUC1/Z. 
However, it has been hypothesised that these considerably shorter forms of MUC1 could have an 
involvement in signal transduction and possibly other intracellular processes. This could be due to the 
changes which have occurred in the splice variants within the extracellular domain, whilst the 
cytoplasmic region has remained identical to the MUC1 protein in all the forms.
1 .5.0 THE POTENTIAL OF OLIGONUCLEOTIDES
The vast pressure to rapidly make revolutionary advances within the science and technology field has led 
to increasing demands in research for the development of novel methodologies in the areas of molecular 
recognition, diagnostics and therapeutics for a wide range of human disorders. There are numerous novel 
therapeutic targets which are emerging that may either have a connection with or be the cause of a 
disease. However, the critical challenge lies in the ability of the ligand or the inhibitor to perform on the 
basis of selectivity and specificity against the chosen target, to bring about the desired functional result. 
For this reason, the need for sophisticated pharmaceutical agents has become an essential requirement 
which has led to the increasing popularity of biologies and oligonucleotide-based applications in 
particular. Oligonucleotides are molecules which are remarkably multipurpose and have shown to be 
employed in a broad variety of applications including molecular biology, diagnostics and therapeutics. 
Oligonucleotide therapies have demonstrated promising outcomes in numerous disorders including 
cardiovascular diseases (ARC1779 55’56, NU172 57'58) viral (Anti-HIV-1 RT 60 A22 61), inflammation
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(NX21909 62’63, Anti-L-selectin 64,65), angiogenesis (NX1838 66‘68), neurological disorders (Anti- 
Substance P 69, Anti-NGF 70) and many different cancers (AS1411 71,72, TTA1 73,74, Anti-PSMA 75). 
Oligonucleotides are single strands of DNA or RNA of varying lengths where the ligands are referred to 
by their own unique terminology. The terminology depends upon their mode of action and application 
such as aptamers, ribozymes, DNAzymes, siRNA, antisense, and spiegelmers. The DNA / RNA based 
technologies are still at an early stage with regards to their development and reaching the market in 
comparison to other established applications like small synthetic molecules, peptides and antibodies. The 
technologies which fall under the umbrella of the DNA / RNA category are all in progress at various 
stages with regards to their development. The antisense approach is the most developed and investigated 
amongst the other methodologies. Currently two oligonucleotide based products are available in the 
market employing different strategies; antisense and aptamer, to perform the necessary functional action. 
In 2005, 229 DNA / RNA products had been established by the Datamonitor global research and all these 
products were active in their research and development programmes. From the 229 products, 19 had 
demonstrated potential of reaching the market within a decade76, hence displaying a remarkable potential 
for oligonucleotide orientated products. The oligonucleotide based technology initially began in 1967 by 
Belikova et al 77 by putting forward a theory suggesting an oligonucleotide sequence, which is 
complementary to the mRNA of a target, is able to prevent expression of that mRNA, thus inhibiting the 
relay of genetic information from the DNA to the protein. Although this was initially proposed for 
prokaryotes, a decade later Zamecnik and Stephenson78 in 1978 demonstrated this antisense strategy in a 
cellular system to block the replication of the virus Rous sarcoma, hence displaying potential for utilising 
this system in therapeutics 19.
1.5.1 AITISEMSE STRATEGY
The core principle behind the antisense strategy is based on the Watson-Crick hybridisation. A short 
single stranded oligonucleotide is generated, which is specifically complementary to the mRNA sequence 
of the selected target. There appears to be a necessity for the oligonucleotide to be of a particular length, 
based on calculations and studies with different length oligonucleotides. The appropriate length was 
established to be typically between 15 and 20 nucleotides long 80. The function of the short antisense
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strand is to hybridise with the mRNA target which is responsible for the expression of a particular 
protein in the cytoplasm. The function of the short antisense strand is to hybridise with the mRNA target 
which is responsible for the expression of a particular protein in the cytoplasm. This hybridisation is 
employed to inhibit the translation of the target protein through the initiation of various mechanisms 
which include; translational arrest of the mRNA when targeted at the 5' terminus via steric hindrance of 
the ribosomal activity, impeding the mRNA maturation by preventing splicing or destabilising the pre- 
mRNA in the nucleus, and degrading the mRNA through the activation of RNase H. The RNase H 
enzyme is an endonuclease which hydrolyses the RNA strand of the RNA-DNA heteroduplex and 
degrades the mRNA, whilst the antisense strand remains unaffected81,82. In theory, the antisense strategy 
can be applied to block expression of any protein known to be associated with or responsible for the 
cause of a disease. Many antisense products have entered the clinical phases and are all at varying stages 
of development. However, one product which has successfully reached the market is Vitravene, also 
known as Fomivirsen. Vitravene is an antiviral drug and the first oligonucleotide treatment to be 
approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis (CMV)83.
1.5.2 ANTK5ENE TECHNOLOGY
An alternative approach is the antigene strategy, which employs a similar approach to the antisense with 
the essential difference being that the short oligonucleotide strand enters the nucleus to bind with 
genomic double stranded DNA, forming a triplex helical structure. The triplex forming oligonucleotides 
operate by sequence specifically recognising the oligopyrimidine*oligopurine present in the major grove 
of the double stranded DNA. The base pairs involved in Watson-Crick base pairing which form the 
double stranded DNA helix through hydrogen bonding can still offer hydrogen bond donor and acceptor 
groups. These groups can specifically engage with the bases of the triplex forming oligonucleotides. This 
specific recognition leads to the establishment of Hoogsteen or reverse Hoogsteen bonds between the 
bases pyrimidine or purine of the triplex forming oligonucleotide and the bases within the duplex of the 
purine strand. The formation of the triplex structure has the potential to inhibit the interaction of 
numerous protein factors for the transcription phase or hinder the initiation or elongation of the
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transcription complex, thus preventing the protein translation process. The distinct advantage of the 
antigene approach is that only a single target is required for inhibition in each cell in comparison to 
requiring several hundreds or thousands of mRNA copies as targets in the antisense strategy84'86.
1 .5 .3  RIBOZYMES
Another oligonucleotide technology under development for as long as the antisense strategy is the 
application of ribozymes. Ribozymes are varying lengths of single stranded RNA molecules possessing 
catalytic activity, making them capable of performing enzymatic cleavage or ligation of other RNA 
molecules. The ability of ribozymes to selectively catalyse the cleavage of their target demonstrates their 
potential to be used in specific gene suppression 80,87. There are six naturally occurring ribozymes that 
cleave phosphodiester bonds of RNA substrates 88: hammerhead89, hairpin90, hepatitis delta virus (HDV) 
91’92, Neurospora Varkud satellite 93, bacterial cofactor-dependent GlmS94, and group I intron 95,96. From 
these six ribozymes, the two classes of ribozymes; hammerhead and hairpin have advanced into 
therapeutic development. Hammerhead ribozymes were first discovered in plant viroids and virusoids 97 
and have also been found in satellite transcripts of various species 88,98'100. They are small, self-cleavable, 
RNA molecules with a secondary structure that possesses a highly conserved catalytic region responsible 
for connecting three base-paired stems. For the structure of a hammerhead ribozyme to take form, ca. 40 
nucleotides are necessary, allowing the ribozymes to be fully automated with regards to their catalytic 
properties and be able to perform in vitro in the absence of any cellular organisation 80. The binding of 
the hammerhead ribozyme is exclusively based on its sequence, which must specifically complement the 
sequence of the target RNA, with the structure consisting of three base-paired stems. It is essential that 
the substrate has the required sequence UH (where H = A, C, or U) adjacent 5' to the cleavage site. Stems 
I and IE of the hammerhead ribozyme specifically bind with the UH sequence of the substrate to ensure 
cleavage can take place, whilst stem II is involved in the structural conformation. The self-cleaving 
catalytic activity of the hammerhead ribozyme ensures complete inactivation of the target’s biological
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function, through the hydrolysis of the RNA substrate ’ ’ . The second type is the hairpin ribozyme, 
whose natural catalytic small structure was first found in the negative strand of the tobacco ringspot virus
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satellite RNA 103’104. The hairpin ribozymes are fully self-processing, thus the molecule is able to 
assemble into an appropriate conformation by itself and perform reversible cleaving of either itself or 
another RNA strand. For hairpin ribozyme catalytic activity to take place, ca. 50 nucleotides are essential 
which form two stems, each consisting of a helix-loop-helix structure. Thus, the two stems generate four 
base-paired helices and two loops, with one loop containing the reactive phosphodiester group. One stem 
is responsible for binding to itself or another RNA molecule and the other stem is present to perform any 
catalytic reactions. Development of these natural ribozymes can aid in understanding the role of naturally 
occurring molecules. Also, ribozyme technology can be used to inhibit the replication of many 
pathogenic viruses and further analyse the functionality of an individual gene in greater depth 105‘107.
1.5 .4  DNAZYMES
An alternative class of molecules very similar to ribozymes are referred to as DNAzymes. However, in 
contrast to ribozymes, DNAzymes are not typically found in nature and have greater biological stability 
as catalytic molecules than ribozymes. DNAzymes, also recognised as deoxyribozymes, are short single 
DNA strands possessing a catalytic motif and were first discovered in 1994, a decade after the discovery 
of the ribozymes, by Breaker and Joyce 108. These molecules are generated through an in vitro selection 
process. A typical structure consists of a central motif with a complementary sequence either side of the 
catalytic region that is utilised to specifically bind with the mRNA target via Watson-Crick interactions. 
Once binding takes place, the catalytic motif cleaves the RNA target, thus inhibiting the mutant gene. 
The catalytic activity is based upon the presence of a metal ion, allowing the cleavage to take place 
between the purine and the pyrimidine nucleotides 109,110. The DNAzymes are used to target genes which 
play an essential role in the development of a disease. Therefore, they are specifically designed to bind to 
mutant sequences and cleave the relevant target, leaving the wild type unaffected by the entire process. 
This technology is selected to effect gene suppression and has shown potential in many different disease 
models, however DNAzymes have not yet advanced in therapeutic applications for dominant genetic 
disorders 110‘113.
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1.5.5 SMALL INTERFERING RNA
Small interfering RNA (siRNA) are short double stranded RNA fragments, which mediate the 
degradation of mRNA, thus inhibiting the gene expression in the RNA interference (RNAi) pathway. 
This natural RNAi process was first described by Fire et a l114, where it was observed in worms, then also 
in plants 115, fungi 116, and humans 117. RNAi involves the presence of double stranded RNA (dsRNA) 
which is homologous in sequence to the silenced gene and this dsRNA is enzymatically cleaved into 
smaller fragments referred to as small interfering RNA (siRNA). siRNAs are approximately 1 9 - 2 3  
nucleotides in length with two nucleotide overhangs at the 3' end on both sides 118’119. The 3' overhang is 
used to incorporate the siRNA into a protein complex named RNA-induced silencing complex (RISC), 
which initiates the unwinding of the siRNA into two single strands of RNA; the passenger strand and the 
guide strand. The guide strand (sense / antisense) will remain associated with the RISC, whilst the 
passenger strand is degraded. The guide strand will bind with the complementary sequence in the target 
mRNA molecule and as a result can either induce the degradation of the mRNA target by the activated 
RISC complex or can block mRNA translation, hence inhibiting protein production 120,121. In the natural 
biological systems, the siRNAs are produced in the cell from double stranded RNA precursors by 
enzymatic nucleolysis to initiate the RNAi process 118’122. However, this can also be achieved by 
introducing synthetic siRNA molecules into the living cells of the host and initiating the processes 
involved in the natural RNAi pathway. This mechanism brings about a specific knock down of the gene 
expression, resulting in depletion of protein levels responsible for the development or promotion of the 
disease117,118,121.
There are numerous technologies available, which are all being developed to investigate and shed light 
on how different biological mechanisms effect the initiation and progression of life threatening diseases. 
However, there is tremendous pressure to have a single agent with multiple functional purposes such as 
detect novel molecular targets, perform as a diagnostic tool and as a therapeutic agent. There is one 
technology, developed only just over two decades ago, that is making remarkable progress and is 
showing great potential to meet these multifaceted criteria. With the exception of the numerous
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oligonucleotides therapies discussed above, other main therapies available in the market include small 
organic compounds, peptides and antibodies. To date, antibodies have met the criteria of molecular target 
recognition, and have been used in diagnostics and therapeutic applications. However, some issues 
related to antibody technology include the long development time and the lack of complete 
reproducibility 123,124. Nevertheless, another novel oligonucleotide based modality, termed aptamers, has 
entered the drug development market and proficiently made a niche for itself, with currently holding the 
position of the only class of agents to rival antibodies. In order for aptamers to be considered as valuable 
molecular tools in all three applications, they must display four main attributes for their selected target. 
Firstly, the agent must be able to differentiate between the native and mutant form of the target. Hence, 
the ability to bind specifically to the mutant form leads on to the second characteristic of having the 
ability to quantify the expression levels of the mutant type. The third trait requires the ligand to perform 
the main functional purpose of binding with high specificity and affinity in in vitro and especially in in 
vivo experiments. Finally, for a ligand to be successful in therapeutic applications, the ligand must be 
able to inhibit progression of the disease with minimal or no toxic effects. A combination of advances in 
the combinatorial libraries and high-throughput screening methods have made it possible to accomplish 
these basic principles for developing suitable drug candidates against many new proteins which are 
emerging as potential therapeutic targets 3. Upon establishing ligands which show promising potential, 
they are further improved through appropriate modifications to improve drug stability and total efficacy 
under physiological conditions, allowing them to be taken into further comprehensive in vivo studies.
Aptamers can be either RNA, DNA or modified nucleic acid molecules and are short synthetic single 
stranded oligonucleotides with remarkable properties that can be compared to antibodies. The meaning of 
aptamers is ‘to fit’ derived from the Latin word ‘aphis’ 125 and the Greek word ‘haptein’ 126 meaning ‘to 
attach to’. Hence, the winning sequences obtained from a vast combinatorial nucleic acid library that are 
‘attached’ to the selected target are designated under the category of aptamers. This class of 
oligonucleotides portrays many advantages and the one which is of utmost benefit is that they can be 
generated against a wide array of molecular targets 127. Targets can range from other nucleic acids 128,
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nucleotides 129'131, proteins 66,132,133, peptides 134’135, amino acids 136’137, small molecules 138,139J ions 140,141j 
cells 142,143 and whole organisms 144. Also included are proteins which are considered as either unstable, 
highly toxic or simply too complicated to be purified, especially if they are membrane-bound. Typically 
the length of the randomised region or of the final binding aptamer sequence, tends to be in the range of 
15-100 nucleotides 145 long. The final length is sufficient enough to fold via intramolecular interactions 
including natural base pairing that lead to the formation of secondary and tertiary structures of the 
aptamer. The secondary structures include short double stranded stems and single stranded loops. An 
amalgamation of these secondary structures leads to the formation of a reasonably stable three 
dimensional (3D) structure for binding to the target146. The binding mechanism, which is also dependent 
upon the target, involves a number of different forms of interactions, such as hydrogen bonding, 
hydrophobic interactions, pi-pi stacking, electrostatic interactions, Van der Waal interactions or shape- 
shape match, much like the lock and key mechanism 147. All these interactions contribute towards the 
aptamers’ high affinity and specificity for their target. Aptamers have been able to discriminate between 
proteins belonging to the same family and differing from each other by only one or a few amino acids. 
Along with great specificity, aptamers have the potential to have a very high affinity to their target, with 
an equilibrium dissociation constant (KD) in the nanomolar (nM) or even picomolar (pM) range. These 
artificial ligands are generated through an in vitro iterative process referred to as a Systematic Evolution 
of Ligands by Exponential enrichment (SELEX), a methodology to acquire high affinity and specificity 
aptamers in one complete process.
1 .5 .7  SPIESELMEES
Spiegelmers are short single stranded oligonucleotides which are not utilised to target the disease at the 
gene level, like many of the previous strategies mentioned above. These nucleic acid based molecules are 
typically raised against targets such as proteins or small biological / chemical molecules which assist in 
the development, enhancement or spread of an ailment. The spiegelmers approach predominantly 
branches from the original aptamer technology and are developed using the same methodology employed 
in the generation of aptamers, with high affinity and specificity for their target. Spiegelmers have come 
about from the essential requirement to develop therapeutic oligonucleotides displaying great stability, in
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particular towards nuclease degradation. These are RNA or DNA ligands in their L -  form of chirality, 
initially introduced in 1996 by Fiirste et al, where spiegelmers were synthesised to bind to arginine 148 
and adenosine 149. Nucleotides in their natural state are in the D -  chiral form, hence the mirror image of 
the oligonucleotide displays remarkable stability as they are able to escape recognition by nucleases. 
However, for the same reason, the selection of spiegelmers cannot be employed using L -  
oligonucleotides, as enzymatic amplification can not take place. Therefore, this requires an adaptation of 
the fundamental selection system, using the vital D -  enantiomeric form of oligonucleotides during 
selection. Spiegelmers are thus generated initially by obtaining a mirror image of the target of interest. So 
in the case of a protein or a peptide which in their natural form are displayed in L -chirality, the 
spiegelmers are initially selected as the natural D -  oligonucleotide against the unnatural D -  enantiomer 
of the target. At the end of the selection process, the winning sequences of oligonucleotides are then 
synthesised in the L -  enantiomeric form, which will then bind with the natural L -  target. Thus, this 
well-designed methodology is able to provide L -  enantiomeric oligonucleotides, termed spiegelmers. In 
addition to their ability to bind to their target with significant affinity and specificity they also 
demonstrate incomparable resistance to nuclease degradation150,151.
1 .6 .0  THE BASIC THEORY BEHIND THE SELEX
The innovative SELEX procedure (Figure 1.4) was developed simultaneously by two independent 
groups, Turek and Gold 152 and Ellington and Szostak 125 in 1990. The basis of this in vitro selection 
method entails the initial binding of the nucleic acid strands to the target of interest over a set incubation 
period, followed by partitioning and separation of the unbound molecules from the bound. The bound 
nucleic acids are then enzymatically amplified, to increase the number of molecules of each species 
present, which brings a close to the first round of selection. The amplified nucleic acid molecules are 
then subjected to the target once again for the second round of selection. Typically, the number of rounds 
of selection are repeated 8 -  15 153 times to obtain a pool of oligonucleotides which are potentially having 
high affinity and specificity for the target of interest. Subsequent to the iterative steps of binding, 
partitioning and amplification, the final pool is cloned and sequenced for the identification of each 
individual sequence present.
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Figure 1.4. An overview of the basic SELEX process. 1) The starting combinatorial library of 
nucleic acids is incubated with the target of interest. 2) The bound nucleic acids are separated from the 
unbound. 3) The bound nucleic acids are eluted amplified. 4) The amplified enriched pool of nucleic 
acids is subjected to the next round of binding to the target for further isolation. The process is repeated 8 
-  15 times. Adapted from r e f154
The combinatorial library utilised in the SELEX process consists of single stranded oligonucleotides. 
Each strand has a randomised region of 15 -  75 nucleotides long, with fixed sequences on either side of 
the randomised region which are necessary for the amplification of each nucleic acid strand. With the 
SELEX library produced from a combination of all four bases (A, G, C, T or U) and assuming that a 
randomised region (N) is to be 40 nucleotides long, hence 4/V. Then this would provide a maximum 
theoretical diversity value of 440 approximately equating to 1024 potential different sequences present
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within the combinatorial library. However, to simplify the synthesis of the library in any standard 
laboratory, most researchers are generally limited to employing a library with a diversity of 1015 different 
molecules. Although the library is synthesised to provide a diversity of 1015, taking into account the 
potential errors during the synthesis that may occur, along with the work up process, the diversity is 
likely to be reduced down to 1014 different sequences. Nonetheless, during the amplification process of 
the sequences, occasional enzymatic error which may occur leads to an introduction of altered new 
sequences adding further variety to the original pool of oligonucleotides 146>154.
Once the oligonucleotide sequences have been identified, screened for sequence and structural motif 
consensus, to reduce cost the sequences are truncated to a minimum length possible without 
compromising on their affinity and specificity for the selected target. The final length of the aptamer 
sequences tends to be between 15 -  45 155 nucleotides long. This length is sufficient enough to form 
three-dimensional structures such as g-quartets, pseudoknots, stem / bulge and hairpin loops 146, which 
are considered to play a vital role in binding. In addition to increasing the number of rounds of selection, 
the stringency of the SELEX protocol can be increased by performing either a negative selection or a 
counter selection. A negative selection involves performing a round of selection where the library is 
subjected to the support medium by which the target of interest is attached with. Hence, any aptamers 
that bind to the support are discarded. The counter selection round entails, incubation of the library 
against molecules very similar to the target or belonging to the same family. Upon completion of the 
incubation period, the bound aptamers are discarded and the unbound aptamers are taken further in the 
following consecutive rounds against the actual target of interest.
The basic SELEX protocol has only been briefly described above. However, aptamers can be generated 
through a variety of different adapted methods of SELEX. Additionally with the continual advancement 
of technology, the SELEX method is no longer restricted to just being a bench top process and can now 
be automated through sophisticated robotic systems. This allows the discovery of aptamers against many 
different targets to take place simultaneously, a system that dramatically reduces the overall selection 
time for obtain high affinity and specificity aptamers.
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1.7*0 APTAMERS GENERATED AGAINST TARGETS INVOLVED IN CANCER
Aptamers have been generated against a broad range of different types of targets, covering a wide array 
of diseases and disease promoting physiological processes which include infections, coagulation, 
inflammation, angiogenesis, and proliferation. However, the following section will focus on aptamers 
generated against cancer associated targets which have demonstrated to be successful by reaching the 
pre-clinical and clinical stages of the drug discovery and development process.
The first aptamer to reach the market for the application in human therapeutics and making a new mark 
by demonstrating outstanding scope in the world of aptamer technology is the anti-VEGFi65 aptamer. 
This aptamer is also commonly known as NX-1838, Macugen, Pegaptanib sodium and EYE001 156. The 
aptamer against the vascular endothelial growth factor (VEGFi65) was initially selected by Ruckman et al 
66 and was further developed by Eyetech Pharmaceuticals and Pfizer 157 where Macugen™ is the trade 
name. VEGF is a growth factor involved in angiogenesis and is responsible for the continuation of 
healthy vasculature. VEGF is also associated with many diseases including age-related macular 
degeneration (AMD), heart disease and tumour growth. VEGF has four main isoforms, where the 
VEGFi65 is the most important. VEGFi65 is composed of two domains containing 165 amino acids: a 
receptor binding domain and a domain involved in the binding to heparin. The anti-VEGFi6 5 aptamer is 
27 nucleotides long and has been selected to bind to VEGF165 through a mechanism where initially the 
binding occurs with the heparin binding domain (HBD) and then possibly with the receptor binding 
domain. Macugen shows no significant binding to the other VEGF isoform, VEGF1 2 1. VEGF121 does not 
contain the HBD, hence clearly suggesting the aptamer specificity for the HBD within the VEGF165, 
with a high affinity of a 50 pM KD 158. The formation of the VEGFi65-Macugen complex leads to the 
inhibition of blood vessel growth and vascular leakage, through blocking the VEGF165 binding to the 
receptors on the surface of the endothelial cells. This, in turn, blocks the commencement of an 
intracellular cascade. The specific inhibitory effect and Macugen’s success in clinical trials has led to its 
FDA approval in the United States in 2004 156 for the treatment of abnormal growth of blood vessels into 
the retina (wet -  AMD) for retardation in the loss of vision. Although the anti-VEGFi65 aptamer has 
entered the market for the treatment of AMD, this aptamer, through the same mechanistic approach, has
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displayed potential for tumour growth inhibition. The glycoprotein VEGFi65 is expressed in normal cells 
as well as malignant cells. However, the expression of this protein is far greater in cancer cells and is 
strongly correlated with tumour progression in particular cancers of the breast, prostate, lung, pancreas, 
stomach, colorectal and melanoma 159. VEGFi65 encourages tumour proliferation and metastasis via 
vasculogenesis, which is the development of new blood vessels in cancer tissues, feeding the total tumour 
mass and allowing the cells to maintain themselves and perform rapid multiplication. Therefore, blocking 
of the normal mechanism of VEGF165 can lead to the inhibition of progressive cellular proliferation and 
metastasis. It appears that even a small amount of malignant cell kill, which is involved in the 
nourishment of the tumour mass, can cause a vital reaction that can halt tumour growth 159. The effect of 
the anti-VEGFi65 aptamer as an anticancer agent has shown to be quite promising. A study performed by 
Huang et a l 160 demonstrated 84% reduction in tumour weight in nude mice cultured with Wilms tumour 
cells in comparison to the controlled animals after daily injections of the aptamer for 5 weeks. In another 
human tumour xenograft study involving the monitoring of growth of the A673 rhabdomyosarcoma 
tumour, after daily injections of the aptamer, on day 16 of the treatment, 74% of tumour growth 
suppression was observed in comparison to the controlled group 156. However, the real potential of anti- 
VEGF165 aptamer to perform as an anti cancer agent will depend upon the results which come about 
during the different stages of the clinical trial phases.
From the range of aptamers selected against oncological targets, the aptamer AS 1411, or previously 
known as AGROIOO, has progressed the farthest, by entering Phase II clinical trials. This particular 26 
mer aptamer has not been selected through the conventional SELEX method but rather based on 
observations obtained from previous analyses of guanosine-rich oligonucleotides (GROs). Studies have 
shown that GROs have the ability to perform anti-proliferative activities in cancer cells and are known to 
bind to a specific phosphoprotein, nucleolin. This protein possesses a molecular weight of 110 kDa and 
is mainly found in the nucleolus of proliferating cells. Increasing concentrations of this protein is found 
in cells, such as cancer cells, which are dividing at rates faster than the normal healthy cells 161. Amongst 
its many roles, one of the functional roles of nucleolin is to perform as a vehicle protein, transferring 
viral and cellular proteins from the cytoplasm to the nucleus or the nucleolus of the cell. This provides an
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indication of possibly which destination an anticancer agent will be transported to for effective action to 
take place. The ability of AS 1411 to inhibit cellular proliferative activity comes through the capability of 
the oligonucleotide to form a stable G-quartet structure. This structure is essential for binding to cell 
surface nucleolin. Upon binding, internalisation of the aptamer takes place, which is then followed by 
another intracellular binding with an essential modulator, the nuclear factor -  KB (NFKB). This, in turn, 
inhibits the activation of NFKB 72 resulting in the initiation of cell arrest in the S-phase of the cell cycle, 
causing a halt in the DNA replication process. AS1411 has been able to demonstrate tumour growth 
inhibition across a wide range of cell lines 162,163 and revealed effective in vivo activity in human tumour 
xenografts 72. These encouraging results have allowed the aptamer to proceed onto phase II clinical 
studies for the treatment renal carcinoma and for the treatment of acute myeloid leukaemia, phase II 
studies are being performed with the aptamer in conjunction with the drug Cytarabine 164.
Another aptamer that is closely following the progress of the nucleolin aptamer AS 1411 is the aptamer 
against the prostate specific membrane antigen (PSMA). PSMA is a transmembrane glycoprotein and 
over expression of this protein has been well established in prostate cancer cells and in endothelial cells 
lining the inner surface of blood vessels found in most solid tumours 165’166. However, PSMA is not 
detected in normal vascular epithelium. The PSMA expression level has been observed to display a 
proportional relationship to the aggressiveness of the tumour, as with each progressing stage of cancer 
the expression of the protein also appears to increase 166,167. Aptamers against PSMA have been generated 
by Lupoid et al 75 with nanomolar affinity for their target. The aptamers were selected against the 
extracellular portion of the protein, composed of 706 amino acids. The two selected high binding 
oligonucleotides are 2'-fluoropyrimidine modified RNA aptamers referred to as xPSM-A9 and xPSM- 
A10 and they do not share sequence homology. The aim for the aptamers was to inhibit the enzymatic 
activity of A-acetyl-a-linked acid dipeptidase (NAALADase). xPSM-A9 inhibits PSMA in a non­
competitive manner with an inhibition constant (Kj) of 2.1 nM and xPSM-AlO inhibits PSMA 
competitively with K; of 11.9 nM 75. From the inhibition studies it has been established that both 
aptamers bind to separate portions of the extracellular region of the protein and do not compete for the 
same epitope. Furthermore, results demonstrated that truncation of the xPSM-A9 by more than 5
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nucleotides resulted in inactivation of the functional aptamer. However, xPSM-AlO could be truncated 
by up to 15 nucleotides before loosing its ability to bind to PSMA. The truncated xPSM-AlO retained 
specificity for the precise epitope present on the target. This was shown by fluorescence microscopy 
studies, where the aptamer bound to the PSMA expressed by LNCaP prostate cancer cells. In contrast, no 
binding or uptake of the aptamer was observed on PC-3 prostate cancer cells, which did not express the 
PSMA protein75. In addition to this, the scrambled xPSM-AlO aptamer showed no significant binding to 
either of the cell lines. Thus, the binding of the aptamer to the target protein is highly sequence specific. 
The findings from all the experimental studies has allowed the exploration of the aptamer as an in vivo 
targeted drug delivery agent168’169.
Platelet derived growth factor (PDGF) is another growth factor against which an aptamer has been 
selected. PDGF is a protein with numerous isoforms and is associated with many proliferative diseases 
such as restenosis, glomerulonephritis, diabetic retinopathy and cancer 170. PDGF is a dimeric protein 
consisting of two homologous chains A and B, which are connected together by three disulphide bridges. 
The chains present the possibility of generating three different isoforms, PDGF-AA, PDGF-AB, and 
PDGF-BB. However, in order to activate the biological functions of this protein, the binding of PDGF to 
two receptors located on cell surface referred to as a  and (3 protein is necessary, a  and p both possess 
five extracellular domains, a transmembrane domain and an intracellular tyrosine kinase domain. The 
PDGF isofoims containing chain A are capable of binding to receptor dimers consisting of minimum one 
a  receptor. Isoforms containing the chain B are able to bind to dimers with a combination composed of 
both receptors. Therefore, depending upon the type of binding that takes place between the PDGF 
isoforms and the type of receptor combinations (aa, ap, pp) that are expressed on the target cells, 
results in the final cellular response that is exerted 132. Expression of the PDGF isoforms and their 
corresponding receptors has been observed in numerous cell lines and has been linked to affect many of 
the cell transformation processes along with tumour growth. This protein has been strongly associated 
with interstitial hypertension in the majority of solid tumours, which leads to poor prognosis and causes 
substantial reduction in the uptake of any anticancer agents. The PDGF-B isoform has been found to be 
responsible for controlling the interstitial fluid pressure (IFP) levels and increased levels can clearly be
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detected in solid tumours, whilst the same is not observed in normal connective tissue. This relationship 
is further supported by evidence demonstrating that the levels of IFP tend to increase proportionally to 
the tumour size and stage of malignancy 170. Aptamers have been selected against the PDGF-B to inhibit 
the protein from binding to the receptor. This should result in reducing tumour hypertension and allowing 
greater uptake of cancer agents, therefore possibly resulting in tumour reduction. The aptamers obtained 
at the end of the selection process all share the same secondary structure motif that consists of triple helix 
with a central conserved single stranded loop region. This loop region is the fundamental motif that is 
required for high specificity binding and binds successfully to PDGF-AB and PDGF-BB, but has a much 
lower binding affinity for PDGF-AA. The specificity in this type of binding lies in the presence and 
detection of the B-chain in either of the isoforms 132. The propensity of the anti-PDGF-B aptamer to 
inhibit the binding of PDGF-B to their corresponding receptors was demonstrated in studies performed 
by Pietras et a l 171. The affinity of the aptamer specifically for PDGF-B is approximately 100 pM and in 
comparison has a trivial affinity for the PDGF-A, and has shown to reduce IFP in a rat colonic carcinoma 
model. This result was comparable to that observed using a synthetic small drug inhibitor STI-571. The 
aptamer was capable of increasing uptake of an anti-cancer agent, Taxol, equally to the drug inhibitor, 
aiding Taxol in tumour growth suppression 172. Although the anti PDGF-B aptamer is demonstrating 
strengths that are equally matching that of synthetic inhibitors, the aptamer is still in the early stages of 
the preclinical phase of development.
A disulphide linked hexameric glycoprotein found on the extracellular matrix, known as tenascin-C, has 
been found to be overexpressed in tumour tissue when compared to the expression levels in normal 
tissue. Tenascin-C is involved in tissue remodelling processes and therefore is present during 
embryogenesis, tissue repair, inflammation and tumour growth 173. Aptamers were developed by Hicke et 
a l 74, from which one aptamer referred to as TTA1 was reduced in length to 39 nucleotides with a final 
molecular weight of 13.4 kDa from the parent aptamer sequence of 71 nucleotides. TTA1 has a high 
affinity for tenascin-C with a KD of 5 nM, whereby the binding of the aptamer to the target occurs 
through structural specificity. The folding of the aptamer adopts a secondary structure with the 
arrangement of three stems (I, n, ID) branching from a central junction, which is considered to be the
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essential binding region. It appears that the specific sequence involved in the make up of stem I is not 
crucially important as is not the closing loops formed at the end of stem II and IH. However, stems II and 
in are vital to allow recognition and binding to take place to the tenascin-C protein. In addition, stem I 
plays an imperative role with regards to the secondary structure. Stem I contributes towards the overall 
structural stability of the entire aptamer and sustains the binding potential presented by stem II and HI 
regions. Studies have shown removal of stem I has led to loss of binding. However, if stem I is 
maintained with a different sequence then the binding remains unaffected, therefore clearly suggesting 
the structural significance of stem I possess no sequence specific relevance 174. An in vivo investigation 
for the delivery of radioisotopes or cytotoxic agents by TTA1 has shown to be promising, as there was 
aptamer uptake by a variety of solid tumours including breast, glioblastoma, lung and colon. The uptake 
of the aptamer by the tumour, accompanied by the rapid clearance from the blood and the other non­
target bearing tissues allowed clear tumour imaging to take place 175. The development of TTA1 is still 
near the beginning and has many in vitro and in vivo experimental studies to go through and demonstrate 
successful results in these investigations before the aptamer can enter clinical trials.
The status of any therapeutic agent that has entered the clinical trials can be monitored through the 
website www.clinicaltrials.gov. Table 1.0 summarises the aptamers developed mentioned above against 
their targets along with their development status.
Name of Aptamer Target Type of Oligonucleotide Clinical Phase
Macugen
(NX1838, Pegaptanib sodium, EYE001)
v e g f 165 RNA Phase IV
AS1411, AGROIOO Nucleolin DNA Phase II
xPSM-AlO PSMA RNA Preclinical
Anti-PDGF-B aptamer PDGF-B DNA Preclinical
TTA1 Tenascin-C RNA Preclinical
Table 1.0. Aptam ers present in clinical and preclinical phases. The targets to which these 
aptamers have been generated against have all shown strong association with distinctive malignancies.
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As seen from these few examples, aptamers have made remarkable progress since their discovery in the 
early 1990’s. There are many other aptamers that have been and are currently being developed against 
numerous different targets associated with various carcinomas which are in early development. However, 
undoubtedly, there is great scope for aptamers to follow suit of the ones that have already proven to be a 
success in the world of diagnostics and therapeutics.
1.6.0 AFTAMER ADVAHTASES Vs ANTIBODIES
Up till the mid 1990s small molecules have been the most dominant in the area of therapeutics, whilst 
antibodies have been leading in the area of medical diagnostics and analytical applications. However, the 
discovery of aptamers has taken the approach to diagnostics and therapeutics to a new level, as they are 
reasonably cost effective and much of their synthetic processes are automated. Aptamers have been 
directly compared to antibodies with respect to their functional attributes. The overall ease in application 
of aptamer has given them many positive characteristics. One of the greatest advantages of aptamers is 
that the entire selection process does not require the use of animals. Hence, this saves time, as typical 
antibody production takes up to six months from the point of animal immunization. Other benefits 
include significant reduction in costs, as the expense of animals and their maintenance is eliminated. 
Furthermore, an in vitro selection method allows generation of aptamers against practically any target. 
This also includes targets which may not bring about an immunogenic response in animals, due to the 
target possessing a similar structure to that of the endogenous molecule. Toxins can also be used as a 
target, which can be problematic in an in vivo system, since the toxins can cause animal death 153. 
Aptamers can easily be site specifically labelled with a fluorophore or modified for pharmacokinetic 
purposes, and modifications can be performed in pH ranging typically from 4 to 8.5 155, temperature or 
solvents necessary, as aptamers are stable in non-physiological conditions. Antibodies on the other hand 
are sensitive molecules, and cannot be subjected to non-physiological conditions. Hence, labelling a 
particular amino acid on antibodies can prove to be a difficult task176. Monoclonal antibodies (mAbs) are 
very large molecules and are restricted to extracellular targets. Hence, mAbs take a considerable amount 
of time to penetrate through the tissues and are not proficient in an intracellular environment, as mAbs 
aggregate and misfold in the cytoplasm 170. Antibodies also possess prolonged blood residence, taking up
CHAPTER ONE 43
INTRODUCTION
to several days to clear from the blood. This limits the effectiveness of the short-lived radionucleotides 
and therefore results in poor in vivo image quality 177Table 1.1 outlines more advantages and 
disadvantages of aptamers relative to antibodies in all different aspects from synthesis and modification 
to applications.
1 .9 .0  CHEMICAL MODIFICATIONS OF APTAMERS
Aptamers have shown remarkable versatility in many of the in vitro applications. However, their 
drawbacks emerge when they are required as therapeutics agents in animal and human models. Other 
than having a high affinity and specificity for their target, aptamers must demonstrate stability against 
nucleases in the blood. Also, aptamers must be able to remain in blood circulation for a period of time 
sufficient enough to bring about a therapeutic dose response before entering renal clearance. Prior to any 
modifications, DNA and RNA strands are highly unstable in plasma, as nucleic acids are subjected to 
exonuclease and endonuclease degradation. Aptamer stability can be measured in vitro and studies have 
shown a typical RNA oligonucleotide to possess a half-life of only a few seconds, whilst DNA strands 
can remain stable from 30 minutes to an hour 154. Modifications to nucleotides can dramatically improve 
plasma stability and these modifications can be pre-SELEX or post-SELEX. In the case of RNA 
oligonucleotides, the library will typically consist of modified RNA strands, as RNA molecules are 
naturally more unstable than DNA molecules. As RNAase found in blood specifically commences 
degradation from the pyrimidine ribonucleotides, the most common modification incorporated in the 
RNA library is the substitution of the 2’ hydroxyl group (2’OH) on the ribose with either a 2’Fluro (2’ F) 
or a T  amino (2’ NH2) group.
Pieken et al 178 have demonstrated effectively that modification of the sugars on the pyrimidines have 
significantly increased resistance towards nuclease degradation for a prolonged period of time. Another 
approach to prevent the action of exonucleases for RNA and DNA is to cap the strands at the 5’ and 3’ 
ends. Through the capping of the 5’ end of the oligonucleotide, exonuclease activity in the direction of 5’ 
—> 3’ is limited and similarly by capping the 3’ end, degradation by the 3’—» 5’ directed exonucleases are
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inhibited to certain degree. The most common modification for the 3’ end is the capping with an inverted 
thymidine (3’-dT) 65 and biotin at the 3’ terminus can also be attached 179. Having only a stable aptamer is 
not sufficient to meet the demands of good pharmacokinetic properties.
Aptam ers Antibodies
• Aptamer selection is a chemical in vitro 
process
• Time taken to complete the selection process 
varies between days to few weeks
• In vitro process allows selection to take place 
against any target proteins, including toxins
• Selection can be performed under any 
conditions, i.e. varying temperatures and pH. 
Ideal for in vitro diagnostic assays
• Target site of the protein is determined by the 
investigator
• Has minimal or no batch to batch variation
• Diverse selection of chemical modifications 
can be performed for the desired functional 
purpose
• high binding affinities in the nM to pM range
• Great specificity, able to distinguish with a 
difference of only a few amino acids
• Small size with good tissue penetration. Rapid 
blood clearance providing higher signal / noise 
ratio in immunoassays
• Small in size, aptamers can be selected for 
extracellular and intracellular targets
• Stable over a broad range of pH, temperature 
and solvents. Regenerated upon denaturation
• Long shelf-life. Can be transported at ambient 
temperatures
• Non-toxic and lack immunogenicity
• Excellent solubility. Injected in volumes as 
little as 500pl
• Not readily available for any given target. • 
Generation depends on properties of the target. 
Significant quantity of the target is required for 
aptamer development
• No one ideal method is available for aptamer •
development. Conditions need to be varied 
depending upon the target__________________
• Antibody production employs a biological 
system, requiring the use of animals 
monoclonal antibody generation takes 6 
months from the time of animal immunization 
Problematic if a protein target is similar to an 
endogenous protein. Hence, low immunogenic 
response. Toxins can result in animal death 
Can only be formed under physiological 
conditions of the animal
Target site of the protein is determined by the 
immune system
Variation of activity observed from batch to 
batch
Limited possibilities for modifications
high binding affinities in the nM to pM range 
Polyclonal antibodies are not highly specific 
for a epitopes on the target 
Large molecules with slow uptake. Blood 
clearance can take up to several days to obtain 
a significant signal / noise ratio 
Large in size, selection restricted to 
extracellular targets as penetration issue 
prevents accessing intracellular targets 
Temperature, pH and solvent sensitive. 
Irreversible denaturation 
Limited shelf life. Needs special care in 
storage. Transported only lyophilised / on ice 
Non-toxic and high immunogenicity 
Poor solubility. Requires large volumes for 
dosing
Not readily available for any given target. 
Generation depends on properties of the target. 
Significant quantity of the target is required for 
antibody development
Same generic method is employed for antibody 
production of using physiological conditions
Table 1.1. Properties of aptam er in comparison to antibodies. A large combination of 
positive attributes placing aptamers as rivalry candidates of antibodies. Adapted from re f124,180,181.
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It is vital that the aptamers remain in circulation and are not eliminated through the kidneys 
within minutes. The length of aptamers selected for therapeutics tends to be in the range of 25 -  40 
nucleotides long. This usually equates to a molecular weight range of 8000 -  12000 daltons (Da), where 
this size has demonstrated to be far too small to display a reasonable rate of clearance in animal models. 
The problem of rapid renal clearance is tackled through further modifications on the aptamer, which 
involve the attachment of a large amphiphilic molecule such as polyethylene glycol (PEG). Various 
different molecular weights of PEG are available and can be linked to the aptamer via several methods, 
the most common of which is the attachment through a primary amine on the 5’ terminus. The attachment 
of PEG on the 5’ end of the oligonucleotide combats two objectives simultaneously; firstly linking of the 
PEG caps the 5’ terminus to prevent attack from exonucleases and secondly this conjugation holds the 
potential to increase circulation of the aptamer from hours to days 182. Another strategy that is recently 
becoming relatively popular is the utilisation of liposomes. In some cases, a combination of liposomes 
and PEG has been employed where the liposome plays the role of a drug delivery vehicle. Modifications 
for the intentions of other than stabilisation and improved pharmacokinetic properties include attaching a 
fluorophore for signalling or fluorescence based studies and the linking of biotin for immobilisation 
purposes. Figure 1.5 indicates the possible modifications which can be performed on aptamers to best 
suit the functional requirement either as a molecular, diagnostic or a therapeutic agent.
1.9.1 MODIFICATION OF NUCLEOTIDES
Nucleotides are the core of the nucleic acid structure, consisting o f three fundamental 
components; a base (purine / pyrimidine), a sugar moiety and a phosphate group, which are all 
linked together. These three individual components provide a platform where modification to 
particular moieties can take place and many modifications can be incorporated during the 
chemical synthesis of the nucleic acid strand. Chemical dressing o f aptamers has vastly 
developed in the recent years, especially for RNA aptamers, due to their severe lack o f stability 
in most non-sterile conditions and biological fluids.
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□  Nuclease resistance
□  Pharmacokinetics
□  Immobilization
□  Signalling2'-OMe Purine 
nucleotides
2'-F /  2'NH2 Pyrimidine 
^ nucleotides
Fluorescence
Biotin /  
NH2 Biotin / NH-
I -Fluorescence 
y dT-Cap = 3'dT
PEG/DAG
Figure 1.5. Overview of potential aptam er modifications. The modifications outlined provide 
solutions for nuclease degradation, improving pharmacokinetics, immobilisation to solid supports and 
signalling for fluorescence studies. Adapted from re f179.
There are two approaches of modifications which can take place. One where modifications are already 
incorporated into the main oligonucleotide library prior to selection or the other where the necessary or 
desired modifications are carried out on only the winning aptamer sequences. The first approach is 
principally more appropriate for RNA aptamers, as it is absolutely necessary that the RNA library 
remains fully intact throughout the entire selection process. Only few modifications can be used in this 
approach, as the majority of these modifications is on the backbone of the nucleic acid and can interfere 
with enzymatic recognition involved in the amplification step of the SELEX process. Hence, the most 
popular modification is the exchange of the 2'OH on the pyrimidine ribose sugars, which is involved in a 
nucleophilic attack on the adjacent 3' phosphodiester bond, with a small group that is either a 2'F or 
2 'NH2 . These 2' ribose sugar modifications are adequate to confer the RNA strands nuclease resistance. 
However, to further enhance the stability of the selected RNA aptamers, modifications on the purines can 
be included during their chemical synthesis. The modification on the purine nucleosides involving the
CHAPTER ONE 47
INTRODUCTION
substitution of the 2'OH on the ribose sugar with the O-methyl group (O-Me) provides protection against 
less significant RNAases present in the blood 183. Typically, half of the 2'OH groups on the purine ribose 
sugar can be substituted and in rare circumstances all the 2'OH groups can be substituted with O-Me 
groups. This substitution does not affect the original binding properties of the RNA sequences. Ruckman 
et a l 66 demonstrated this modification by substituting all the 2'OH groups on the purine ribose sugars 
with 2'OMe groups on the VEGF aptamer, which already had 2'F pyrimidine modifications prior to 
SELEX. Another type of modification, though not as widely used as the 2'F or 2'NH2 is the 
phosphorothioate modification. This involves the substitution of the oxygen present in the phosphate 
backbone, the oxygen that is not involved in the bridging of the sugars, with a sulphur atom. Like the 
phosphodiester, the phosphorothioates also provide a negative charge to the backbone, but provides 
greater protection against nuclease degradation. The negative aspect of phosphorothioate modification is 
that this modification leads to non-specific binding to proteins, along with the formation of a 
phosphorous chiral centre, resulting in numerous enantiomeric forms, hence counteracting the positive 
aptamer attributes 184,185. Another alternative modification is similar to that of the phosphorothioates. In 
this case the same oxygen on the phosphate backbone is substituted with a methyl group and this form of 
strand is referred to as methylphosphonates 186,187. The methylphosphonates have the same advantages 
and disadvantages with the phosphorothioates in providing resistance against nucleases and chiral 
formation, with an additional drawback. The solubility of the entire molecule is lowered due to the lack 
of charge on the phosphate. A further implication of this modification is the occurrence of steric 
hindrance, caused by the presence of the methyl groups, which leads to inadequate duplex formation 185. 
Other than the 2' position of the sugar, the C5 position of pyrimidines and C8 position of purines has also 
been investigated for modification. Position C5 of pyrimidines have had bulky groups, such as benzoyl 
groups, attached to the base which have shown no evidence of interfering with the enzymes employed in 
the SELEX process. These forms of more elaborate chemical dressing of the bases have been 
summarised by Bruce Eaton 188 and Booth et a l 189. The basic and most common chemical modifications 
have been illustrated in figure 1.6 within a short oligonucleotide sequence of 5'-TACG-3'.
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N NH2
Position Modification
X '0  Phosphodiester
'S Phosphorothioate
CH3 Methylphosphonate
Y H Deoxyribose
OH Ribose
O-CH3 2/-0-methyl ribose
F 2 '  Fluoro ribose
NH2 2!  Amino ribose
T = Thymine (Pyrimidine) 
A = Adenine (Purine)
C = Cytosine (Pyrimidine) 
G = Guanine (Purine)
Figure 1.6. Possible sites for common chemical modifications. Structure of a short 
oligonucleotide sequence of 5'-TACG-3' indicating the main substitution sites: X = Backbone 
modifications and Y = sugar modifications. The pyrimidines can be modified at position C5 and the 
purines at C8. Adapted from re f185.
Most DNA aptamers are stable prior to any modifications in a variety of conditions and have 
demonstrated relatively good stability even in biological fluids for a limited period of time, allowing 
DNA aptamers to be used directly for many in vitro studies. Nonetheless, for applications in diagnostics 
or in vivo work, modifications such as terminal capping using an inverted thymidine residue, aiding in the 
protection against exonucleases, would be inevitable. Attaching functional moieties at the end of the 
DNA strand, such as an amine linker, allows conjugation to fluorophores (Cy3, Cy5, TAMRA, FITC) 
hydrophobic molecules (PEG) 179, providing a means of attaching the aptamer to a solid support and 
offers protection towards exonucleases. Following aptamer selection, modifications to DNA aptamers 
can be directly incorporated during the chemical synthesis. The critical challenge remains in the
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attachment of large hydrophobic molecules for which currently an external ordering service and 
automated synthesis is not available.
1 .9 .2  PEQVLATION
In addition to overcoming the drawback of nuclease degradation in aptamers, the second predicament to 
resolve is to reduce rapid renal clearance and the obvious method has been through the attachment of a 
large hydrophobic molecule. The most common and versatile macromolecule employed for such a 
purpose is polyethylene glycol (PEG) and through a process referred to as pegylation it allows the 
covalent linking of PEG to the aptamer through variety of different chemical reactions. The pegylation 
process was first developed by Abuchowski et al 190 in the late 1970s using low molecular weight 1.9 
kDa and 5 kDa PEG molecules to covalently attach to a protein via the amino groups. Abuchowski and 
his group observed enhanced circulation of the pegylated protein in the blood and displayed no indication 
of any onset to an immune response. Furthermore, PEG did not display any adverse effects with 
reference to tissue or organ damage. The polymer has numerous attractive properties such as being non 
toxic and non immunogenic. Furthermore, the polymer is neutral and does not hold an overall charge, 
permitting PEG to be amphiphilic by nature. This renders the polymer soluble in aqueous solutions as 
well as in organic solvents. Lastly, PEG also possesses a chemically inert backbone which does not react 
during chemical activation of the PEG terminus.
Pegylation presents several advantages, and the main advantage is the increase in molecular weight of the 
therapeutic molecule, which significantly improves the blood circulation time and in vivo half life of the 
pegylated molecule and reduces rapid renal clearance. The prolonged in blood circulation suggests a far 
slower absorption rate into the tissues, where saturation of the receptor will also be at the same rate. 
Thus, the pegylated therapeutics cannot quickly and easily diffuse back out of the tissues into the blood 
circulation for excretion. Although pegylation encourages greater blood circulation of the therapeutic 
drug, the modified molecules are not found to be accumulated in large amounts in the reticuloendothelial 
system (RES) organs, now more commonly known as the mononuclear phagocyte system, the liver or the 
spleen. A constructive knock on effect of the enhanced circulatory half life is the increase in potency,
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which clearly improves patience convenience as the frequency of dosing can be reduced, providing 
greater patience flexibility. Shielding and protection of the therapeutic drug is another direct benefit of 
pegylation. For example, the large polymer will mask the therapeutic surface from degrading enzymes 
and protect the drug like molecule from any other interfering substances by means of steric hindrance 
1 91 ,192 (fjgUre 1 7 ^ The excretion of the pegylated molecules is highly dependant upon the total molecular 
weight and PEG is cleared in vivo without any structural change. It has been found that a molecular 
weight below 20 kDa is typically cleared in the urine, whilst larger PEG moieties in excess of 20 kDa are 
removed at a slower rate through the urine and the faeces. Evidence indicates that small PEG oligomers 
of molecular weights of less than 400 Da are susceptible to in vivo degradation by alcohol 
dehydrogenase, to metabolites which are toxic. However, conversely, the toxicity of PEG has in essence 
been diminished with oligomers above the molecular weight of 1000 Da. This has further been reinforced 
by the examples of the FDA approval of the use of PEG in pharmaceuticals, foods and cosmetics193.
Reduces accessibility to 
enzymes responsible for 
degradation and other 
unwanted substances
Aptamer Capped at the 
terminus
Increases size and 
molecular weight 
to reduce rapid 
renal clearance
> PEG
Figure 1.7. The key advantages of pegylated aptam er. An illustration of PEG able to shield the 
vulnerable termini of the aptamer from degradation initiation most importantly increases the size of the 
overall therapeutic drug to limit rapid renal clearance. Adapted from192.
CHAPTER ONE 51
INTRODUCTION
Although there are enormous advantages of conjugating PEG to the desired therapeutic molecule, there 
are a few minor drawbacks with the use of PEG, which need to be taken into consideration. Firstly, as the 
PEG polymer is chemically synthesised by the means of linking ethylene oxide subunits together, there is 
strong likelihood of PEG polymer batch to batch variation occurring as each batch will have different 
number of ethylene oxide subunits 194. This is referred to as polydispersity. Polydispersity will affect the 
pool of pegylated drugs, consisting of varying molecular weights that can lead to assorted biological 
properties with respect to in vivo circulation times. Nonetheless, the extent of polydispersivity is not as 
large due to recent improved synthesis and purifications methods. Elowever, this limitation needs to be 
taken into consideration if low molecular weight drugs are to be conjugated to PEG, as the overall 
molecular weight of the molecule plays a crucial role in its required therapeutic effect. The second issue 
is related to the excretion of the polymer, as typically PEG is cleared from the body either through the 
urine or faeces. However, very high molecular weight polymers, though exact weight threshold is 
unknown, can lead to accumulation in the liver causing macromolecular syndrome. The kidney clearance 
threshold for proteins is approximately 60 kDa, but the exact kidney excretion threshold for PEG cannot 
be determined through an extrapolation from different molecular weight proteins, as this is dependent 
upon a single factor. This important factor is the total molecular weight of the polymer after all the water 
coordination, which drastically increases the volume of the polymer by 3 - 5 times that of a protein of the 
same molecular weight192. This reduces the kidney clearance maximum for polymers and to some extent 
restricts PEG’s normal movement across the glomerular membrane through a ‘snake like’ movement. 
Another potential drawback is the way the therapeutic drug is dressed with PEG. For example, PEG can 
either be conjugated to the drug at single site or at multiple sites and both options have different 
consequences. PEG attached at a single site is most likely to retain the original activity of the active site 
if attachment is carefully chosen, as the effect of steric hindrance and the possibility of the attachment 
occurring at the binding site is reduced. On the other hand if pegylation is to occur at multiple sites on 
the therapeutic molecule, then the chances of steric hindrance and attachment at the binding site is 
increased resulting in a probable reduction or a total loss of bioactivity 192,194.
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Each ethylene oxide monomer, which is used to generate a larger PEG polymer, is represented by a 
whole digit n which has a molecular weight of 44 Da. Therefore the result of n multiplied by the 
molecular weight of ethylene oxide (n x 44 Da) would equate to the average molecular weight of the full 
PEG chain length. The general structure of the polymer is: HO -  (CH2CH20 )n -  CH2CH2 -  OH, with both 
ends terminated with hydroxyl groups and from this structure the PEG polymer can either be linear or 
branched (figure 1.8). A common modification which is often carried out on the general structure of the 
polymer for the purpose of simplifying the functionalisation of PEG is converting one of the hydroxyl 
groups to a methoxy group, generating monomethoxy PEG (mPEG). mPEG has a typical structure of 
CH30  -  (CH2CH20 )n -  CH2CH2 -  OH.
o
(A) h — ^CH2CH2oV^OH d  ch3o— C^H2CH2oj-C NH^ o
/ CH— \(B) CH3O C^H2CH20-j— OH CH30-^ CH2CH20^-C N <
^  CH30 — -^CH2CH20 j - Y / /
X 
\
o
o
CH.O—Ach2CH2o4—C NH o
(E) ' \  / /
v J CH-----
CH30-f-CH2CH20 i — C N fCH2 L  ^)“t t --- N (cX r  || n
o
A = Linear PEG
B & C = Linear mPEG o
D -> F = Branched mPEG CH30 —^ch2ch2o j - c  nh^  o ^
(F) pH--- C----Y
4 XCH30-^ CH2CH20 ^ -C  N—
Figure 1.8. Various linear and branched structures of PEG. (A) Linear PEG, (B) linear 
mPEG, (C) functionalised linear forked mPEG, (D) branched mPEG, (E) functionalised branched mPEG,
(F) functionalised branched forked mPEG. Y = a group carbon branch moiety and X = a linker or a 
functional group for conjugation. Adapted from 193,194.
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This creates a unifunctional polymer with a functional group only on one end, eliminating the potential 
of cross-linking from occurring during conjugation to the therapeutic molecule, hence avoiding formation 
of unwanted by-products. The polydispersity (MW/Mn) of PEG is fairly low, as for PEG chains with a 
molecular weight of less than 5 kDa is ~ 1.01, and for PEG polymers with a molecular weight of greater 
than 50 kDa the polydispersity is ~ 1.1. Independently of the type of PEG chains, linear or branched, 
each ethylene oxide unit present within the PEG chain is capable of binding to 2 -  3 water molecules. 
This increases the overall volume of the polymer and further aids in the action of shielding and masking. 
However, it appears that the branched chain of PEG has a greater gain than the linear PEG, as the 
branched PEG along with increasing the molecular weight can also increase the overall size of the 
molecule without the need to pegylate the therapeutic drug at multiple sites. Furthermore, as the 
branched PEG comes across larger in size than the linear PEG of the same molecular weight, it provides 
the possibility to employ a smaller molecular weight branched PEG than if it was a linear PEG chain
193,195
An mPEG or PEG with hydroxyl groups at both termini does not allow conjugation to take place between 
the polymer and the target molecule directly. It is necessary that the hydroxyl groups either at both ends 
or at one terminus are first activated with a reactive functional group. Functionalisation of the native 
PEG is performed through a relevant chemical modification of the hydroxyl group. The type of chemical 
modification carried out is dependent upon the functional group that is selected on the basis of the 
reactive group present on the therapeutic molecule. There are numerous chemical modifications which 
can be carried out to activate the PEG terminus with electrohphilic functional groups such as active ester, 
active carbonate, aldehyde or tresylate (figure 1.9). These activated functional groups of PEG are able to 
react with specific groups of the therapeutic molecule such as amines, sulphydryl group or other 
nucleophiles for conjugation 195’196.
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Figure 1.9. Functional groups for activated PEG. A) Cyanuric Chloride, B) variation of 
cyanuric chloride, Ci) PEG-succinimidyl succinate, C2) substitution of succinate by glutarate, C3) 
substitution of aliphatic ester in Cj by an amide bond, D) imidazoyl formate, E) and F) variations using 
phenyl carbonates of PEG, G) succinimidyl carbonates of PEG, H) succinimidyl active ester of PEG.
Adapted from 196
1.9.3 PROJECT AIMS
The isoform MUC1/Y has been selected as a tumour biomarker for the development of high affinity and 
specificity aptamers. This isoform has been the most investigated amongst many known MUC1 splice 
variants. Although aptamers have been developed against the MUC1 protein l97, it is expected that 
aptamers against MUC1/Y can be far more promising and advantageous for a number of reasons.
The make up of the MUC1/Y splice variant is far less complicated compared to the MUC1 protein, due 
to the lack of the tandem repeat region, which results in the absence of the carbohydrate structures that
PE G -----
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are characteristically present. This has resulted in the loss of adhesive properties typically present in the 
MUC1, allowing over-expression of MUC1/Y to take place with the ability to invade far more easily into 
the lymph vessels and metastasise to the lymph nodes and other organs, proving to be a more aggressive 
isoform of MUC1. Furthermore, the lack of the tandem repeat region eliminates the possibility of false 
negative results caused by the inconsistent glycosylation pattern and therefore resulting in a variation in 
the exposure of the specific epitope expressed on the MUC1 protein.
An additional structural advantage of MUC1/Y is that this isoform does not undergo proteolytic 
cleavage, hence the protein is not shed from the originating cellular surface. For this reason the 
interacting therapeutic agent, which in this case will be an aptamer, has a greater probability of reaching 
the tumour site. By eliminating the effect of having futile aptamer circulating in the bodily fluids, this 
could provide a better scope for a greater tumour uptake of the aptamer and increases its potential effects 
as a therapeutic agent.
The main aim of the project is to generate aptamers against the MUC1/Y splice variant, with a dual 
motive. The first aim has been to develop a selection method which is a practical bench top process, 
simple with respect to the facilities required and can be completed within a few days as opposed to 
several weeks. The basic SELEX method, which on average consists of 10 rounds of selection, can take 
as long as twenty days to generate the final pool of potentially high binding aptamers. However, the key 
objective here would be to develop a selection protocol which generates high binding and high affinity 
aptamers, and the entire selection can be completed in a single day. To further simplify the process, the 
starting combinatorial library will be consisting of DNA nucleic acid strands as opposed to RNA 
molecules. The rationale behind opting for DNA aptamers is primarily for the reason that DNA strands 
are far more stable than unmodified RNA strands 198. Therefore, the synthesis of the DNA combinatorial 
library is simpler and more cost effective as modifications prior to selection to prevent nuclease 
degradation are not necessary as it would be if RNA aptamers were to be employed.
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An obvious challenge upon selection and identification of the aptamers against the MUC1/Y splice 
variant is the apparent lack of in vivo stability of the unmodified aptamer and its fast renal clearance from 
the system. With the intention of improving the stability of the aptamers and improve its pharmacokinetic 
properties, the attachment of PEG would appear the most suitable approach, as the polymer possesses 
numerous advantages. Other than the functional benefits of PEG, the main advantage of using PEG 
would be that the polymer is not toxic and does not induce an immunogenic response, which coincides 
with the properties of the aptamers. With the aim to pegylate the selected aptamers, functional groups 
that need to be incorporated on the aptamer require careful consideration, so as to be reactive with the 
moieties available on PEG. The conditions which yield the greatest pegylated product need to be defined 
based on the reactive moieties present on the PEG and the aptamer. In addition to the conjugation 
process, it is essential to determine a method to purify the conjugated aptamer from the free aptamer and 
PEG. Also necessary is a bench top detection system that is rapid, simple to use and provides evidence 
for the presence of the conjugated aptamer relatively to the free PEG and aptamer without the need to use 
mass spectrometric analysis. Finally, subsequent to the modification and purification steps, vitally 
important is to establish any potential changes in the affinity of the aptamer for the target through several 
in vitro investigations before these aptamers can be considered further for in vivo studies.
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2.1 M UCl/Y PEPTIDES
The 10 amino acid (lOmer) and 20 amino acid (20mer) MUC1/Y peptide sequences were designed by Dr 
Huma Khan in the aptamer group of the Open University. The lOmer peptide has a sequence of 
TEKNAFNSSL, with a molecular weight of 1110.17. The 20mer peptide has a sequence of 
SVPSSTEKNAFNSSLEDPST, with a molecular weight of 2097. The peptides were supplied HPLC 
purified by the Oligonucleotide and Peptide Synthesis Unit, Queen’s Medical Centre, University of 
Nottingham (Nottingham, UK).
2 .2  SINQLE STRANDED DNA LIBRARY & PRIMERS
Each DNA strand in the single stranded oligonucleotide combinatorial library used in the SELEX method 
was composed of a central 25 nt randomised region flanked by hybridising sequences comprised of 23 
and 24 nt on the 5' and 3' end respectively. The hybridising sequence at the 5' was 
GGGAGACAAGAATAAACGCTCAA and at the 3' TTCGACAGGAGGCTCACAACAGGC. The 
amplification primers are 5'-GGGAGACAAGAATAAACGCTCAA (forward primer) and 3' - 
GCCTGTTGTGAGCCTCCTGTCGAA (reverse primer). The primer sequences were selected based on 
previous research 197. The combinatorial oligonucleotide library and the amplification primers were 
supplied HPLC purified by the Oligonucleotide and Peptide Synthesis Unit, Queen’s Medical Centre, 
University of Nottingham (Nottingham, UK).
2 .3  BIOTINYLATIOR OF MUCl/Y PEPTIDES
The MUCl/Y peptides (lOmer and 20mer) were labelled with biotin-XX using a FluoReporter Biotin- 
XX protein labelling kit. Each peptide (5.1 mg) was dissolved in 0.1 M sodium carbonate pH 8.4 (1 mL). 
A 20 mg/mL (35.2 mM) solution of biotin-XX SE was prepared by dissolving 8.0 mg of biotin-XX SE in 
DMSO (0.4 mL). The reaction was carried out according to the manufacture’s protocol with the 
exception of using a 1 : 2  molar ratio instead of the recommended 1 : 1 0  molar ratio of peptide to biotin. 
260.93 pi and 130.83 pi of the biotin-XX SE solution was added to the lOmer and 20mer peptide 
solution respectively. The mixtures were stirred at ambient temperatures for 2 hours. The reaction
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mixtures were loaded on a PD-10 desalting column, using PBS (pH 7.2) as the eluant. The first 3 mLs of 
flow through were collected in 1 mL fractions and analysed by UV-Vis spectroscopy at an absorbance 
wavelength of 256 -  258 nm. The fractions were further purified by Reverse Phase HPLC (RP-HPLC) 
on a Waters 616 Millennium 32 system using a Waters Symmetry™ Qg column (4.6 x 250 mm). The 
absorbance was recorded on a Waters 996 Photodiode Array UV-Vis detector at the wavelength of 215 
nm. The solvent gradient at a flow rate of 1 mL/ min was O': A = 85% / B = 15%, 5': A = 75% / B = 
25%, 25': A = 35% / B = 65%, 25.01': B = 100%, 30': B = 100%, 30.01': A = 85% / B = 15%, where A 
= 0.1% trifluoroacetic acid (TFA) in 2% acetonitrile (ACN), B = 0.1% TFA in 90% ACN.
Materials: FluoReporter® Biotin-XX protein labelling kit was purchased from Invitrogen Molecular 
Probes (Paisley, UK). PD-10 desalting columns were purchased from GE Healthcare (Chalfont St Giles, 
UK). Acetonitrile and trifluoroacetic acid (TFA) (HPLC grade) were purchased from Fisher Scientific 
UK (Loughborough, UK). Dimethyl sulfoxide (DMSO) (molecular biology grade) was purchased from 
Sigma-Aldrich (Dorset, UK).
2 A  PGR AMPLIFICATION OF THE SELEX LIBRARY
The PCR reaction was performed in a thin walled PCR tube as previously described 197. The PCR 
amplification mixture was composed of 1015 ssDNA 72 mer SELEX library (10 pM), 5' forward primer 
(250 pM), 3' reverse primer (10 pM), 0.1 pl/pl of lOx PCR buffer containing MgCl2  (40pl in 400pl final 
volume), 10 mM of dNTP mixture containing 25 mM of dATP, dCTP, dTTP, dGTP), MgCl2 (0.675 
mM), and Taq DNA polymerase (3 pi 5U/pl).
The following PCR cycle programme involves a total of 100 cycles. Each PCR cycle consisted of: • 
initial denaturation step (95°C, 10 min) • addition of first 1.5 pi Taq DNA polymerase • second 
denaturation step (95°C, 1.5 min) • annealing step (56°C, 0.5 min) • extension step (72°C, 1.5 min). • 
upon completion of the first 50 cycles, further 1.5 pi Taq DNA polymerase was added and a further 50 
cycles were performed. • final extension step (72°C, 10 min). The final reaction solutions were stored at 
4°C until used for selection.
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Materials: For combinatorial library and amplification primer refer to section 2.2. 0.2 mL thin walled 
PCR tubes and magnesium chloride hexahydrate were purchased from Fisher Scientific UK 
(Loughborough, UK). PCR lOx buffer and Taq DNA polymerase were purchased from Sigma-Aldrich 
(Dorset, UK). dNTP’s were obtained from Promega (Hampshire, UK).
2 .5  DOUBLE STRANDED DMA PCR
To perform the double stranded PCR amplification of the ssDNA obtained from selection, a reaction 
mixture of the following composition was used: 50 pi of DNA from selection, 5’ forward primer (1 pM), 
3’ reverse primer (1 pM), lOx PCR buffer containing MgCl2 (0.1 pl/pl), dNTP mixture (0.5 mM), MgCl2  
(0.69 mM), and Taq DNA polymerase (1 pi 5U/pl).
The following PCR cycle programme involves a total of 50 cycles. Each PCR cycle consisted of: • initial 
denaturation step (95°C, 10 min) • addition of 1 pi Taq DNA polymerase • second denaturation step 
(95°C, 1.5 min) • annealing step (56°C, 0.5 min) • extension step (72°C, 1.5 min). • final extension step 
(72°C, 10 min). The final reaction solutions were stored at 4°C until further use. Refer to section 2.4 for 
materials.
2 .6  IMMOBILISATION OF M UCl/Y PEPTIDES ON STREPTAVlDIH COATED TUBES
The biotinylated MUCl/Y peptides (lOmer and 20mer) were immobilised onto the streptavidin coated 
tubes according to the manufacture’s protocol. The biotinylated peptide solutions containing ca 30ng of 
either lOmer or 20mer peptide in PBS, pH 7.2 (300 pi) to give a final concentration of 65.54 nM and 
41.29 nM respectively, were added to the streptavidin coated tubes. The solutions were incubated for 3 
minutes at 37°C and removed after incubation. The tubes were washed with 300 pi binding solution and 
blot dried five times. The tubes were stored in binding solution at 4°C until used for selection.
Materials: Streptavidin coated PCR tubes were purchased from Roche Applied Science (Burgess Hill, 
UK).
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2 . 7  i n  Vit r o  s e l e c t i o n  u s in g  s a l t  g r a d i e n t  e l u t i o n  t e c h n i q u e
The amplified single stranded DNA library (130 pi) was added to the tubes containing previously 
immobilised lOmer or 20mer peptides. After incubation at ambient temperature for an hour under gentle 
shaking, any excess library solution was removed and the tube was washed with binding solution (300 
pi). A gradient elution of the bound aptamers was performed by washing the tube with NaCl solutions 
(50 pi) of increasing concentration starting from 0.2 M to 1.5 M elution solution using 0.1 M increments 
and incubating with gentle mixing for 1 minute. Each 50 pi washing obtained from the different 
concentration steps were desalted using microcons (3 kDa MWCO). The desalted 1.3 M, 1.4 M, and 1.5 
M fractions were amplified as described in section 2.5 and analysed by 2 % agarose gel electrophoresis 
where the presence of aptamers was detected at 75 bp. Aptamers present in these fractions were selected 
for cloning.
1.5 M elution solution, pH 7.2: 1.5 M NaCl, 20 mM KC1, 5 mM MgCl2. The pH was adjusted with 0.01 
M NaOH. The incremental molarity of the elution solution is solely based on the concentration of NaCl. 
The concentrations of KC1 and MgCl2 remain constant throughout all the elution solutions. The elution 
solution was prepared as previously described in literature 191, with the addition of KC1.
Materials: Sodium chloride (laboratory grade), magnesium chloride hexahydrate, and microcons (3kDa, 
lOkDa, 30kDa MWCO) were purchased from Fisher Scientific UK (Loughborough, UK). Potassium 
chloride and sodium hydroxide pellets were purchased from Sigma-Aldrich (Dorset, UK).
2 .6  IN P?7iK? SELECTION USINS TEMPERATURE GRADIENT ELUTION TECHNIQUE
The incubation of the library to the immobilised peptides was performed as described in section 2.7. 
After incubation, any excess library solution was removed and the tube was washed with binding 
solution (300 pi). The aptamers were eluted with successive washings using sterile water (50 pi) at 
increasing temperatures from 25 °C to 95 °C, increasing by 5°C increments with gentle mixing for 2 
minutes for each step. The washings obtained from the 85°C, 90°C and 95°C were amplified as described
CHAPTER TtfO 62
MATERIALS AND METHODS 
in section 2.5 and were analysed by 2 % agarose gel electrophoresis where the presence of aptamers was 
detected at 75 bp. Aptamers present in these fractions were selected for cloning.
2 3  AO AROSE GEL ELECTROPHORESIS
The 2% (w/v) agarose gel was prepared by adding 2g of agarose to lx  TBE (100 mL) solution. The 
solution also contained the DNA stain ethidium bromide (5 pi of 10 mg/ mL solution). The samples (10 
pi) containing 6 x loading dye (2 pi) were loaded into gel wells for analysis. A 25bp or lOObp DNA step 
ladder (5 pi) containing 6 x loading dye (2 pi) was loaded into a separate gel well for comparing band 
size present in the samples. The electrophoresis was performed at 100 V in lx  TBE running buffer. The 
gel was imaged on the Kodak digital image station 440CF.
lx  TBE (Tris-Borate EDTA): Trizma base (5.4 g), boric acid (2.74 g) and EDTA (0.46 g) were 
dissolved in UHP water (500 mL).
Materials: Agarose was purchased from Fisher Scientific UK (Loughborough, UK). Boric acid, trizma® 
base, ethylenediaminetetraacetic acid (EDTA) and ethidium bromide were purchased from Sigma- 
Aldrich (Dorset, UK). 25bp DNA step ladder, lOObp DNA step ladder, and 6 x loading dye were 
purchased from Promega (Hampshire, UK).
2 .10  CLONING AND SEQUENCING
The pool of aptamers amplified from sections 2.7 and 2.8 were cloned into TOPO vectors, using the 
TOPO TA cloning kit, according to the manufacture’s protocol. Each transformation mix (10 pi and 50 
pi) was spread onto the LB agar plates and left to incubate at 37°C overnight. The colonies from each 
fraction were PCR amplified as described in section 2.11 and analysed by 2 % agarose gel 
electrophoresis. The presence of aptamers was detected at 275 bp. The positive clones were sent for 
sequencing to Macrogen, Korea.
Luria Bertani (LB) Agar plates: The LB medium contained tryptone (5g), yeast extract (2.5 g), NaCl 
(2.5 g), Agar (7.5 g) and UHP water (500 mL). The solution was autoclaved and once cooled to ca 50°C,
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500 (0.1 of ampicillin (50 mg/mL) was added to the medium which was immediately poured into the 
plates. The prepared LB agar plates were stored at 4°C until further use.
Materials: TOPO TA cloning® kit was acquired from Invitrogen molecular probes (Paisley, UK). 
Tryptone, yeast extract, agar, and ampicillin were purchased from Sigma-Aldrich (Dorset, UK). Sodium 
chloride (laboratory grade) was purchased from Fisher Scientific UK (Loughborough, UK). Petri dishes 
(100mm x 15mm) were purchased from PAA Laboratories (Somerset, UK).
2 .11  PCR OF POSITIVE CLONES
Each clone was added to a PCR mixture with the following composition of M l3 forward primer (0.25 
pM), M13 reverse primer (0.25 pM), lOx PCR (0.1 pi/pi) buffer containing MgCl2, dNTP mixture (0.5 
mM), MgCl2 (0.69 mM), sterile water (15.98 pi) and Taq DNA polymerase (1 pi 5U/pl).
The following PCR cycle programme involves a total of 50 cycles. Each PCR cycle consisted of: • initial 
denaturation step (95°C, 10 min) • addition of 0.2 pi Taq DNA polymerase • second denaturation step 
(95°C, 1.5 min) • annealing step (56°C, 0.5 min) • extension step (72°C, 1.5 min). • final extension step 
(72°C, 10 min). The final reaction solutions were stored at 4°C until further use.
Materials: Forward and reverse M l3 primers purchased from Invitrogen life technologies (London, 
UK). For other materials refer to section 2.4.
2 .12  PEQYLATION OF APTAMERS
Linear 32 kDa m-PEG (8.464 mg, 259.49 nmol) dissolved in 170 pi of dimethylformamide (DMF) was 
added in 1 mg portions every 20 minutes to a solution of 3' C6 amino modified aptamer (12 pi, 6  nmol) in 
30 pi of sodium carbonate pH 10. The reaction was performed at 60°C under gentle shaking. After the 
addition of the final 1 mg portion of PEG, the mixture was mixed for a further 1 h at 60°C. The mixture 
was lyophilised using speed vacuum GenevacSF50. The solid residue was reconstituted in 170 p.1 of 
sterile water for purification by anionic exchange HPLC on a Waters 616 Millennium 32 system, using a
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Mono Q® HR 5/5 1 mL column (10 jum). The absorbance was recorded on a Waters 996 Photodiode 
Array UV-Vis detector at the wavelength of 260 nm. The elution gradient at a flow rate of 1 mL/ min 
was O': A = 40% / B = 60%, 20': A = 80% / B = 20%, 21': A  = 100%, 25': A = 100%, 26': A = 40% / B 
= 60%, 39': A = 40% / B = 60%, where A = 1.8 M ammonium formate pH 8, B = Water. The purified 
conjugated aptamer was lyophilised and analysed by 2% agarose gel electrophoresis.
53.4 mM Sodium carbonate, pH 10: Na2CC>3 (0.566 g), NaHC03 (0.391 g) in a final volume of 100 mL 
UHP water and filtered using stericup filter units.
1.8 M Ammonium formate, pH 8: Formic acid (135.86 mL) in a final volume of UHP water (2 L). pH 
adjusted with concentrated ammonia and filtered using Empore Cig disk.
Materials: NHS-modified 32kDa polyethylene glycol was purchased from NOF Corporation (Tokyo, 
Japan). 3’ C6 amino modified 25 nt and 3’ C6 amino modified- 5’ Cy3 labelled 25 nt oligonucleotides 
were purchased from Integrated DNA Technologies (Budapest, Hungary). Mono Q HR anionic exchange 
column was purchased from GE Healthcare (Chalfont St Giles, UK). TV,TV, Dimethylformamide (DMF) 
(molecular biology grade) and empore Cjg 47 mm disks were purchased from Sigma-Aldrich (Dorset, 
UK). Sodium carbonate, sodium hydrogen carbonate, formic acid (98%), and 35% ammonia solution 
were purchased from Fisher Scientific UK (Loughborough, UK). Stericup Filter Units were acquired 
from Millipore (Durham, UK).
2 .13  NATIVE POLYACRYLAMIDE SEL ELECTROPHORESIS
To prepare polyacrylamide gels using 29:1 acrylamide : bisacrylamide, the volume of acrylamide 
required in the mixture was determined by the formula: % needed / % acryl:biacryl (30%) * final volume 
(mL). An 18 % native PAGE was used to analyse aptamer samples. A 10 mL solution contained 30% 
acrylamide (6 mL), 5x TBE (2 mL), UHP water (1.87 mL), 10% (w/v) ammonium persulfate (110 pi) 
(APS) and TEMED (20 pi). The APS and TEMED solutions were added to the mixture immediately 
prior to pouring the gel solution for gel formation. The samples (10 pi) containing 6x loading dye (2 pi) 
were loaded into gel wells for analysis. A 25bp or lOObp DNA step ladder (5 pi) containing 6x loading
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dye (2 pi) was loaded into a separate gel well for comparing band size present in the samples. The 
electrophoresis was performed at 100 V in lx TBE running buffer. The gels were post stained in 100 mL 
of lx TBE containing the DNA stain ethidium bromide (10 pi oflO mg/ mL solution) for 10 minutes. The 
gel was imaged on the Kodak digital image station 440CF.
TBE (Tris-Borate EDTA) (5x): Trizma base (13.5g), boric acid (6.86g) and EDTA (1.16g) were 
dissolved in UHP water (250 mL).
Materials: acrylamide / bisacrylamide 30% solution, etramethylethylenediamine (TEMED),
and ammonium persulfate (APS) were purchased from Sigma-Aldrich (Dorset, UK). For other materials 
refer to section 2.9.
2 .14  BARIUM CHLORIDE-IODINE STAIN FOR QELS TO VISUALISE PES
In order to visualise either free or conjugated PEG, either the agarose or the native polyacrylamide gels 
were post stained in 0.1 mol/L barium chloride solution (100 mL) for 20 minutes at ambient temperature 
with gentle shaking, followed by the gradual addition of 0.05 mol L'1 iodine aqueous solution (10 mL). 
The gels were further soaked in the barium chloride-iodine solution with gentle shaking until brown 
stained bands of PEG were visibly observed.
Materials: 0.1 mol/L barium chloride solution and 0.05 mol L'1 iodine aqueous solution were purchased 
from Sigma-Aldrich (Dorset, UK).
2.15 APTAMER AFFIMIlY CHROMATOGRAPHY
The MUCl/Y peptides, lOmer (10.76 pmol) and 20mer (10.04 pmol) were individually immobilised to 
the NHS-activated 1 mL HiTrap sepharose columns according to the manufacturer’s instructions. 
Depending on the aptamer, the concentrations of the solutions to analyse were in the range of 1.17 pM -  
4.27 pM having an optical density of 1.0. Each 1 mL aptamer in binding solution was added to the 
column and incubated for 1 h at ambient temperature. The column was then eluted with the elution 
solutions (1 mL) of increasing NaCl concentrations ranging from 0.2 M -  1.6 M, at 0.2 M increments.
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The column was finally washed with a 3 M sodium thiocyanate solution (1 mL x 3), followed by binding 
solution (1 mL x 3), to regenerate the column. Each eluted fraction was analysed by UV-Vis 
spectroscopy measuring the absorbance at 260 nm on a UVkon XL spectrophotometer (Bio-Tek 
instruments).
Binding solution, pH 7.2: 100 mM NaCl, 20 mM KC1, 5 mM MgCl2. The pH adjusted with 0.01 M 
NaOH.
Materials: Unmodified 72 nt oligonucleotides were purchased from MWG (Ebersberg, Germany). 
Unmodified 25 nt oligonucleotides were purchased from Integrated DNA Technologies (Budapest, 
Hungary). HiTrap NHS-activated affinity column was purchased from GE Healthcare (Chalfont St Giles, 
UK). Sodium thiocyanate and potassium chloride was purchased from Sigma-Aldrich (Dorset, UK). 
Sodium chloride (laboratory grade) and magnesium chloride hexahydrate were purchased from Fisher 
Scientific UK (Loughborough, UK).
£.16 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
Each aptamer was incubated with the lOmer and the 20mer peptides in a 1:1000 ratio. Aptamer (2 pM) 
and either lOmer or 20mer peptide (2000 pM) was incubated in binding solution. The incubation was 
performed with two different conditions: 1) For 1 h at ambient temperature under gentle shaking 2) at 
95°C for the first 5 minutes and then for 1 h at ambient temperature under gentle shaking. After 
incubation, the samples were analysed by native PAGE at ambient temperature at 100V in lx  TBE 
running buffer. 1 4 - 1 6 % ,  18% and 7 % native polyacrylamide gels were used for resolving 75nt, 25nt 
and pegylated 25nt long aptamers respectively. The bands were visualised as described in sections 2.13 
and 2.14. For materials refer to sections 2.13 and 2.15.
2.17 APTAMER THERMAL DENATURATION & RENATURATION
A mixture composed of the aptamer (0.180 pM), and either the lOmer or 20mer peptide (180 pM) in a 1: 
1000 ratio aptamer to peptide in binding solution was incubated for 1 h at ambient temperature.
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Subsequently, the lOx SYBR green I nucleic acid gel stain (2.5 pi) was added to the reaction mixture 
which was kept on ice (4°C) for 30 minutes. The aptamer-peptide mixture was heated from 3°C to 100°C 
at a 1°C/ min rate (denaturation step), followed by a cooling down process from 100°C to 3°C at a 1°C/ 
min rate (renaturation step). The fluorescence emission was recorded every minute during the 
denaturation step and every 10°C increments from 80°C to 10°C and thereafter, at 5°C and 3°C. The 
denaturation-renaturation cycles were made in triplicates and ran on a DNA Engine Opticon 2 Real Time 
PCR (MJ Research) at 520 nm using excitation at 497nm. Final analysis of the data was carried out using 
the software Origin 6.0.
Materials: SYBR green I nucleic acid gel stain was purchased from Sigma-Aldrich (Dorset, UK).
2.1$ CELL CULTURE
MCF-7, DU145, CALU-6 and A498 cells were grown at 37°C and 5% CO2 in minimal essential medium 
eagle (MEM) cell culture medium supplemented with 10% foetal bovine serum and 1% L-glutamine.
Materials: DU145 (human prostate carcinoma), MCF-7 (human mammary gland carcinoma), Calu-6 
(human lung carcinoma) and A498 (human kidney carcinoma) cell lines were provided by Antisoma 
Research Limited (Hertfordshire, UK). Trypsin EDTA, minimal essential medium eagle (MEM), L- 
Glutamine, foetal bovine serum and cell culture flasks (75 cm2, surface treated with filter cap) were 
purchased from PAA Laboratories (Somerset, UK). Hanks balanced salt solution was obtained from 
Sigma-Aldrich (Dorset, UK).
2.19 FLUORESCENCE ACTIVATED CELL SORTING (FACs)
Cy3 fluorescently labelled aptamers (2 pM) were incubated with MCF-7, DU 145, CALU-6 and A498 
(400,000 cells) in 200 pi of PBS at 37°C for 1 h. Upon incubation, the cells were washed with PBS (400 
pi x3) and resuspended in PBS (400 pi). The analysis was performed on FACSCalibur, Becton 
Dickinson flow cytometer with a maximum sort rate of 10,000 total cells / second.
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Materials: 5’ Cy3 labelled 25 nt oligonucleotides were purchased from Integrated DNA Technologies 
(Budapest, Hungary).PBS tablets were purchased from Sigma-Aldrich (Dorset, UK). 5 mL FACs 
polystyrene tubes (12 mm x 75 mm) were purchased from Greiner Bio-One LTD (Stonehouse, UK). For 
other materials refer to section 2.18.
2.20 FLUORESCENCE MICROSCOPY
MCF-7, DU145, CALU-6 and A498 cells (50,000 cells) were plated in duplicates on round glass inserts, 
placed inside each well of a 24 well cell culture plate and grown overnight. The adhered cells were 
washed with PBS (100 pi), followed by incubation with aptamer (0.5 pM, 150 pmol) in serum free MEM 
(300 pi) per well for 15 min, lh  and 3 h at 37°C. Subsequently, the cells were washed with PBS (200 pi 
x3), followed by the addition of 4% paraformaldehyde (PFA) (200 pi) and incubated for 15 min at 
ambient temperature. The cells were then washed with PBS (200 pi x2), treated with 0.1 % triton (200 
pi) for 10 min at ambient temperature, followed by a PBS wash (200 pi x2). The cells were then 
incubated with Hoechst 33258 (75 pi of 1 mg / mL) for 15 min at ambient temperature, followed by a 
PBS wash (200 pi x3). The glass inserts were mounted on to glass microscope slides using CFPVOH 
poly vinyl alcohol and AF100 anti-fadent (10:1 ratio). The slides were visualised under a BX61 
motorised Olympus DP72 fluorescence microscope digital camera, using Cy3 and DAPI filter with 40x 
magnification. The images were analysed using the ImageJ software.
Materials: 24 well tissue culture plate, flat bottom were purchased from PAA Laboratories (Somerset, 
UK). Round glass coverslips (12 mm) and glass microscope slides (76 mm x 26 mm) were purchased 
from Fisher Scientific UK (Loughborough, UK). Paraformaldehyde (PFA), triton xlOO, and 
bisBenzimide H33258 were purchased from Promega (Hampshire, UK). CFPVOH (Poly vinyl alcohol) 
and AF100 (Antifadent) were purchased from Citifluor LTD (London,UK).
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3.0 INTRODUCTION
Since the development of the systematic evolution of ligands by exponential enrichment (SELEX) 
process, numerous aptamers have been generated against various different selected targets. Typically the 
conventional method of SELEX employs the use of affinity chromatography columns and magnetic 
beads for the immobilisation of the target or nitrocellulose membrane for ultrafiltration. Successive 
purification steps are performed of the nucleic acid based combinatorial library against the selected 
target. However, as the demand for aptamers is rising in the area of molecular recognition, diagnostics 
and therapeutics, prerequisites of improving the standard selection technology has become essential. 
Many researchers have developed new alternative methods which are based on the core principles of 
SELEX for the discovery of aptamers possessing high affinity and specificity for their target. Moreover, 
the new established selection techniques aim to offer a much faster, less laborious, low reagent 
consuming, and hence cost effective systems.
8.1 NGN^ONVENTIONAL SELECTION METHODS
New variations to the classical SELEX system have been approached by various researchers to overcome 
many of the existing issues such as the laborious and time consuming process, along with utilisation of 
large reagents quantities, thus increasing the costs of the entire process.
A new one-step selection method, MonoLex has been applied to generate high affinity binding DNA 
aptamers to a Vaccinia virus, which was employed as model organism representative of complex targets. 
The MonoLex system was developed to eliminate repetition of the successive rounds of selection and 
minimize the process to a single affinity chromatography with a final amplification step. The selection 
entails a combinatorial library consisting of oligonucleotides 64 bases long of which, the central 
randomised region is comprised of 20 nucleotides. Primarily the combinatorial library was subjected to 
the affinity capillary column that was coupled to virus free cell culture supemant, preventing any non­
specific binding. Subsequent to the negative selection, the unbound library was applied to the affinity 
column per-coupled to the heat inactivated virus particles. The low binding oligonucleotides were
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removed by repeated buffer washes, preparing the column to be sliced into many segments. The target 
bound oligonucleotides captured within each segment were released by denaturation of the target, 
followed by quantitative real-time PCR amplification. Results showed that in each segment more than 
one species of aptamers were present, hence, the amplified mixture was referred to as “polyclonal” 
aptamers. Although the cloned and sequenced aptamer pool of interest showed no sequence homology, in 
vitro binding studies demonstrated the aptamers obtained from the selection having great affinity and 
specificity for the target virus. The binding of the target to the aptamer could be monitored and detected 
at extremely low concentrations of target and aptamer, 109 particles/ mL and lOpM respectively. The 
studies also provided evidence of aptamer specificity, with the aptamer binding only to the virus particles 
and not to the control particles of a similar size. This result was also consistent, as non-specific binding 
was not detected even when repeated with higher aptamer concentrations. In further investigations 
involving three different cell types, the biological activity was inhibited and spread of infection was 
prevented at an aptamer concentration of 2.5pM.
The MonoLex system has demonstrated that aptamers possessing high affinity and specificity can be 
successfully generated against a virus, which is a realistic representative of a complex target model. An 
additional benefit this system brings is that competition between oligonucleotides of similar or differing 
affinities during the PCR amplification step is dramatically reduced, thus, significantly improving the 
identification of high binding aptamers for the chosen target199.
The cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) is a method used 
to generate aptamers capable of identifying cell surface biomarkers present on whole living cells. The 
key advantage cell-SELEX compared to many other selection methods is that details of the biomarker 
does not need to be known prior to selection and multiple aptamers can be generated against different 
cell surface biomarkers simultaneously. The oligonucleotide library employed in this selection 
incorporated a central random region of 45 nucleotides flanked by 20 bases long primer region. The PCR 
amplification primers were modified, where the 5’ primer was labelled with a fluorescent tag, fluorescein 
isothiocyanate (FITC), and the 3’ primer was triple biotinylated. A double stranded (ds) PCR
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amplification was performed on the combinatorial library and incubated with streptavidin coated beads. 
Succeeding this, the dsDNA molecules were denatured and the FITC labelled single stranded 
oligonucleotides were separated from the biotinylated ssDNA strands. The fluorescent labelled ssDNA 
pool was incubated with whole cells, followed by the removal of majority of the library representing the 
non-binding selection. The bound aptamers were eluted by thermal denaturation and amplified by double 
stranded PCR. The dsDNA was separated to ssDNA as mentioned above for the next round of selection. 
However, between each selection round, flow activated cell sorting (FACs) was performed to ensure the 
enriched library of oligonucleotides is gradually showing greater binding and specificity compared to the 
starting combinatorial library. Throughout the successive rounds of selection, stringency of the process 
was progressively improved by extending the wash time, increasing the wash volume as well as the total 
number of washes. Aptamers at the final 23rd round of selection were sequenced and those which 
revealed sequence homology were taken further for investigation. The results demonstrated that with 
each enriching round of selection, the binding affinity of the evolving aptamers increased. This was 
suggested by the amplified fluorescence intensity observed during flow cytometric analysis, which 
differed from that observed in the control cell line (CCRF-CEM). The selected aptamers possessed 
binding affinities ranging from nanomolar to the picomolar Kd values. However, also present in the final 
panel of aptamers, were a minority of sequences which displayed greater interaction with the CCRF- 
CEM cells compared to the positive cell line (Ramos). This proposed the likelihood of greater expression 
of a particular target present on the CCRF-CEM cells than on the Ramos cells. Thus, increasing the 
stringency of the wash steps during the selection rounds assisted in achieving aptamer interaction with 
biomarkers expressed at low levels. The selected aptamers also displayed target specific binding in real 
human biological samples (bone marrow mixture) and were able to distinguish between normal and 
diseased cells. This selection system did not entail a counter selection, as the aim was to generate 
aptamers against as many different receptors as possible on the surface of target cells and is an efficient 
starting point to discovering biomarkers existing on the surface of diseased cells 200.
Prior to the cell-SELEX described above, Weihong Tan’s group had also performed a cell-SELEX 
method, which had incorporated a counter selection within the protocol. However, in this selection, the
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target cell line was exchanged with the control cell line and vice versa. Thus, the targets cells were the 
CCRF-CEM cells and the control cells were the Ramos cells. The protocol followed steps as described 
above with the exception that upon incubation of the library with the CCRF-CEM cells, the bound 
sequences were eluted and subjected to 5-fold excess of Ramos cells. The unbound aptamers to the 
negative cell line were amplified for another round of selection. A total of 20 rounds of selection were 
performed in this method and the enriching library was monitored by flow cytometry at the end of each 
round of selection. The counter selection aided in reducing the number of aptamer sequences that bound 
to the Ramos cells. Thus, the Ramos displayed no sizeable shift in the fluorescence intensity, though the 
fluorescence intensity increased with each progressive round of selection with the CCRF-CEM cells. 
This resulted in a pool of DNA molecules possessing high specificity for receptors expressed on the cells 
surface 142. A similar selection was also demonstrated by Blank et a l143, performing SELEX employing a 
counter selection and screening each successive pool by FACs analysis. The incorporation of flow 
cytometric analysis in the SELEX process has allowed each pool of DNA molecules obtained at the end 
of each round of selection to be analysed, providing a clear indication of the potential interaction which 
may be taking place between the aptamer and the target. Furthermore, the benefit of employing flow 
cytometry is that as the binding affinity and specificity of the aptamers for their targets increases, this is 
effectively demonstrated by the increase in the fluorescence intensity. Hence, the changes in the 
fluorescence intensity are an accurate display of evaluating at each round of selection if further rounds of 
selection are necessarily required.
In most of the well known traditional SELEX protocols, a combinatorial library typically consists of 
primer hybridising sequences flanking either side of the unknown random domain. By and large the 
primer sequences comprise fifty percent if not more of the library sequences. Hence, it has often been 
suggested that primer sequences have the potential to interfere in the binding of the unknown region with 
the target. Typically, the final pool of aptamer sequences can consist of a section of the primer sequence 
which is either involved in base pairing with the random region to adopt secondary structures or is 
involved in the selected binding sequences. This form of involvement of the primer sequences can lead to 
non-specific binding and can produce false positive binding sequences with relevance to the unknown
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random region. Therefore, to eliminate the compromise on the binding potential of the randomised region 
to the target alone, two novel selection methods have been devised. One method entails a combinatorial 
library consisting of minimal primers (MP) flanking the central unknown domain and the second method 
involves a primer free (PF) library of oligonucleotides. The initial library for both protocols is double 
stranded by PCR with primer sequences flanking the central variable region of 27 nt long for the MP 
library and 30 nt for the PF library. The MP library contains an endonuclease site at the 5' end for an 
enzymatic cleavage to take place, where the enzyme is capable of recognising the dsDNA but will only 
cleave one strand. An endonuclease restriction site is also present at the 3' end to ensure cleavage of the 
dsDNA substrate. The cleavage at the 5' and 3' regions leaves adjoined 2 nt (dock sites) of the primer 
sequences at either sides of the unknown random region, resulting in a ssDNA library of 31 nt long. The 
cleaved library was gel purified and subjected to melanoma cells for selection. The dock sites of the 
bound sequences were hybridised with their respective 5' and 3' end bridge pair sequences and ligated to 
regenerate the primer regions, which were previously removed through enzymatic cleavage. The ligated 
products were amplified by PCR and this entire process was repeated for each additional round of 
selection. The second protocol involving the PF library contains an endonuclease site at both the 5’ and 
the 3' end, where the endonuclease can recognise the dsDNA but will only cleave one strand. This primer 
free approach explores two different sequence based libraries: in one library, the cleavage takes place at 
the 3’ end leaving adjoined 2 nt (dock sites) of the primer sequence to the unknown random region, 
resulting in a ssDNA library of 32 nt long. The second library only contains the 30 nt unknown random 
regions only, as both primers from the 5' and 3' end had been enzymatically cleaved. Both libraries were 
subjected to selection and as with the MP library method, the bound aptamers were obtained for 
regenerating primer regions through a hybridisation and ligation processes. The ligated products were 
amplified by PCR and these processes were repeated for each additional round of selection201.
This SELEX system, which employs either the minimal primer or primer free library, also includes 
additional steps such as enzymatic cleavage of primer, primer regeneration and purifying the amplified 
library via polyacrylamide gel electrophoresis, which are lacking in a typical SELEX method.
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Nonetheless, this method provides a different approach for incorporating primers for sequence 
amplification without their interference in the binding of the unknown random sequences to the target. 
An additional benefit of this system is that the necessissity to reduce the total length of the aptamer 
sequence is eliminated, whereas truncation would be essential if a typical library containing full primer 
sequences was employed.
Aptamer selection has also been performed using capillary electrophoresis (CE) integrating the classical 
principles of SELEX. In the CE-SELEX method, the binding sequences are separated from the non­
binders via electrophoresis. This method allows incubation of the target with the combinatorial nucleic 
acid library to take place in free solution, removing the prerequisites of stationary supports. The 
incubated mixture is then separated under high voltage through a capillary, whereby the non-binders 
travel through the capillary at the same mobility, in spite of their sequence or length. However, the 
binding sequences bring about a mobility shift as, upon binding to the target, a change in the size and 
charge occurs. Based on this mobility shift, the binding sequences are collected for PCR amplification to 
be taken into further rounds of selection. This technique has been demonstrated by successfully obtaining 
aptamers against the human IgE with nanomolar affinity. To obtain the IgE aptamers, a library which 
contained sequences composed of two primer regions of 20 nt flanking a 40 nt unknown random region 
was incubated with the target at room temperature for 30 minutes. The incubated samples were injected 
onto the capillary with a current applied of ~ 70 pA during separation, maintaining the capillary column 
temperature at 25°C during electrophoresis. The unbound and bound sequences flowing through the 
column were monitored by UV detection at 254 nm. The non-binding DNA sequences, which are 
negatively charged, migrate swiftly through the capillary in CE buffer, pH 8.0, as a single band. 
However, the migration of the bound DNA sequences is decelerated due to the complex formation with 
the IgE, which is a large molecule and is slightly positive in the CE buffer. The CE fractions of the bound 
sequences were PCR amplified for further rounds of selection. A total of four rounds of selection were 
performed before the sequences were cloned. The nanomolar affinity of the sequences obtained 
compared to the aptamer sequences obtained for IgE using the conventional SELEX method consisting 
typically of 8-15 rounds of selection. CE-SELEX can be completed in as short as 2 days. However, this
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method has a limitation, whereby the system is not applicable for all types of target molecules. For 
example, aptamers can only be generated in the CE-SELEX method against target molecules with a 
minimum size of ~ 4 kDa, as the target needs to be relatively large to cause a mobility shift upon binding 
to the DNA molecules 202’203.
Another selection process adapted from the CE-SELEX method is known as the non-equilibrium 
capillary electrophoresis of equilibrium mixtures (NECEEM). NECEEM is referred to as a non-SELEX 
selection method for generating aptamers against a known target, as this process only involves the 
partitioning steps and eliminates the necessity to amplify between each round of selection. It has been 
observed that only three partitioning steps were necessary with the NECEEM system to enhance the 
affinity of the DNA library for the target by beyond 4 orders of magnitude. The entire selection process 
takes 1 hour to complete, which typically entailed incubating the library with the target in free solution 
and upon incubation the mixture is injected into the capillary. Upon injection, voltage is applied to 
separate the bound sequences from the unbound as in the CE-SELEX system. However, the order of 
separation differs with the NECEEM, as the system is set up to allow separation to take place in the 
following order, eluting firstly with: (1) unbound free target, (2) bound target dissociated from the 
complex, (3) undissociated DNA-target complex, (4) DNA dissociated from the complex and finally (5) 
unbound free DNA. The NECEEM system was demonstrated by employing h-RAS protein as a target 
with a molecular weight of 21 kDa. The DNA library which was incubated with the h-Ras protein 
consisted of a random region of 39 nt flanked by two primer regions of 19 and 22 nt long and with the 5' 
end of the DNA sequences fluorescently labelled. The incubated mixture containing the protein and the 
library was injected into the capillary and electrophoresis was performed applying an electric field of 600 
V/cm in a buffer at pH 8.0. The eluting fractions containing the DNA sequences were detected by 
fluorescence at 520 nm and the protein was detected by UV at 280 nm. The fraction containing the 
target-DNA complex was further incubated with additional protein and subjected to another CE 
separation as in the first round. This process was repeated for a total of three rounds of partitioning, 
followed by separation of the aptamers from the complexes for a final PCR amplification and cloning.
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The aptamers obtained via the NECEEM method had affinities of 0.3 pM which were comparable to 
aptamers that were obtained from the classical SELEX method of 0.6 pM 204’205.
Amongst many of the modified selection systems which are capable of reducing the total period of time 
taken to complete the selection process, NECEEM offers a further advantage, whereby PCR 
amplification is not required between each round of selection. Thus, this can be beneficial for employing 
non-amplifiable libraries consisting of modified bases and, furthermore, greater part of this system can be 
automated, thus producing an effortless aptamer selection system.
Another one step selection method was developed to save time and avoid the labour intensive process 
involved in the traditional SELEX system is referred to as the Aptamer Selection Express (ASExp) 206. 
This technique employs three different combinatorial ssDNA libraries consisting of 1015 oligonucleotide 
sequences. The library consisted of a central random region of 30 nt, 40 nt or 50 nt, which was flanked 
by hybridising primer sequences composed of 20 nt for PCR amplification. The ssDNA library was 
amplified to generate a dsDNA library, which was ethanol precipitated and subsequently resuspended in 
PBS containing Mg +2 and Ca +2. To this resuspended solution, the target (botulinum neurotoxin type A 
or B, light chain) was allowed to incubate with the library for 30 minutes, which causes the denaturation 
of the dsDNA, resulting in a formation of an ssDNA-target complex. Following incubation, magnetic 
beads covalently attached to random ssDNA (60mer) was added to the solution containing the ssDNA- 
target complex, which further forms a complex of ssDNA-target-magnetic bead-ssDNA. This complex is 
separated from the unbound dsDNA library using a magnet, whereby the supernatant containing the 
unbound dsDNA library is removed and the complex is thoroughly washed with water. Finally the bound 
aptamers were PCR amplified, cloned and sequenced. Although the ASExp system was in the early 
stages of development, the entire selection process was completed in 10 hours thus, accomplishing the 
original goal of developing a system which could generate aptamers by eliminating many of the standard 
time consuming process of the conventional SELEX system.
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Aside from aiming to reduce the number of processes involved in the traditional SELEX method, some 
researchers have also aimed at adapting the separation technique involving the partition of aptamers 
bound to the target from the unbound oligonucleotides. Other than the typical separation processes, such 
as magnetic beads or some form of chemical treatment, electrophoretic separation is also seen as 
alternative for nucleic acids, proteins and their complexes. Gel electrophoresis allows separation to take 
place based on size and charge of each component, which will migrate across the gel at varying speeds. 
This approach was employed in an in vitro selection of RNA-based inhibitors of the human neutrophil 
elastase (hNE). In this selection process, an RNA library was utilised of which each strand in the library 
is modified with a splint oligonucleotide. A splint oligonucleotide is a DNA strand which is 
complementary to the hybridising primer sequence at the 5' end of the RNA strand in the library and this 
splint oligonucleotide was conjugated at the 5' end to a reactive valyl phosphate moiety (valP) via an 
amino linker, referred to as a DNA: valP complex. The DNA: valP complex was annealed to the RNA 
strands in the library (RNA: DNA: valP complex), which then followed by incubating the library 
complex with the target (hNE) for 5 -  10 minutes at 37°C. The resulting complex (RNA: DNA: valP: 
hNE) was resolved from the unbound complex (RNA: DNA: valP) on a 4% polyacrylamide gel. From 
the gel, the target containing complex (RNA: DNA: valP: hNE) was removed and the RNA was extracted 
through a crush and soak method. The recovered RNA was PCR amplified and subjected to another 
round of selection. In total, ten rounds of selection were performed before cloning and sequencing 207. 
This principle of separation was also employed in other similar processes 208-210 for the partitioning of 
oligonucleotide-target complexes from the unbound oligonucleotides.
Amongst other typical methods of separation such as affinity chromatography and membrane filtration 
and those not so typical mentioned above, another method for separation is the surface plasmon 
resonance (SPR) technique. This biosensor technology is typically used to monitor molecular interactions 
between two or more molecules in real time and has been used to monitor interactions between different 
biomolecules such as nucleic acids, proteins, and peptides 211,212. This technique has also been employed 
in aptamer selection against the hemagglutinin (HA) protein of the human influenza virus. The selection 
process entailed immobilisation of the HA protein to the NHS activated sensor chip, followed by
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injection of the RNA library into the flow cell for 2 minutes. The RNA library contained 1013 different 
sequences with a randomised region of 30 nt. Subsequently to the injection of the library, binding buffer 
was injected and different fractions were collected. The bound aptamers were removed by ethanol 
precipitation and PCR amplified to enter another round of selection. In total five rounds of selection were 
performed. Aptamers obtained from this system possessed sequence consensus and displayed high 
affinity for the target HA protein 213. In addition to employing the SPR technique in separation, this 
system has been shown to be valuable in the enrichment of binding aptamers from an oligonucleotide 
pool 214. The advantages of employing this technique is that once the target is immobilised onto the 
sensor chip, the target can be repeatedly used, thus requiring the minimum quantity of the target. 
Furthermore, along with achieving separation of the molecules, affinity of the aptamers can 
simultaneously be obtained during the selection process.
Of all possible selection methods available, the most revolutionised system is of the microarray analysis, 
whereby high throughput screening of aptamers can be performed. On a single small glass chip, 
thousands of oligonucleotides of different sequences can be allocated in specific positions to which the 
chosen target can be incubated with and through fluorescence imaging the specific sequence can be 
identified from the emitting signal. An example of aptamer selection employing this techniques was 
demonstrated by Collet et a l215, where aptamers were screened against the lysozyme protein. Each 80 nt 
long biotinylated RNA from the aptamer template obtained from a previous selection (12th round), was 
spotted on streptavidin coated slides and incubated for 30 minutes. Upon incubation, blocking solution 
was incubated for an hour, which was then followed with 30 minutes of incubation with the fluorescently 
labelled target protein. Subsequent to target incubation, the slides were washed with blocking solution to 
remove the unbound protein. After the washing step, the slides were stained with an oligonucleotide stain 
and then analysed. For the labelled protein, the limit of detection was 1 pg/ mL. The aptamer microarray 
analysis has also been thoroughly described by Ellington and coworkers 216,217. The advantage of this 
technique dramatically reduces the overall time required to generate aptamers against a target, by 
eliminating the cloning and sequencing steps. Furthermore, this entire system can be automated, thus it is 
not labour intensive and requires minimal volume of target and oligonucleotides.
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S .2  THE SIMPLEX METHOD
Upon taking into consideration the basic principles of the conventional SELEX along with the many 
advantages of the modified selection systems, a one-round selection system, termed “SimpLex”, based on 
the original SELEX methodology had been designed within the group 197 with the aim to achieve high 
affinity binding aptamers. SimpLex is a simple, unique, one-round selection intended to serve the 
purpose of providing aptamers against the MUC1/Y peptides using minimal quantity of the combinatorial 
oligonucleotide library and target, in combination with providing efficiency pertaining to time and cost. 
The distinctive feature of this system is the elimination of the several rounds of amplification and 
enrichment of the library. With these stages avoided, each progressive elution step is potentially 
conditioned to facilitate the process towards acquiring high affinity aptamer(s) for the target ligand.
The SimpLex method, like most SELEX systems, utilises a synthetic single stranded (ss) DNA pool 
comprised of a 1015 random oligonucleotide sequences. Each oligonucleotide encompasses a unique 
central randomised nucleotide region which provides great variety of secondary DNA structures and is 
flanked either side by fixed primer sequences essential for PCR amplification. Prior to selection, the 
target (MUC1/Y peptides) was required to be modified via conjugation to biotin, for immobilisation to 
streptavidin coated PCR tubes. The amplified aptamer library is incubated with the pre-immobilised 
biotinylated peptides, allowing innumerable distinctive three-dimensional shaped aptamers to selectively 
interact with differing affinities for the biomarker. It is expected that the weak binding aptamers will be 
separated from the strong binders via a step elution gradient with either a sodium chloride based salt 
solution or a temperature gradient system. The aptamers obtained from the highest salt concentration 
and/or temperatures in the final selection step are PCR amplified for cloning and sequencing. Sequencing 
identifies the exact nucleotide arrangement of the randomised region for each aptamer, from which 
potential secondary structures can be determined using an oligonucleotide structure predicting 
programme. Prediction of secondary structures can aid in ascertaining the possible trends in the 
formation of particular structures that may be involved in binding.
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S.S MUC1/V PEPTIDES: 10HER & 20MER
As the MUC1/Y splice variant is a transmembrane protein, the full protein cannot be utilised in the 
selection procedure, due to the complexities involved in its isolation and purification. Thus, to avoid this 
time consuming procedure, two short synthetic peptides were designed composed of amino acids which 
flank the splice site present in the MUC1/Y protein. The MUC1/Y peptides used as targets for selection 
consist of 10 and 20 amino acids, referred to as lOmer peptide and 20 mer peptide respectively. The 10 
mer peptide sequence (TEKNAFNSSL) was selected on the basis of 5 amino acids before the splice site 
and 5 amino acids after the splice site which distinguishes the MUC1/Y from the MUC1 extracellular 
domain protein sequence. The 20 mer peptide sequence (SVPSSTEKNAFNSSLEDPST) is an extension 
to the 10 mer peptide of 5 additional amino acids either side, hence, 10 amino acids before the splice site 
and 10 amino acids after the splice site. There are two splicing sites: splice site 1 occurs between amino 
acids alanine (A) and valine (V) and the splice site 2 occurs between amino acids glutamine (Q) and 
phenylalanine (F) (figure 3.0). The section between the two splicing sites has the amino acids which 
constitute the MUC1 tandem repeat array and its flanking sequences. Removal of this central section will 
result in formation of the MUC1/Y splice variant with a single splice site between the amino acid alanine 
(A) and phenylalanine (F)21.
The purpose of the MUC1 /Y peptides is to mimic the splice site present in the MUC1/Y protein, which is 
a specific portion of the amino acid sequence that differentiates the MUC1/Y isoform from the MUC1 
protein and its other splice variants. Furthermore, the two peptide sequences used as targets in the 
selection process will ascertain whether the additional amino acids present in the 20mer peptide 
influence the binding with the aptamers in comparison to the lOmer peptide. Hence, the comparison of 
the two resulting aptamer pools will determine any sequence homology within each pool and between the 
lOmer and 20mer aptamer pools.
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Figure. 3.0 Partial amino acid sequence of MUC1 and MUC1/Y protein. For simplicity, the 
majority of the spliced out region consisting of the MUC1 tandem repeat array and its flanking sequence 
have been removed and this is indicated by the dashed line. The amino acids in red are the 5 amino acid 
flanking the splice site representing the 10 mer peptide and the 5 amino acids in blue on either side of the 
lOmer peptide represent the 20 mer peptide. Adapted from re f21.
3.4 BIOTINYLATION OF THE MUC1/Y PEPTIDES
The SimpLex selection process, on this occasion was performed utilising streptavidin coated tubes for 
target immobilisation. Thus, to immobilise the peptides to the surface of these tubes and ensure that the 
peptides remain attached to the surface during the entire selection, it was necessary to biotinylate the 
peptides. Biotin has an extremely high affinity, a KD of 4 x 10' 14 M 218 for the tetrameric streptavidin 
protein and will form a stable irreversible bond with the protein that is strong yet non-covalent. The bond 
between streptavidin and biotin typically remains unaffected in high salt concentrations, solvents 218, high 
temperatures and wide range of pH solutions 219.
The MUC1/Y peptides were labelled with biotin-XX protein using a FluoReporter® Biotin-XX protein 
labelling kit. Each peptide was dissolved in 0.1 M sodium carbonate, pH 8 and incubated with the biotin- 
XX succinimidyl ester (SE) in DMSO for 2 hours at ambient temperatures. The solution of biotin-XX SE 
in DMSO was only prepared the moment prior to adding to the peptide solution to prevent the hydrolysis
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of SE. Subsequent to incubation, the reaction mixture was purified with the aim to separate the 
biotinylated peptide from the free N-hydroxy succinimide (NHS) and biotin-XX, using a size exclusion 
PD-10 column with PBS as the eluant. The first 3 mL of flow through were collected in 1 mL fractions 
and the final fourth 1 mL was collected in 0.5 mL fractions (washout). Biotinylation of the peptides was 
carried out according to the manufacture’s instructions with the exception of using a 1:2 instead of the 
recommended 1:10 molar ratio of peptide to biotin-XX SE. A reduced ratio of biotin-XX SE was used to 
avoid biotin conjugation taking place at more than one primary amine sites present in the peptide 
sequence. To determine the presence of the biotinylated peptides in the individual fractions collected, 
they were analysed by UV-Vis spectroscopy using an absorbance wavelength scan ranging from 200 nm 
to 600 nm (figure 3.1). The 10 mer and 20 mer peptides were detected by the absorbance of the amino 
acid phenylalanine at 256 -  258 nm. For reference, biotin-XX SE and DMSO were also analysed to also 
determine their presence in any of the fractions collected. The UV absorbance of the flow through from 
the biotinylated 10 mer peptide has shown presence of the peptide in fractions 2 and 3. The UV 
absorbance of the flow through from the biotinylated 20 mer peptide indicates the presence of the peptide 
mainly in the fractions 2 and 3 and possibly a small amount in fraction 1. However, there is a possibility 
that these fractions could also contain the presence of the unreacted biotin-XX as the biotin-XX has a 
similar absorbance wavelength as the peptides.
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Figure 3.1. UV absorbance spectra of the biotinylated M U Cl/Y  peptides. The absorbance at 
256 -  258 nm was considered for the detection of (A) the biotinylated 10 mer peptide and (B) the 
biotinylated 20 mer peptide.
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From the UV absorbance spectra, the purity of each fraction cannot be established and neither can the 
conjugation of the peptides with the biotin-XX SE be determined. Thus, to ascertain whether 
biotinylation of the peptides has taken place and that the fractions containing the peptides are pure and 
free of any unreacted biotin-XX, these fractions were further analysed and purified by RP-HPLC. The 
non-biotinylated lOmer peptide had a retention time (Rt) of 9.34 minutes, which also appeared to contain 
an impurity that eluted at 15.99 minutes (Figure 3.2). The biotin conjugated lOmer peptide had a delayed 
Rt of 15.97 minutes. Biotin-XX alone has an Rt of ca. 3.5 minutes and the presence of biotin-XX has 
been observed in both of the biotinylated peptide solutions (fraction 3) which had eluted at 3.48 minutes.
(A) 0 .7 0 -
9-34 Peptide
0.60
0 .5 0 -
0 .4 0 -
0.20 15.99
0 . 10 -
0.00
3 0 .0 0I.00 10.00 1 4 .0 0  16 .00
Minutes
2 8 .0 04 .0 0 i .0 0 12.00 20.00 2 4 .0 0 2 6 .0 02.00
0.70-
15.97 Biotinylated peptide
0.60-
0.50-
S '  0.40-
O
5  0.30-cd•e 3.48
0 . 10-
0 .00 -
- 0 . 10-
10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Minutes
4.00 I.002.00 6.00
Figure 3.2. HPLC chromatograms of the MU C l A7 lOmer peptide. (A) The non-biotinylated 
lOmer peptide eluted at 9.34 minutes. (B) The biotinylated lOmer peptide in fraction 3 eluted at 15.97 
minutes.
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The non-biotinylated 20mer peptide had a retention time (Rt) of 10.03 minutes, which also appeared to 
contain an impurity that eluted at 12.89 minutes (Figure 3.3). The biotin conjugated 20mer peptide had a 
delayed Rt of 15.46 minutes.
(A) 0.60-
10.03 Peptide
0.50-
0.40-
0.30-
< 0 .20 -
12.89
0 . 10-
0 .00 -
10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Minutes
I.002.00 4.00 6.00
0.80-
1 5 .46 Biotinylated peptide
0.60-
o  0.40-
3.48
<  0 .20-
0 .00-
10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.002.00 6.00 8.004.00
Minutes
Figure 3.3. HPLC chrom atogram s of the MU C l A7 20mer peptide. (A) The non-biotinylated 
20mer peptide eluted at 10.03 minutes. (B) The biotinylated 20mer peptide in fraction 3 eluted at 15.46 
minutes.
The HPLC analysis of the lOmer and the 20mer biotinylated peptides have evidently shown that both of 
the MUCl/Y peptides have been biotinylated, indicated by the increase in retention times in comparison 
to the retention times of the peptides prior to biotinylation. Furthermore, the biotinylation reaction
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appears to have occurred in great efficiency, since unreacted peptide was not detected in all the analysed 
fractions, which would otherwise be denoted by the retention times corresponding to that of the free 
peptide. However, analysis of the collected fractions did indicate the presence of the biotin-XX in both of 
the biotinylated peptide solutions. Hence, all the fractions which contained the biotinylated peptides were 
purified by RP-HPLC.
3.S THE COMBINATORIAL LIBRARY & PRIMERS
Each DNA strand in the single stranded combinatorial oligonucleotide library is composed of a central 
randomised region of 25 nt flanked by hybridising primer sequences. The forward hybridising primer 
sequence is 23 nt on the 5' end and the reverse hybridising primer sequence is 24 nt on the 3' end of the 
variable region. Thus, each DNA strand is 72 nt long in length (Figure 3.4a). The PCR amplification 
primers consist of the forward primer, which has a sequence identical to the forward hybridising 
sequence, and the reverse primer sequence is complementary to the reverse hybridising primer (Figure 
3.4b). These primer sequences were used in the selection of aptamers for MUC1 197.
(A)
5' 5' 3' 3'
GGGAGACAAGAATAAACGCTCAA RANDOM (25) REGION TTCGACAGGAGGCTCACAACAGGC
Forward hybridising primer Reverse hybridising primer
(B)
5'___________________________ 3'
Forward primer GGGAGACAAGAATAAACGCTCAA ^
Reverse primer <(  GCCTGTTGTGAGCCTCCTGTCGAA
5' 3'
Figure 3.4. The SELEX DNA library  and PCR amplification prim ers. (A) Single stranded 
DNA template entailing hybridising primer sequences flanking a randomised region of 25 nt. (B) PCR 
amplification forward and reverse primers.
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The 72 nt long DNA sequence is appropriate in length to generate secondary structures, such as stems 
and loops, hairpins or G-quadruplexes. In addition, a random sequence of 25 nt gives a molecular 
diversity of 425 which approximately provides 1015 different sequences in the library of single stranded 
DNA oligonucleotides, hence resulting in numerous different conformations. This vast diversity of 
structural conformations is likely to provide a pool of DNA molecules with a range of affinities, 
accompanied by the involvement of the different type of interactions with its target.
8 .6  AMPLIFICATION OF THE SELEX LIBRARY
The combinatorial single stranded DNA library was asymmetrically PCR amplified using a forward and 
reverse primer ratio of 100:4 respectively to generate additional copies of each sequence. The increased 
number of copies will allow each sequence with its unique folded structure a greater opportunity to 
compete with the other sequences within the pool for the target. During the PCR amplification, a hot start 
PCR approach was employed to prevent any incorrect amplification from occurring due to potential 
mispriming or primer dimerization. The likelihood of mispriming and primer dimerization occurring is 
typically at low temperatures (ambient temperature) during PCR sample preparation and until the sample 
reaches the optimal annealing temperature. The hot start PCR method entails withholding an essential 
reagent for PCR amplification, Taq polymerase, until the reaction mixture has reached a temperature that 
inhibits primer hybridisation to any non-target sequences. The enzyme Taq polymerase was thus 
withheld until the reaction mixture reached 95 °C (denaturation step) and was added prior to the 
annealing step at 56°C. Upon annealing of the primers, the temperature is raised to 72°C, optimum for 
Taq polymerase, whereby enzymatic extension of the primers can take place. This process can aid in 
increasing the possibility of ensuring the target sequences are amplified correctly.
3 .7  IMMOBILISATION OF M U C l/Y  PEPTIDES TO THE STREPTAVIDIN CO ATED TUBES
The biotinylated MUCl/Y peptides were immobilised onto the streptavidin coated tubes according to the 
manufacturer’s protocol in preparation for aptamer selection. Two tubes were immobilised with the 
lOmer peptide and another two tubes with the 20mer peptide. For each peptide, one tube was utilised in
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the salt gradient selection method and the second tube was utilised in the temperature gradient selection. 
The binding capacity of the streptavidin coated tubes is 15ng/tube for biotin and the immobilisation of 
the biotinylated peptides was performed in a ratio of 1:2 biotin binding capacity to the biotinylated 
peptide (30ng). The biotinylated peptides in PBS, pH 7.2 were incubated in the streptavidin coated tubes 
for 3 minutes at 37°C. Subsequent to incubation, excess biotinylated peptide was removed and the tubes 
were washed several times with the binding solution (100 mM NaCl, 20 mM KC1, 5mM MgCl2), and 
finally blot dried for the aptamer selection.
3.6  THE SALT GRADIENT SELECTION METHOD
The amplified single stranded DNA combinatorial library was added to the tubes coated with the pre­
immobilised MUCl/Y peptides and incubated for 1 hour at room temperature with gentle shaking. Upon 
completion of the incubation period, excess aptamer library was removed and the tubes were washed 
once with binding solution to ensure the non-specific sequences were removed. A gradient elution of the 
bound sequences was performed by washing the tubes with an elution solution (0.2 M - 1.5 M NaCl, 20 
mM KC1, 5mM MgCl2) of increasing concentrations of NaCl starting from 0.2 M to 1.5 M at 0.1 M 
increments (Figure 3.5). Each elution solution was incubated with the bound sequences for 1 minute at 
ambient temperature with gentle mixing. Following the completion of the elution step, washings obtained 
from the NaCl concentrations (1.5M, 1.4 M, 1.3 M, 1.2M) were desalted using microcons (3 kDa 
MWCO).
Increasing NaCl concentration 
solutions consecutively added to 
the PCR tube
0.2M 0.3M 0.4M 0.5M 0.6M 0.7M 0.8M 0.9M 1.0M 1.1M 1.2M 1.3M 1.4M 1.5M
Figure 3.5. The salt gradient elution method. The MUCl/Y peptide bound sequences were 
eluted with an elution solution of increasing NaCl concentrations, ranging from 0.2 M to 1.5 M in 0.1M 
increments.
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NaCl was used as a chaotropic agent to destabilise the aptamer-peptide complex formed by non-covalent 
interactions such as hydrogen bonding, Van der Waals or ionic bonding. By employing a NaCl gradient 
elution system, the bound sequences were separated based on their affinity and specificity for the 
individual peptides. The weaker binding oligonucleotides expected to dissociate from the peptide at 
lower NaCl concentrations, and likewise the stronger binders to elute at the higher molarity salt 
solutions.
The desalted samples obtained from the highest four NaCl concentrations (1.5M, 1.4 M, 1.3 M, and 
1.2M) were PCR amplified to generate dsDNA and analysed on a 2% agarose gel to determine the 
presence of DNA (Figure 3.6). The presence of any oligonucletotides is indicated by observing the DNA 
at cci. 75 bp.
bp
175 
125
IS
50
Figure 3.6. 2% agarose gel: Screening for aptam ers in varying NaCl concentration
samples. (1) 25 bp ladder, 2 -  1.5 M: (a) lOmer, (b) 20mer, 3 -  1.4 M: (a) lOmer, (b) 20mer, 4 -  1.3 
M: (a) lOmer, 25 (b) 20mer, 5 -  1.2 M: (a) lOmer, (b) 20mer.
From the gel, it is evident that there were oligonucleotides present in all four NaCl concentrations eluted 
from both of the MUCl/Y lOmer and 20mer peptides. At this stage it cannot be ascertained whether the 
samples contain a pool of oligonucleotides of identical or different sequences. As potential aptamers 
were detected at the highest NaCl concentration of 1.5 M, this fraction was taken further for cloning and 
sequencing.
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3.9 THE TEMPERATURE GRADIENT SELECTION METHOD
As with the salt gradient elution method, the amplified aptamer library was incubated with the pre­
immobilised MUCl/Y lOmer and 20mer peptides in the PCR tubes for 1 hour at room temperature with 
gentle shaking. Following incubation the excess library was removed and the tubes were washed once 
with binding solution to ensure the unbound sequences were removed. A temperature elution gradient of 
the bound sequences was performed by washing the tubes with equilibrated sterile water at increasing 
temperatures from 25°C to 95°C, increasing by 5°C increments, with gentle mixing for 2 minutes during 
each step (Figure 3.7). The increase in the temperature allows denaturation of the DNA to take place and 
thus, the disruption in the interactions involved between the aptamer-peptide complex and of the 
aptamers’ secondary structures can cause the release of the bound sequences from the peptides into the
agitating water.
Sterile water at increasing 
temperature consecutively added 
to the PCR tube
25°C 30°C 35°C 40°C 45°C 50°C 55°C 60°C 65°C 70°C 75°C 80°C 85°C 90°C 95°C
Figure 3.7. The tem perature gradient elution method. The MUCl/Y peptide bound aptamers 
were eluted with equilibrated sterile water at increasing temperature, ranging from 25°C to 95°C in 5°C 
increments.
Similar to the NaCl gradient elution system, the temperature gradient elution method also dissociates the 
aptamers from their target peptides based on their affinity and specificity. The less stable binding 
aptamers were expected to be released from the complex at lower temperatures whilst, the stronger 
binding sequences were presumed to be eluted at much higher temperatures, as it was expected that 
strong binding would offer stabilisation of the DNA structure and complex formation. The samples 
obtained from the highest three temperatures (85°C, 90°C, and 95°C) were PCR amplified to generate
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dsDNA and analysed on a 2% agarose gel to determine the presence of aptamer (Figure 3.8). The 
presence of any oligonucleotides is indicated by observing the DNA at ca. 75 bp.
bp
175 
125
75
50
Figure 3.8. 2%  agarose gel: Screening for aptam ers in varying tem perature samples. (1)
25 bp ladder, 2 -  95°C: (a) lOmer, (b) 20mer, 3 -  90°C: (a) lOmer, (b) 20mer, 4 -  85°C: (a) lOmer, 25 
(b) 20mer.
The presence of oligonucletotides in all three temperature elution samples obtained from both the 
MUCl/Y lOmer and 20mer peptides is observed from the gel electrophoresis analysis. The 
oligonucleotide sample obtained at the highest temperature of 95°C was taken further for cloning and 
sequencing.
3.10 CLONING & SEQUENCING
The amplified oligonucleotide pools of the NaCl concentration (1.5 M) and temperature (95°C) for both 
lOmer and 20mer peptides were cloned into the TOPO vectors, using the TOPO TA cloning kit, 
according to the manufacture’s protocol and as described in 2.10. Once the product is cloned into the 
PCR® 2.1 TOPO vector, this recombinant vector is then transformed into competent E.Coli cells 
and grown onto LB agar plates overnight at 37°C. Individual colonies of 1.5M and 95°C samples 
from both peptides grown onto the LB agar plates were swabbed for PCR amplification, as 
described in 2.11., and analysed on a 2% agarose gel. A successful insert of a 72 bp
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oligonucleotide into the vector between the M l3 forward and reverse primers will be determined 
by the presence of a DNA band observed at 272 bp referred to as a positive clone. On the other 
hand, a negative clone will be detected by a band at 200 bp representing only the M l3 forward 
and reverse primers and the region between the primers within the vector, lacking the 72 bp 
aptamer insert. Colonies from the 1.5M and 95°C samples for both peptides were analysed until 10 
positive clones were obtained from each sample (Figure 3.9).
bp V
X
II m  ’*
400 —  
300 _
200 _
X ***
100 _
X
Figure 3.9. 2% agarose gel: Screening for positive clones. (1) 100 bp ladder. Colonies from 1.5
M fractions: (A) lOmer peptide, (B) 20mer peptide. Colonies from 95°C fractions: (C) lOmer peptide, 
(D) 20mer peptide. = indicates an example of a positive clone at 272 bp. * = indicates examples of 
negative clones, lacking the 72 bp insert within the vector.
Forty randomly selected positive clones (10 each from the 1.5M and 95°C samples for both peptides) 
were sent for sequencing to Macrogen (South Korea) to identify the 25 nt unknown random region.
3.11 SEQUENCE & m-FOLD STRUCTURAL ANALYSIS
The forty aptamer sequences identified (appendix 1.0) displayed no sequence homology, thus a variety of 
aptamer sequences were obtained from both selection methods for both of the MUC1/Y lOmer and
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20mer peptides. However, selection of aptamers against the MUC1/Y 20mer peptide was repeated (by 
Dr Huma Khan in the aptamer group at the Open University) with a protocol using the standard SELEX 
method which employed an affinity chromatography system, entailing several rounds of selection. The 
aptamer library was incubated with the 20mer peptide in potassium phosphate buffer with salts (100 mM, 
20 mM KC1, and 5mM MgCl2), pH 7.2 for 1 hour. Subsequent to incubation, the bound sequences were 
eluted with increasing salt concentrations from 1 M to 1.5 M in 0.1 M increments and then with a final 
wash with 3 M NaSCN. The aptamers obtained at 3M NaSCN were subjected to further rounds of 
selection which was then followed by cloning and sequencing. Oligonucleotide sequences obtained from 
this SELEX protocol displayed sequence consensus for three different sequences, SI la, S51a and S75a 
(table 3.0), which were named after the number allocated to the colony sent for sequencing. These three 
sequences were also present within the set of sequences obtained from the SimpLex system using the salt 
and temperature gradient elution method. Hence, the sequence homology obtained for these three 
sequences in the affinity chromatography selection, along with their elution at the highest salt 
concentration and temperature in the Simplex system, was the rationale behind taking S ll , S51 and S75 
forward for further investigations.
Name of 
Sequence
Forward hybridising 
primer
Central variable region Reverse hybridising 
primer
S l la
GGGAGACAAGAATAAACGCTCAA GGCAACATACTGTAAAGCTCAGGAC TTCGACAGGAGGCTCACAACAGGC
S51a
GGGAGACAAGAATAAACGCTCAA AGATAAAAAGGCTGTCTGAAAATT TTCGACAGGAGGCTCACAACAGGC
S75a
GGGAGACAAGAATAAACGCTCAA CTGGTATCTATATGAAGGTTGTAGC TTCGACAGGAGGCTCACAACAGGC
Table 3.0 A ptam er sequences of S l la ,  S51a and S75a. In blue are the forward and reverse 
hybridising primer sequences necessary for PCR amplification. In red are the variable (previously 
unknown) regions identified through sequencing.
From the SimpLex system, sequences S lla  and S75a were selected against the lOmer peptide which was 
eluted at the 1.5 M NaCl concentration, whilst the aptamer S51a was also selected against the lOmer 
peptide but eluted at 95 °C. However, these sequences were obtained under different conditions in the 
affinity chromatography SELEX method, where they were selected against the 20mer peptide and eluted
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with 3 M NaSCN. Thus, this can be an indication that these three oligonucleotides are capable of forming 
a complex with both of the MUC1/Y peptides. Furthermore, another possible insight to their means of 
binding to the peptides is that the formation or stabilisation of the potential aptamer secondary structures 
is not dependent upon the cations present in the solutions during binding and may not be involved in the 
peptide-aptamer complex formation. This assumption is deduced based on the difference between the 
solutions in which the aptamer libraries were incubated in with the peptide. In the Simplex system, the 
combinatorial library was incubated with the peptide in the solution which the library was amplified in, 
containing PCR buffer and PCR reagents, whilst in the affinity chromatography selection the aptamer 
library was incubated with the peptide in potassium buffer containing the binding solution salts at pH 
7.2.
The predicted secondary DNA structures for the sequences Slla, S51a and S75a were obtained from in­
fold web server 220, an algorithm used to predict the secondary structures of DNA and RNA molecules. 
The predicted structures provide a broad indication of the different type of base parings which can occur 
to generate the stem and loop structures that could be play an important role in the binding to the 
MUC1/Y peptides. However, the full length of the aptamers of 72 nt long is not a feasible length for 
commercial purposes whereby the aptamer yield of such a length is considerably reduced upon synthesis 
and purification. Also the synthesis of aptamers greater than 45 nt can be expensive and thus non-viable 
for therapeutic scale-up applications. Therefore, to reduce costs, sequences were truncated for further 
investigation along with the full length oligonucleotides for comparison. The 72mer sequences were 
truncated by two alternative means. One was to remove the hybridising primer sequences, leaving only 
the 25 nt variable region, and these were referred to as SI lb, S51b and S75b (table 3.1). The second 
method was based on their predicted secondary structures obtained from the m-fold structure prediction 
programme. Sequence truncation by this method was based on removing the bases which were not 
involved in the formation of the largest stem-loop structure and only incorporating the nucleotides of the 
secondary structure motif. These sequences were referred to as S llc, S51c and S75c (table 3.1). The 
predicted secondary structures of the c series of oligonucleotide sequences have shown that the base 
pairing and structure formation occurs between the reverse hybridising primer and the random variable
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region. The forward hybridising primer is not involved in the secondary structure formation. 
Furthermore, the S75c sequence largely consists of the bases present in the reverse hybridising primer 
sequences rather the bases of the random variable region in comparison to the SI lc and S51c sequences.
The aptamer ‘b’ series
Name of 
Sequence
Forward hybridising Central variable region Reverse hybridising 
primer primer
S l lb
GGCAACATACTGTAAAGCTCAGGAC
S51b
AGATAAAAAGGCTGTCTGAAAATT
S75b
CTGGTATCTATATGAAGGTTGTAGC
The aptamer ‘c’ series
Name of 
Sequence
Forward hybridising Central variable region Reverse hybridising 
primer primer
S l lc
ACTGTAAAGCTCAGGAC TTCGACAGG
S51c
GGCTGTCTGAAAATT TTCGACAGGA
S75c
GGTTGTAGC TTCGACAGGAGGCTCACAACA
Table 3.1 A ptam er sequences for the ‘b ’ and ‘c’ series. The b series entails the aptamer 
sequences which have had the hybridising primers removed and only contain the central variable region. 
The c series are the aptamer sequences which were truncated based on the predicted secondary 
structures.
There are several structural possibilities that each aptamer can adopt which is presented by the m-fold 
predicting programme and the predicted secondary structures of each aptamer and its truncated versions 
are shown in figures 3.9-3.11. The structures of the S ll oligonucleotide series (Figure 3.10) display a 
combination of a short hairpin motif and the long hairpin containing a bulge. The full length S lla  
aptamer contains two hairpins, whilst the truncated versions of the potential aptamer contain a single 
stem-loop region with the formation of an open structure for the shorter hairpin motifs. The structures of 
the S51 series (Figure 3.11) are very similar to that of S ll sequences. However, S51b of the central 
variable region forms less open structures and produces a dumbbell like structure. The S75 series exhibit
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structures (Figure 3.12) which also contain stem and loop regions. However, the aptamer S75a forms a 
long tight hairpin structure and two of the predicted structures show greater base pairing tendency.
Slla S llb
C x/ x V '
\  TT - * X  ✓ \
S llc
C —
Figure 3.10 The predicted secondary structures of S l l  and the truncated  versions. S lla  of 
72 nt ( g g g a g a c a a g a a t a a a c g c t c a a g g c a a c a t a c t g t a a a g c t c a g g a c t t c g a c a g g a g g c t c a c a a c a g g c )  
is the full length aptamer. S llb  of 25 nt ( g g c a a c a t a c t g t a a a g c t c a g g a c )  is the variable region. S llc  
of 26 nt ( a c t g t a a a g c t c a g g a c t t c g a c a g g )  is the stem-loop region obtained from the predicted 
structure of S lla  highlighted by orange dotted box. The structure was predicted at 37°C with 100 mM 
and 5 mM MgCl2.
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S51a S51c
S51b
T —  G'
A —A —
G —
?  A —A —
!•  T
A —A —
Figure 3.11. The predicted secondary structures of S51 and the truncated  versions. S51a of
71  nt (GGGAGACAAGAATAAACGCTCAAAGATAAAAAGGCTGTCTGAAAATTTTCGACAGGAGGCTCACAACAGGC)
is the full length aptamer. S51b of 24 nt ( a g a t a a a a a g g c t g t c t g a a a a t t )  is the variable region. S51c of 
25 nt ( g g c t g t c t g a a a a t t t t c g a c a g g a )  is the stem-loop region obtained from the predicted structure of 
S51a highlighted by orange dotted box. The structure was predicted at 37°C with 100 mM and 5 mM 
MgCl2.
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S75a
S75b S75cT ^
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T —■
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 C —  A
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Figure 3.12. The predicted secondary structures of S75 and the truncated  versions. S75a of
72 n t (GGGAGACAAGAATAAACGCTCAACTGGTATCTATATGAAGGTTGTAGCTTCGACAGGAGGCTCACAACAGGC)
is the full length aptamer. S75b of 25 nt ( c t g g t a t c t a t a t g a a g g t t g t a g c )  is the variable region. S75c 
of 30 nt ( g g t t g t a g c t t c g a c a g g a g g c t c a c a a c a )  is the stem-loop region obtained from the predicted 
structure of S75a highlighted by orange dotted box. The structure was predicted at 37°C with 100 mM 
and 5 mM MgCl2.
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Thus, a total of nine aptamer sequences were taken forward for investigating further of which the 3 full 
length aptamer sequences (Slla, S51a and S75a) were the original sequences obtained from the 
selection. The b series (Sllb, S51b and S75b) are the central random region sequences and the c series 
SI lc, S51c and S75c) are the stem-loop regions from the predicted secondary structures.
3 .12  CONCLUSIONS
Taking into consideration the traditional SELEX system, involving numerous rounds of selection, and 
many of the non-conventional aptamer selection methods mentioned previously, an alternative approach 
for generating aptamers to potentially any target was considered. SimpLex, a one round selection method 
was developed to obtain aptamers against the MUC1/Y peptides, lOmer and 20mer, possessing high 
affinity and specificity for their target. In brief, the biotinylated peptides were immobilised to the 
streptavidin coated PCR tubes, to which the single stranded combinatorial library was added and 
incubated with the target peptides. The bound sequences were separated according to their binding 
strength to the target peptides via either a salt gradient or a heat gradient elution. Of the final forty 
sequences obtained from both elution methods against the lOmer and 20mer peptides, only three 
sequences (Slla, S51a, S75a) were considered for further studies. The rationale to consider these three 
sequences in further experimental research was based on the appearance of these sequences from the 
repeat selection employing the affinity chromatography method against the 20mer peptide. Additionally, 
another six sequences were designed from the parent sequences, which consisted of two different 
constructs. The first construct involves the removal of the hybridising primer sequences leaving only the 
central variable region (SI lb, S51b, and S75b) and the second construct entails the sequence forming the 
stem-loop obtained from the predicted secondary structures.
From the forty sequences that were obtained, sequence homology was not observed between the 
sequences from either elution methods and amongst both peptides. The lack of sequence consensus could 
be the outcome of either or a combination of two possible reasons: first, that only a small number of 
clones for each elution method and peptide were sequenced and second, that the elution methods may not 
have been stringent enough. The analysis of only a small number of clones could imply that the
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probability of acquiring sequence homology is significantly reduced as opposed to screening a hundred 
or more clones. Moreover, the stringency of the eluting system could have been increased by subjecting 
the aptamers obtained from the 1.5 M NaCl concentration and 95°C temperature fractions to another 
round of selection. In addition, to further refine the selection process, the final pool of aptamers from 
both elution systems could be subjected to negative and counter selections. For a negative selection, the 
final pool of aptamer could be incubated with only the streptavidin coated tubes, thus removing any 
potentially non-peptide specific aptamers. The counter selection could be performed by incubating the 
aptamer pool with the MUC1 peptides 197 which would remove any sequences which may have affinity 
for a non-selected target, therefore enhancing the specificity of the aptamers obtained for MUC1/Y. 
Although, potential aptamers Sllb, S51b, and S75b were all generated against the lOmer peptide in the 
SimpLex system and not present in the pool of prospective aptamers obtained for the 20mer peptide, this 
does not suggest that these three lead sequences do not bind to the 20mer peptide. In fact, the contrary 
was affirmed as in the affinity chromatography SELEX selection these three lead sequences were 
generated against the 20mer peptide and eluted from the column at the higher salt concentration of 3 M 
instead of the 1.5 M. Furthermore, the utilisation of two different selection protocols exemplifies that the 
three sequences do not possess any affinity for the medium in which the selection took place. For 
example, in the case of the SimpLex system, the support medium is the streptavidin which coats the PCR 
tube whilst in the affinity chromatography system an activated sepharose resin was employed. 
Furthermore, the binding of these three aptamers is not dependent upon the cationic salts in the buffer as 
in both selection methods the combinatorial DNA library was incubated with the peptides in different 
cationic salt solutions.
The SimpLex, one round selection system, has shown to have the potential to generate aptamers against a 
known target in a simple and cost effective manner. The aptamer generating protocol can be replicated on 
a lab bench without the requirement of any sophisticated and expensive instruments. The key advantages 
of this protocol are that it is extremely fast, not practically laborious and can be performed using small 
quantities of reagents. This selection process can.be completed in two hours from immobilising the 
target, incubating the combinatorial library to eluting the bound aptamers. Even if the final pool of
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aptamers obtained at the highest NaCl concentration and temperature is subjected to a second round of 
selection, this can still be completed within a day. Additionally, provided that the target in question can 
be immobilised on streptavidin coated PCR tubes, there are no other limitations with respect to the size 
of the molecule which can be used as a target.
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4 .0  INTRODUCTION
Aptamers present remarkable potential as therapeutic agents. However, they cannot be directly taken into 
in vivo studies prior to any modification due to their poor pharmacokinetics properties and sensitivity to 
nuclease degradation. Unmodified aptamers are subjected to rapid renal clearance, thus preventing the 
aptamer from reaching the biomarker to result in an adequate therapeutic response. This limitation can be 
addressed through a chemical modification referred to as pegylation, which typically entails conjugating 
the aptamer to a high molecular weight polymer, polyethylene glycol (PEG), at both or either of its 
terminal ends. Pegylation has been shown to alter the pharmacokinetics of aptamers by increasing their 
blood circulating half-life from minutes or hours to days 221. This allows the aptamer sufficient time to 
reach the target of interest and bring about the desired effect. The molecular weight cut off for 
glomerular filtration is noted to be between 30 kDa and 50 kDa 222, whereby urinary excretion of 
pegylated molecules appears to be directly proportional to the mass of PEG; urinary clearance reduces as 
the molecular weight of the PEG increases. On the other hand, liver clearance has an inverse response, as 
the molecular weight of PEG increases so does liver clearance. However, this effect has been reported to 
take place only when the minimum size of 50 kDa of the molecule is exceeded 223.
The covalent attachment of PEG to biological molecules was initially introduced to increase the 
molecular weight of peptides and proteins, amongst many other advantages, which was then later applied 
to aptamers. The most commonly noted methods described in literature for pegylation involve reacting a 
functional moiety of PEG with either an amine or a thiol group present in proteins and peptides. 
Activated functional groups of PEG which can covalently form an amine linkage with an amino group 
include active ester, active carbonates, aldehyde or tresylate. Thiol group present on the amino acid 
cysteine can be attached to PEG via thiol reactive derivatives of PEG such as maleimide, vinyl sulfones, 
iodoacetamide and orthopyridyl disulfide 193,196,224. Hence, aptamers can be modified to possess the 
functional groups present in proteins or peptides to be able to react with the activated PEG.
The truncated MUC1/Y aptamers of series b and c (Sllb, S51b, S75b and S llc , S51c, S75c, 
respectively) have been pegylated as the full length MUC1/Y aptamers of 72 nt would not be appropriate
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or for therapeutic and commercial applications as explained previously. Several different parameters for 
aptamer conjugation had been explored before the optimised condition was obtained to provide a high 
yielding aptamer pegylation reaction.
4.1 POLYETHYLENE q lYcol c q n ju q a ted  a p t a m e r s
Numerous aptamers have been conjugated to PEG of different molecular weights, structures and 
functional groups to alter the pharmacokinetics of the unmodified aptamers. A pegylated aptamer known 
as Pegaptanib is currently in the market for the cure of age-related macular degeneration. Pegaptanib is a 
27 nt long RNA aptamer generated against the VEGFi65 protein which has an amino modification on the 
5' end and is conjugated to a 40 kDa NHS PEG to reach an overall molecular weight of ca. 48 kDa. Due 
to the conjugation to PEG, the aptamer showed no degradation in plasma at ambient temperature for 
longer than 18 hours, however a four fold decrease in its binding affinity to the target VEGF165 was also 
detected. Although a reduced binding was observed as a result of pegylating the aptamer, the inhibition 
of vascular permeability stimulated by VEGF was improved to 83%. It has been suggested that this 
increase in the inhibitory activity by Pegaptanib is the potential effect of a decrease aptamer rate of 
diffusion due to the increase in the molecular weight from the conjugation to a 40 kDa PEG polymer
66,157
An anti-PDGF DNA aptamer, ARC 127, used to reduce interstitial tumour pressure for promoting greater 
uptake chemotherapeutic agents into the tumours has also been conjugated to a 40 kDa PEG polymer. 
Also in this case, the 29 nt long aptamer with a primary amine group modification at the 5' end was 
reacted with the NHS activated PEG ester, increasing the overall molecular weight of the aptamer to ca. 
49 kDa. The pegylated ARC 127 showed an increase in the in vivo aptamer half-life from a few minutes 
to 8  hours when administered intravenously. Furthermore, the pegylated aptamer was able to reduce 
tumour cell proliferation by 95% over a period of 9 days and inhibited the process induced by the PDGF
170,225
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Another therapeutic aptamer which has been conjugated to PEG is the 15 nt long DNA anti-thrombin 
aptamer employed as an anticoagulant. The anti-thrombin aptamer was attached to a 40 kDa PEG in a 
different manner, where the aptamer had two C6 amino linkers at its 5' end that were reacted with two 
linear 20 kDa NHS activated PEGs, resulting in a branched type structure. The final molecular weight of 
the pegylated aptamer was increased to ca. 44 kDa. The anti-thrombin aptamer prior to modification had 
a whole blood clotting time (WBCT) of 382 seconds which was increased to 456 seconds once pegylated
170,226
The ARC83 aptamer is a 32 nt long scrambled form of the aptamer generated against the transforming 
growth factor-p2 (TGF-J32). ARC83 having an amino functionality at the 5' terminus was attached to two 
different molecular weight PEG polymers 20 kDa and 40 kDa via the activated succinimidyl ester moiety 
of PEG to form ARC120 (30 kDa) and ARC122 (50 kDa) respectively. The plasma pharmacokinetics in 
in vivo rat models revealed the un-pegylated aptamer had a half-life (ti/2) of 5 hours with a mean 
residence time (MRT) of 1.7 hours. ARC120 showed a higher ti/2 of 7 hours with a MRT of 8 hours 
while ARC122 had a ti/2 of 12 hours with a MRT of 16 hours. Both pegylated aptamers have 
demonstrated significantly slower clearance from the circulatory volume, further enhancing the 
distribution of the aptamer to the tissues. Moreover, the 40 kDa pegylated aptamer demonstrated an MRT 
ca. 10 fold higher than the unmodified aptamer ’ .
Anti-human L-selectin RNA and DNA aptamers have also been conjugated to 20 kDa and 40 kDa PEG in 
the same way described previously for the ARC83 aptamer. The final molecular weights of the aptamers 
were 30 kDa and 50 kDa when they were pegylated to the 20 kDa and 40 kDa PEG respectively. Studies 
of the pegylated aptamers revealed that the MRT of the DNA aptamers <30 kDa varied with the different 
overall molecular weights, but the MRT of the conjugated aptamers >30 kDa remained constant. This 
indicated that renal filtration was the most important rate determining step for low molecular weight 
DNA aptamers, though this was not the case for the DNA aptamers above the molecular weight of 30 
kDa65.
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4.2  PE6VLATI0N OF THE MUC1/Y APTAMERS
For aptamers to become viable as therapeutic agents it is important that their molecular weight is 
increased above 30 kDa. To achieve this, in literature, 20 kDa and 40 kDa PEG have been employed, 
increasing the overall molecular weight of the pegylated aptamers to approximately 30 kDa and 50 kDa 
respectively. For the pegylation of the truncated MUC1/Y aptamers (Sllb, S51, S75b, S llc, S51c, and 
S75c) with a molecular weight of 7 -  9 kDa, a 32 kDa linear PEG was employed, increasing the 
molecular weight of the pegylated aptamers to ca. 40 kDa. The increase in overall molecular weight of 
the truncated aptamers is likely to aid in the prevention of rapid renal clearance, as it takes them above
1 CM OOC _the effective cut-off for the retardation in glomerular filtration ranging between 40 -  60 kDa ’ . The 
method typically described in literature for pegylation involving amine coupling was used for 
conjugating the MUC1/Y aptamers to PEG. The C6 amino linker is attached to the phosphate group in the 
3' position of the ribose at the beginning of the solid phase synthesis of the oligonucleotides. The amino 
group can then react with the activated NHS-ester of 32 kDa linear PEG forming a stable covalent bond 
(scheme 4.0).
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Scheme 4.0. A ptam er pegylation. The 3'-amino modified aptamers were reacted with NHS- 
activated PEG. (a) 53.4 mM sodium carbonate buffer, pH 10, 60°C, 1 hour, n = 736 ethylene oxide 
monomers.
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Initially, the reaction was performed following a combination of protocols described in literature. The 
aptamer was reacted with a 3 molar excess of the NHS activated PEG in 100 mM sodium carbonate 
buffer (pH 9.3) for 1 hour at ambient temperature 221 229 but no product was obtained based on the 
analysis performed by agarose gel electrophoresis (figure 4.0, lane 4). The presence of a pegylated 
aptamer was expected to be indicated by an aptamer band (stained with ethidium bromide (EtBr)) 
significantly retarded within the gel compared to the unmodified aptamer (lane 5) which migrates at a 
faster rate and is observed at 25 bp. Conditions such as pH, temperature and aptamer to PEG ratios were 
altered with the aim to achieve a high yielding pegylation reaction. Using 53.4 mM sodium carbonate 
buffer (pH 10), 1: 20 molar ratio of aptamer to NHS-PEG and performing the reaction at 37°C for 1 hour 
resulted in aptamer conjugation even though significant unreacted aptamer was also observed (figure 
4.0_Lane 3). The pegylation reaction was also analysed by agarose gel electrophoresis where a new band 
close to the well in lane 3 was observed which do not correspond with the starting reagents. This may 
indicate the formation of a potential aptamer-PEG conjugate.
bp
150 
100
50 
25
Figure 4.0. 2% agarose gel: Analysis of aptamer-PEG reaction mixtures. (1) 25 bp ladder,
(2) free PEG, (3) 1: 20 aptamer: PEG molar ratio, (4) 1: 3 aptamer: PEG molar ratio, (5) free aptamer (25 
nt).
Potential conjugate
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To optimise the reaction further a 1: 40 aptamer: NHS-PEG molar ratio was used and analysed by gel 
electrophoresis (figure 4.1). Gel A, stained with EtBr showed the potential aptamer conjugate from the 1: 
40 molar ratio reaction mixture in lane 4 close to the well, along with unreacted aptamer corresponding 
to the free aptamer in lane 5. Staining from this indicated that majority of the aptamer had reacted with 
the activated PEG, as the unreacted aptamer had not stained with the same intensity as the free aptamer. 
Gel B was stained with a barium chloride iodine (BaClI) solution to detect the presence of PEG as 
described in literature 230'232. This form of staining is based on a complex formation between the barium 
ions and PEG. When iodine solution is added to this complex, the complex becomes insoluble resulting 
in a visible rusty coloured stain in the gel. Gel B, showed that the free PEG had migrated towards the 
cathode in lane 4 which corresponds with the free PEG in lane 2. Although the free PEG had stained 
quite significantly in lane 4, the conjugated aptamer had not stained with the BaClI solution as expected.
The concentration of the potential conjugate may not have been sufficiently high for the formation of a 
detectable barium iodide-PEG complex. Therefore the 1: 40 molar ratio reaction mixture was also 
analysed by 7 % native PAGE. Gel C, after EtBr staining in lane 2 is the free aptamer and lane 1 is the 
pegylation mixture where the potential conjugated aptamer is detected close to the well and the unreacted 
aptamer has migrated with the 25 bp marker. In this case, the band corresponding to the unreacted had 
the same intensity of staining as the free aptamer. Once treated with BaClI solution, the band of the 
potential conjugate was clearly visible as a rusty coloured stained in gel D.
To ascertain whether the reaction has led to aptamer covalently bound to PEG and not only an 
entrapment of the aptamer within the large PEG polymer a control reaction was performed. The control 
reaction involved repeating the previous reaction (1: 40 aptamer: NHS-PEG molar ratio). Prior to the 
addition of PEG to the aptamer, NHS ester moiety of PEG was hydrolysed to release the unreactive 
carboxylic group by incubating the NHS- PEG in 53.4 mM sodium carbonate buffer (pH 10) at 37°C 
with gentle mixing for 2 hours. Subsequently, the hydrolysed PEG solution was added to the aptamer and 
the mix was incubated at 37°C for a further 1 hour. The control reaction was analysed by agarose gel 
electrophoresis (figure 4.1). In gels A and B, lane 3, only the band of free aptamer visible at 25 bp and
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the free PEG were visible indicating that the conjugation had not taken place. Therefore, indicating the 
new band in lane 4 is not present due to entrapment of aptamer in the large PEG molecule and is likely to 
be the pegylated aptamer.
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Figure 4.1. 2% agarose gel: Analysis of aptamer-PEG reaction mixtures. (A-B): (1) 25 bp
ladder, (2) free PEG, (3) control reaction, (4) 1: 40 aptamer: PEG molar ratio, (5) free aptamer (25 nt). 
7% native gel: (C-D): (1) 1: 40 aptamer: PEG molar ratio, (2) free aptamer (25 nt).
The control and pegylation (1: 40 aptamer: PEG molar ratio) reaction mixtures were also analysed by
anion exchange HPLC (figure 4.2). The chromatogram of the control reaction (figure 4.2A) showed that 
the hydrolysed PEG and NHS have an Rt of 2.29 minutes and the unreacted aptamer elutes at 16.68 
minutes. The chromatogram of the pegylation reaction mix (figure 4.2B) showed new peak having an R,
of 12.26 minutes with a yield of 13 % quantified from peak area.
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Figure 4.2. HPLC chrom atogram  of the pegylation reaction mixtures. (A) Control reaction: 
The hydrolysed PEG and NHS elutes at 2.29 minutes. The unreacted aptamer elutes at 16.68 minutes. (B) 
Pegylation reaction: The peak at 2.47 minutes is PEG and NHS. The aptamer elutes at 16.6 minutes and 
the pegylated aptamer has an Rt of 12.26 minutes.
The formation of the product with a Rt of 12.26 minutes was increased when the pegylation reaction was 
performed by reacting amino modified aptamer with 40 molar excess of the NHS activated PEG in a 50: 
50 (v/v) mixture of 53.4 mM sodium carbonate buffer (pH 10) and DMF at 37°C for 1 hour (figure. 4.3). 
The pegylated aptamer elutes at 12.09 minutes with a yield of 36 %.
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Figure 4.3. HPLC chrom atogram  of the pegylation reaction: addition of DMF. The
hydrolysed PEG and NHS elutes at 2.17 minutes. The unreacted aptamer elutes at 16.60 minutes and the 
pegylated aptamer elutes at 12.09 minutes.
The increase in temperature from 37°C to 60°C and the percentage of DMF volume to 85 % and reducing 
the buffer volume to 15 % also led to a small increase in the product (figure. 4.4). The conjugated 
aptamer elutes at 12.04 minutes with a yield of 42 % of the pegylated aptamer.
PEG
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Figure 4.4. HPLC chrom atogram  of the pegylation reaction: 85 %  DM F a t 60°C. The
hydrolysed PEG and NHS elutes at 2.38 minutes. The unreacted aptamer elutes at 16.01 minutes and the 
pegylated aptamer elutes at 12.04 minutes.
CHAPTER FOUR 112
FUNCTIONALISATION OF MUC 1 / Y  APTAMERS
As the increase of DMF and temperature did not make a significant difference, the previous reaction was 
repeated with the addition of the 40 molar excess NHS-activated PEG to the aptamer solution in portions 
every 20 minutes (figure. 4.5) whereby the conjugated aptamer elutes at 12.26 minutes with a yield of 79 
%.
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Figure 4.5. HPLC chrom atogram  of the pegylation reaction: NHS-PEG added in 
portions. The hydrolysed PEG and NHS elutes at 2.35 minutes. The unreacted aptamer elutes at 16.63 
minutes and the pegylated aptamer elutes at 12.26 minutes.
This pegylation condition resulting in a 79 % yield of the conjugated aptamer was employed for the 
pegylation of all six truncated MUC 1/Y aptamer (Sllb, Sllc, S51b, S51c, S75b and S75c). The 
pegylated aptamers were purified and isolated by anion exchange HPLC. The isolated pegylated 
aptamers were analysed on a 2 % agarose gel (figure 4.6). In gel A, the pegylated aptamers S llb  and 
SI lc in lanes 3 and 4 respectively have migrated close to the loading wells whilst the free aptamer has 
migrated in line with the 25 bp mark. In gel B, lane 2, the free PEG is observed migrating towards the 
cathode. This analysis confirms that the high molecular weight molecule retarded in the gel does contain 
the aptamer and the PEG, observed as a band as a result of EtBr and BaClI staining.
The isolated aptamer was also analysed by MALDI mass spectrometry for a concluding confirmation 
(figure 4.7). The free PEG is observed due to the fragmentation of the conjugated molecule and is 
indicated by its molecular weight with a peak at 33204 Da. The conjugated aptamer is denoted by the 
peak 40484 Da.
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Figure 4.6. A nalysis o f  the isolated conjugated aptam er. 2% agarose gel: (1) 25 bp ladder, 
(2) free PEG, (3) pegylated SI lb , (4) free aptamer, (5) pegylated S l l c .
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Figure 4.7. M A L D I m ass spectrum  o f the pegylated aptam er. Pegylated aptamer: 40484 Da, 
Free PEG: 33204 Da.
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For the purpose of fluorescence in vitro cell binding studies, the six truncated aptamers were labelled on 
the 5' terminus with a fluorescent Cy3 dye, via phosphoramidite chemistry, and conjugated to the 32 kDa 
PEG on the 3' end using the optimised conditions to yield ca. 80 % of pegylated aptamer. The Cy3 
labelled pegylated aptamers were purified and isolated by anion exchange HPLC and analysed on a 2% 
agarose gel (figure 4.8) where in lane 1, the conjugated aptamer has migrated close to the well indicated 
by a bright pink band. The free PEG is observed as rusty coloured band in lane 2 migrating towards the 
cathode.
Figure 4.8. Analysis of isolated Cy3 labelled conjugated aptam er. 2%  agarose gel: (1)
pegylated aptamer (2) free PEG.
A total of 12 truncated MUC 1/Y aptamers were pegylated on the 3' end of which a set of six aptamers 
were non-labelled and the other set of 6 aptamers were labelled with the Cy3 fluorescent dye on the 5' 
terminus.
4.8  CONCLUSION
The short versions of the MUC 1/Y oligonucleotid with a molecular weight of ca. 8 kDa have been 
conjugated to a large molecular weight polymer, PEG of 32 kDa with the objective to increase the 
molecular weight of the aptamers above the minimum glomerular filtration threshold. Increasing the 
overall molecular weight of the aptamers has shown to appreciably reduce the rate of renal clearance and 
therefore extend their in vivo circulatory half-life. The most described and widely used method in 
literature for aptamer pegylation has involved an amino coupling with the 3' amino modified aptamers 
and the activated NHS-ester moiety of PEG, which was also employed for the pegylation of the MUC 1/Y
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aptamers. The initial conditions applied for aptamer conjugation was based on those presented in 
literature however, with these conditions aptamer pegylation was not achieved. Therefore, following a 
series of modifications involving changing parameters such as buffer pH, addition of solvent, 
temperature and PEG ratios, have led to the optimised pegylation conditions with a yield of ca. 80% of 
pegylated aptamer. Optimisation of the pegylation conditions increased the aptamer conjugation yield 
from 13 % to 79 %. This 66 % improvement in aptamer pegylation yield was clearly observed in the 
HPLC chromatograms as the additional peak at ca. 12.05 was increasing with each modification. The 
addition of DMF alone has led to a 23 % increase in the formation of the conjugated aptamer, whilst 
increasing the volume of DMF and temperature to 60°C, a rise of only 6% in the yield was observed. The 
greatest increase in the formation of the aptamer conjugate was 37 % as a result of adding PEG to the 
reaction mixture in portions. Thus, most significant improvements are largely attributed to the addition of 
the PEG in portions and the incorporation of the DMF. Both of these alterations contribute towards a 
single factor of reducing the rate of hydrolysis and increasing the portion of activated PEG available to 
the amino modified aptamer for coupling to take place. The final conditions used to pegylate the twelve 
aptamers (unlabelled and Cy3 labelled) involved reacting a 3' amino modified aptamers with 43 molar 
excess of the NHS activated PEG, which was added in portions, in a 15 : 85 (v/v) mixture of 53.4 mM 
sodium carbonate buffer (pH 10) and DMF at 60°C over a period of two hours. The formation of the 
pegylated aptamer has been confirmed by HPLC, gel electrophoresis (using EtBr and BaClI staining) and 
MALDI mass spectrometry.
Analysis of aptamer pegylation via BaClI staining on a 2 % agarose gel has shown to be an ineffective 
method for the detection of aptamer-PEG complex at low concentrations. However, this was not the case 
when using the BaClI stain on a 7 % native page. Furthermore, gel electrophoresis analysis can present 
discrepancies in the analysis of the reaction mixture such as the potential conversion of the free aptamer 
to pegylated aptamer, which are eliminated when analysed using HPLC.
As PEG is a large bulky molecule, the attachment of this polymer to the aptamers may have the potential 
to affect the specificity and affinity of the aptamers to their target peptides, thus it is essential that the
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pegylated aptamers are characterised alongside the unmodified aptamers. The characterisation of the 
aptamers will determine any potential change in the binding of the aptamers to the biomarker subsequent 
to conjugation. Therefore, only after establishing whether the pegylated aptamers retain their affinity and 
specificity for their target can they be taken further for in vivo studies. The fluorescently labelled Cy3 
aptamers were pegylated for comparing their potential with the unpegylated aptamers in the in vitro cell 
binding and internalisation studies.
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5.0  IKTRODUCTIGN
The generation of three particular MUC1/Y aptamers (SI 1, S51 and S75) from two different selection 
methods could be an indication of a significant relationship with respect to their affinity and specificity 
for their MUC1/Y target peptides (lOmer and 20mer). However, qualitative and quantitative 
characterisation studies are necessary to reveal the affinity and specificity of these aptamers. The 
determination of aptamer affinity will provide information on the strength of the interaction between the 
aptamer and its target, which can also be indicated by the stability of the aptamer-target complex. Whilst, 
specificity of an aptamer can be determined by evaluating the interaction of aptamers, those selected 
against the target and those randomly chosen as a control, with the target and other random peptides. To 
ascertain the affinity and specificity of aptamers towards their target, numerous approaches can be 
employed, such as nitrocellulose partitioned aptamer binding 65’66, enzyme-linked immunosorbent assay 
(ELISA) 197’233, surface plasmon resonance (SPR) 234’235, thermal denaturation 66’234, electrophoretic 
mobility shift assay (EMSA) ’ , or affinity chromatography . Many biophysical assays require 
modification of the aptamers. In the case of nitrocellulose partitioned aptamer binding and ELIS As, the 
aptamer is modified with a radioactive label or biotin respectively, for establishing binding constants. 
However, such modifications hold the potential to alter the original affinity of the aptamer, therefore 
binding constants determined from these assays cannot be verified as the true affinity of the unmodified 
aptamer. To assess the binding affinity and specificity of MUC1/Y aptamers of series a (SI la, S51a and 
S75a), series b (SI lb, S51b and S75b) and series c (S llc, S51c and S75c), the primary focus was placed 
on employing qualitative biophysical assays such as EMSA, affinity chromatography and thermal 
denaturation studies which do not require the aptamers under investigation to be modified.
5.1 PRINCIPLE OF THE EMSA
The electrophoretic mobility shift assay (EMSA), also known on occasions as the gel or band shift or gel 
retardation assay, is used for studying complex formation between typically an oligonucleotide and
AAA
protein ’ . Non-denaturing polyacrylamide gel electrophoresis is used to monitor the separation of the 
complex from the unbound components. The migration of the molecules through the gel is mainly
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dependent upon their size and charge, although the conformation of a molecule can also have an 
influence on the mobility. A protein-oligonucleotide complex will have a lower mobility than the 
unbound oligonucleotide and protein due to its overall molecular weight. However, in the absence of any 
complex formation, retardation of the oligonucleotide will not be observed and will possess the same 
mobility as the free oligonucleotide used as a control. The critical element in this technique for optimal 
results is the pore size of the gel which is controlled by the concentration of the acrylamide and 
bisacrylamide used to form the gel. The pore size of the gel is tailored to accommodate not only the 
molecular weight of the unbound protein and oligonucleotide but also the complex. A small pore size of 
the gel will prevent the large protein-oligonucleotide complex from entering the gel, whilst a very large 
poor size may not participate in the retardation of the complex thus, resulting in an insufficient separation 
of the complex from the unbound molecules. This EMSA technique has been applied to resolve the 
aptamer-peptide complexes from the unbound aptamer.
5 .2  EMSA WITH THE MUC1/V APTAMERS
Each aptamer (SI la, SI lb, S llc, S51a, S51b, S51c, S75a, S75b, and S75c) was incubated with the 
peptides (10 mer and 20 mer) in a 1: 1000 molar ratio in binding solution. The incubation of the aptamer- 
peptide solutions was carried out using two different conditions: 1) incubating the solution for 1 hour at 
ambient temperature with gentle shaking, 2) heating the solution at 95 °C for 5 minutes, followed by 
incubating the solution for 1 hour at ambient temperature with gentle shaking.
Subsequent to incubation, the samples were analysed on native PAGE and the gels were post stained with 
ethidium bromide. Figure 5.0 shows the analysis of the solution mixture of aptamers SI la, S51a and 
S75a (72 nt long) on a 14 % native PAGE. The free aptamer, used as a control is seen are lanes 5 and 8. 
The SI l a - 10 mer, SI la- 20 mer, S51a-10 mer and S51a- 20 mer mixtures are seen are lanes 4, 6, 7 and 
9 respectively. The band in lane 6 (SI la- 20 mer mixture) appears to be migrating just very slightly faster 
than the free aptamer and band 4 (SI la- 10 mer mixture). The band in lane 7 appears to be migrating 
vaguely faster than the free aptamer (lane 8). The samples which were not exposed to heat show the
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presence of the aptamers at ca. 75 bp with very low band shift patterns due to the low molecular weight 
of the 10 mer and 20 mer peptides of ca. 1 kDa and 2 kDa. When the aptamer-peptide mixtures heated at 
95°C were analysed by PAGE no bands were detected, lanes 1,2, 10 and 11 (Figure 5.0), suggesting that 
after the thermal denaturation, the aptamer is blocked from re-forming a secondary structure, necessary 
for the detection by the EtBr dye which is unable to intercalate with the aptamers to result in 
fluorescence during the exposure to UV light. Similar shift patterns were also observed for the S75a 
aptamer (appendix 2 .1).
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Figure 5.0. Analysis of the S l l a  and S51a-peptide mixture. 14% native PAGE: S lla : (1)
SI la + 10 mer at 95°C, (2) SI la + 20 mer at 95°C, (3) 25 bp ladder, (4) SI la  + 10 mer, (5) free S lla , (6) 
S lla  + 20 mer, S51a: (7) S51a + 10 mer, (8) free S51a, (9) S51a + 20 mer, (10) S51a + 10 mer at 95°C, 
(11) S51a + 20 mer at 95°C. The peptides do not stain with ethidium bromide and therefore were not 
analysed with the samples.
The solutions of 25 nt long MUC1/Y aptamer (S Ilb  S llc , S51b, S51c, S75b and S75c) and peptides 
were analysed on a 18 % native PAGE (figure 5.1). The free aptamer, used as a control is seen in lanes 5 
and 8 . The S 11 b- 10 mer, S 1 lb- 20 mer, SI lc- 10 mer and SI lc- 20 mer mixtures are seen in lanes 4, 6 , 7 
and 9 respectively. When the heated at 95°C aptamer-peptide mixtures were analysed, lanes 1,2, 10 and 
11, no bands were detected. For both aptamers (SI lb and Sl lc)  distinguishable shifts were not obtained 
whilst no aptamer bands are observed with the heated aptamer peptide solutions. Similar shift patterns 
were also observed for the aptamers S51b, S51c, S75b and S75c (appendix 2.2 - 2.4).
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Figure 5.1. Analysis of the S l lb  and S llc-pep tide mixture. 18% native PAGE: S llb : (1)
SI lb + 10 mer at 95°C, (2) Sl l b  + 20 mer at 95°C, (3) 25 bp ladder, (4) Sl l b  + 10 mer, (5) free Sl lb,  
(6) Sl l b  + 20 mer, Sllc: (7) Sl l c  + 10 mer, (8) free Sl lc,  (9) Sl l c  + 20 mer, (10) Sl l c  + 10 mer at 
95°C, (11) Sl l c  + 20 mer at 95°C. The peptides do not stain with ethidium bromide and therefore were 
not analysed with the samples.
EMSA’s of the control aptamers with the 10 mer and 20 mer peptides at ambient temperature and heating 
to 95°C, were performed using aptamers Sllb-smd, SI lc-smd and S75b-smd (scrambled versions of the 
Sl lb,  S l l c  and S75b respectively), SP6 8  (selected against a non-MUCl tumour target peptide) and S2.2 
(selected against MUC1)197. The sequences and the predicted secondary structures of the control 
aptamers are in appendix 2.0. The mixtures were analysed on an 18 % native PAGE (figure 5.2). The free 
aptamers correspond to the bands in lanes 5 and 8 . The bands of Sllb-smd-10 mer, Sllb-smd-20 mer, 
SI lc-smd-10 mer and SI lc-smd-20 mer mixtures were present in lanes 4, 6 , 7 and 9 respectively. Both of 
the scrambled aptamers (Sllb-smd and SI lc-smd) appear to have a faster mobility than the 25 bp marker 
and compared to the MUC1/Y aptamers SI lb and Sl lc.  Also in both cases the aptamer-20mer band is 
migrating slightly faster than the free aptamer and the aptamer-1 Omer band. The aptamer-peptide 
mixtures heated at 95°C were analysed in lanes 1, 2, 10 and 11, where bands around the 25 bp mark were 
not observed. EMSA’s of S75b-smd, SP6 8  and MUC1-S2.2 control aptamers also show either no or 
insignificant band shifts (appendix 2.3 and 2.5).
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Figure 5.2. Analysis of the S llb-sm d and Sllc-smd-peptide mixture. 18% native PAGE: 
Sllb-smd: (1) SIlb-smd + 10 mer at 95°C, (2) Sllb-smd + 20 mer at 95°C, (3) 25 bp ladder, (4) S11 b- 
smd + 10  mer, (5) free Sllb-smd, (6) Sllb-smd + 20 mer, SI lc-smd: (7) SI lc-smd + 1 0  mer, (8) free 
SI lc-smd, (9) SI lc-smd + 20 mer, (10) SI lc-smd + 1 0  mer at 95°C, (11) SI lc-smd + 20 mer at 95°C. 
Smd = scrambled aptamer. The peptides do not stain with ethidium bromide and therefore were not 
analysed with the samples.
The pegylated aptamers Sllb-PEG, Sllc-PEG, S51b-PEG, S51c-PEG, S75b-PEG and S75c-PEG were 
also incubated with the two peptides under the previously described conditions and the mixtures were 
analysed on a 7 % native PAGE (figure 5.3). All the pegylated aptamers were significantly retarded in 
the gel as expected and have migrated slightly further away from the loading wells. The free aptamer, 
used as a control is seen in lanes 5 and 8 . The Sllb-PEG-10 mer, Sllb-PEG-20 mer, Sllc-PEG-10 mer 
and SI lc-PEG-20 mer mixtures are seen in lanes 4, 6 , 7 and 9 respectively. For both aptamers, the 20 
mer band was migrating slightly faster than the 10 mer band and the free aptamer. The pegylated 
aptamer-peptide mixtures heated at 95°C were analysed in lanes 1, 2, 10 and 11 and no bands were 
detected when stained with EtBr, however the presence of the pegylated aptamer was indicated by the 
rusty coloured bands when stained with BaClI solution. Comparable shift patterns were also observed for 
the pegylated aptamers S51b-PEG, S51c-PEG, S75b-PEG and S75c-PEG (appendix 2.6 - 2.7).
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Figure 5.3. Analysis of the pegylated S l lb  and S llc-pep tide m ixture. 7 % native PAGE:
(A) Sllb-PEG: (1) Sllb-PEG + 10 mer at 95 °C, (2) Sllb-PEG + 20 mer at 95°C, (3) 25 bp ladder, (4) 
Sllb-PEG + 10 mer, (5) free Sllb, (6) Sllb-PEG + 20 mer, Sllc-PEG: (7) Sllc-PEG + 10 mer, (8) 
free S llc, (9) Sllc-PEG + 20 mer, (10) Sll-PEG c + 10 mer at 95°C, (11) Sllc-PEG + 20 mer at 95°C.
(B) Same as gel A, but stained with BaClI for staining of PEG. The peptides do not stain with ethidium 
bromide and therefore were not analysed with the samples.
All analysed MUC1/Y aptamers (full length, truncated, and pegylated) and the control aptamers exhibit 
negligible band shifts when incubated with the 10 mer and 20 mer peptides since the MUC1/Y peptides 
have a low molecular weight ( 1 - 2  kDa) compared to the full length (22 kDa), truncated (8 kDa) and 
pegylated (40 kDa) aptamers. The EMSA is a not a suitable technique to detect the aptamer-peptide 
complex formation due to the inability to resolve the very small molecular weight differences. Moreover, 
all the aptamers including the control aptamers, when heated to 95°C for 5 minutes appeared to interact 
with the peptides which interfered with the formation of the secondary structure of the aptamer. This 
effect was indicated in the gel by the disappearance of the aptamer bands after staining with EtBr, an 
intercalating dye. This suggests that non-specific aptamer binding to the target when fully denatured 
(presence of no secondary structure) is likely to take place.
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S.S PRINCIPLE OF THE AFFINITY CHRQMATOSRAPHYTECHNIQUE
Affinity column chromatography is mostly employed for aptamer selection against a target but can also 
be used for the assessment of aptamer specificity and affinity for its target. The ionic strength required to 
disrupt the target-oligonucleotide complex is correlated to the affinity and specificity of the 
oligonucleotides for their targets. In this system, the target is immobilised onto a column containing an 
NHS activated sepharose matrix to which the oligonucleotide solution is then loaded and incubated with 
the stationary target. The elution is performed using a solution gradient of increasing salt concentrations. 
Any excess or unbound oligonucleotide is eluted from the column at the lowest concentration of salt 
solution. The remaining bound aptamer is eluted by the mobile phase of increasing polarity. Each eluted 
fraction corresponding to the different molar salt concentrations is analysed by UV spectroscopy to 
detect the presence of oligonucleotide. The salt concentrations required to elute each aptamer from the 
target are compared to determine the affinity and specificity of the aptamers for their target as described 
in the literature 197.
5.4 a f f i n i t y  c h r o m a t o g r a p h y  W ith  t h e  m u c i/Y  a p t a m e r s
The MUCI/Y peptides (10 mer and 20 mer) were individually immobilised onto a NHS activated 
sepharose matrix of a 1 mL HiTrap affinity chromatography column. Each aptamer, S ll series (S lla, 
S llb, Sllb-smd, Sllb-PEG, Sllc, SI lc-smd, and Sllc-PEG), S51 series (S51a, S51b, S51b-PEG, S51c, 
S51c-PEG and SP68), and S75 series (S75a, S75b, S75b-smd, S75b-PEG, S75c and S75c-PEG) in 
binding solution, was added to the affinity column and incubated at ambient temperature for 1 hour. The 
column was then eluted with elution solutions (1 mL each) of increasing NaCl concentrations ranging 
from 0.2 M -  1.6 M at 0.2 M increments. Subsequently, to regenerate the affinity chromatography 
columns, these were washed with a 3 M sodium thiocyanate solution and re-equilibrated with binding 
solution. Each eluted fraction was analysed by UV-Vis spectroscopy measuring the absorbance of the 
aptamer at 260 nm. The UV absorbance of each eluted aptamer was subtracted from the initial 
absorbance of the aptamer prior to loading on to the column to ascertain the presence of the aptamer 
remaining on the affinity column. As indicated in the table shown in appendix 2.8, the UV measurements
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for all the aptamers analysed showed the majority of the aptamer had eluted at the lowest NaCl 
concentration of 0.2 M and the bound aptamers could not be eluted even at the highest NaCl 
concentration of 1.6 M. NaCl. Concentrations above 1.6 M were not used to avoid the risk of dehydrating 
the matrix of the chromatography column. Figure 5.4 shows the analysis of the S ll  aptamer series. A 
significant difference of aptamer binding to the two peptides was not observed, suggesting that the length 
of the target does not appear to have an effect on the binding potential of the aptamers. The binding of 
the full length aptamer S l l a  (25.9 % and 29.3 %) is comparable to the truncated SI lb (31.6 % and 21.5 
%) and the control aptamer Sllb-smd (27.1 % and 20 %) to the 10 mer and 20 mer peptide respectively. 
However, the binding of the truncated Sl l c  (39.1 % and 35.4 %) is moderately higher than Sl la,  S l lb  
and the control aptamer SI lc-smd (28.1 % and 25.0 %) to the 10 mer and 20 mer peptide respectively. 
Interestingly, the Sllb-PEG (47.4 % -20 mer) and Sllc-PEG (77.7 % and 83.2 %) has shown substantial 
increase in binding for the 1 0  mer and 2 0  mer peptides respectively compared to that of the unmodified 
aptamers.
S lla  - 10 mer
S lla  - 20 mer
S llb  - 10mer
S llb  - 20 mer
Sllb-smd - 1 0  mer
Sllb-smd - 2 0 mer
£  S llb -P E G -10mer 
g
S Sllb-PEG - 2 0 mer
SI lc - 10 mer 
S llc  - 20 mer 
SI lc-smd - 1 0  mer 
SI lc-smd - 2 0  mer 
Sllc-PEG - 10 mer 
S llc-PEG -20 mer
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Figure 5.4. A ptam er binding of S l l  aptam er series. Each bar represents the percentage of 
bound aptamer subsequent to the 1.6 M NaCl elution of the affinity column for each MUCI/Y peptide 
(10 mer and 20mer). Values are expressed as mean % (n = 3), with the exception of the pegylated 
aptamers and S 1 lb-smd (n = 1).
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Figure 5.5 shows the analysis of the S51 aptamer series and the SP68 control aptamer with the MUCI/Y 
peptides. In this series, each aptamer has a greater percentage of binding to the 10 mer peptide than the 
20mer peptide and the truncated aptamers (S51b and S51c) bind less than the full length aptamers 
(S51a). The binding of the full length aptamer S51a (50 % and 45.2 %) is notably higher than the 
truncated S51 b (29.5 % and 24.5 %) and truncated S51c (33.8 % and 25.7 %), whilst the binding of the 
control aptamer, SP68 (a non-MUCl tumour target peptide) (26.4 % and 25.4 %) did not show 
substantial difference in binding compared to truncated aptamers. Also, like in the S ll series, S51b-PEG 
(79.8 % and 59.8 %) and S51c-PEG (89.3 % and 76.2 %) have shown a significant increase in the 
binding to the lOmer and 20 mer peptides respectively compared to the unmodified aptamer.
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Figure 5.5. A ptam er binding of S51 aptam er series. Each bar represents the percentage of 
bound aptamer subsequent to the 1.6 M NaCl elution of the affinity column for each MUCI/Y peptide 
(10 mer and 20mer). Values are expressed as mean % (n =3), with the exception of the pegylated 
aptamers (n = 1).
Figure 5.6 shows the analysis of the S75 aptamer series. A significant difference in the aptamer binding 
to the two peptides did not seem apparent as the percentage of aptamer bound to both peptides was 
relatively similar, as observed in the analysis of the S ll aptamer series. The binding of the full length 
aptamer S75a (30.5 % and 31.4 %) is comparable with the binding of the truncated aptamers S75b (33.3
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% and 24.7 %) and S75c (25.4 % and 28.8 %) to the 10 mer and 20 mer peptides respectively. The 
binding of the control aptamer S75b-smd (28.9 % and 21.6 %) to the MUCI/Y peptides is slightly 
reduced by 4.4 % and 3.1 % respectively. Furthermore, like in the pervious aptamer series, the enhanced 
binding of the pegylated aptamers S75b-PEG (41 % and 37.2 %) and S75c-PEG (54.4 % and 55.2 %) is 
shown for the 10 mer and 20 mer peptides respectively compared to the unmodified aptamers, though in 
this case it is perhaps not as pronounced as it has been for the two previous aptamer series.
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ci,
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30.5
31.4
33.3
24.7
Aptamer incubated with 
10 mer peptide
Aptamer incubated with 
20 mer peptide
28.9
21.6
41.0
37.2
25.4
28.8
54.4
55.2
0
1111)1111 I i
10 20 30 40
i | i i i' i | i i i i | i i■!'i [ i
50 60 70 80
' I 1 ' ' ' I
90 100
Bound Aptamer (%)
Figure 5.6. A ptam er binding of S75 aptam er series. Each bar represents the percentage of 
bound aptamer subsequent to the 1.6 M NaCl elution of the affinity column for each MUCI/Y peptide 
(10 mer and 20mer). Values are expressed as mean % (n = 3), with the exception of the pegylated 
aptamers (n = 1).
Considerable changes in the percentages of aptamer bound to the peptides were not observed between the 
full length and the truncated aptamers, or with the control aptamers. The affinity chromatography 
technique has shown that for all the aptamers analysed, 0.2 M NaCl fraction contained DNA being 
possibly the excess and unbound aptamer. Aptamer elution in any other salt concentrations was not 
observed. For aptamer series S ll and S75 it was observed that the length of the peptides did not signify 
an importance in the binding of the aptamer. Although, this was not the case for the S51 aptamer series, 
where binding of the aptamers to the 10 mer peptide was enhanced compared to the 20 mer peptide. The
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S51a full length aptamer has greater binding to both MUC 1 AT peptides compared to the SI la and S75a. 
Also, evident from the results for all three aptamer series was the remarkable increase in binding of the 
pegylated aptamers to the peptides compared to the unmodified aptamers and to the full length aptamers. 
This could be an implication that the large PEG polymer may affect the structure of the aptamer which 
has resulted in enhanced binding to the peptides. The specificity of the aptamer for the peptides could not 
be identified as the percentage of control aptamer bound to the peptides was comparable to the aptamers 
selected against the MUCI/Y peptides.
5 .5  PRINCIPLE OF THE THERMAL DNA DENATURATION TECHNIQUE 
Thermal denaturation of oligonucleotides, also referred to as melting, is the dissociation of a double 
stranded oligonucleotide, resulting in two single strands. This technique utilises heat to break the 
hydrogen bonds between the bases responsible for the formation of a duplex strand. This can also be 
applied to single stranded oligonucleotides to assess their conformational changes, whereby the breaking 
of hydrogen bonds of base-pairs, involved in the formation of the stem structure, is monitored. The 
melting temperature (Tm) is the temperature at which 50 % of the oligonucleotide secondary structure has 
been denatured and the remaining 50 % still retains its original conformation. Melting temperature of an 
oligonucleotide is extensively dependent upon the length and sequence composition of the 
oligonucleotide. Thus, a sequence rich in guanine-cytosine (G-C) pairs will be more stable than a 
sequence rich in adenosine-thymine (A-T) pair and therefore higher melting temperatures are observed. 
The oligonucleotide melting can be monitored by 1) UV absorbance or 2) fluorescence using an 
intercalating or high resolution melting (HRM) dye. When the UV absorbance is analysed, as the 
oligonucleotide melts, the signal at 260 nm increases as the temperature rises. In the case of fluorescence 
analysis, an HRM dye, such as SYBR Green, which binds only to the double stranded section of the 
oligonucleotide structure, is employed. The binding of the SYBR Green dye to the double stranded 
oligonucleotide shows fluorescence at 520 nm when excited at 497 nm. During thermal denaturation, as 
the oligonucleotide melts, the dye is dissociated free into solution, resulting in a decrease in the 
fluorescence emission. In both methods of analysis, UV and fluorescence, the melting temperature 
provides an indication of the stability of the secondary structure of an oligonucleotide. Thus, the
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determination of the melting temperature can be employed to assess the effects of any modifications 
made to the oligonucleotide, i.e. whether the alterations are stabilising or weakening the bonds which 
form the secondary structure.
5.6  THERMAL DENATURATION OF THE MUC1/V APTAMERS
For the determination of the thermal denaturation of the MUCI/Y aptamers, the fluorescence analysis 
approach was employed using the HRM SYBR green dye, as this technique is considerably more 
sensitive than the UV absorbance method. Each aptamer of the SI 1 series (S lla, SI lb, SI lb-smd, SI lb- 
PEG, Sllc, SI lc-smd, and Sllc-PEG), the S51 series (S51a, S51b, S51b-PEG, S51c, and S51c-PEG), 
the S75 series (S75a, S75b, S75b-smd, S75b-PEG, S75c and S75c-PEG) and the additional control 
aptamers SP68 (selected against a non-MUCl tumour target peptide) and S2.2 197 (selected against 
MUC1) was incubated with the peptides (10 mer and 20 mer) in a 1: 1000 molar ratio, in binding 
solution, for 1 hour, at ambient temperature. Upon incubation, the SYBR green dye was added to the 
aptamer solution and incubated for 30 minutes on ice. This thermal denaturation cycle (TDC) was 
performed three times from 3°C to 100°C at a rate of 1°C/ min with a gradual renaturation process 
between each cycle. The emission was detected at 520 nm when excited at 497 nm. Figure 5.7 shows 
plots for SI la  (A) and Sl la  with the 20mer peptide (B) at each TDC. In the case of SI la  (figure 5.7A), a 
minimal variation in fluorescence was observed between the three TDC. When Sl la  was incubated with 
the 20 mer peptide (figure 5.7B) on the other hand, the fluorescence value at the beginning of the 
analysis is slightly lower compared to the free aptamer (figure 5.7A). However, dramatic changes in 
fluorescence were observed during the second and the third TDCs where the values at the beginning of 
the cycle were ca. 0.5 and ca. 0.2 respectively. This effect suggests that the peptide is inhibiting the 
renaturation of SI la, resulting in the aptamer to remain mainly in an open conformation. A similar trend 
of gradual decrease in fluorescence through each cycle was also observed when the 10 mer peptide was 
used.
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Figure 5.7. Thermal denaturation of S lla . (A) Fluorescence melting profiles of S l l a  alone at 3 
TDC. (B) Fluorescence melting profiles of SI la with the 20 mer peptide at 3 TDC.
Moreover, all the aptamers, including the control aptamers, exhibited the same behaviour thus indicating 
that all aptamers appear to bind to the peptide when denatured. Therefore, for the purpose of greater 
accuracy in the analysis of the thermal denaturation data and for the simplicity of the discussion, only the 
first TDC for each aptamer with each peptide will be from now analysed and discussed. To determine the 
effect the peptides have on the conformation of the aptamer, and thus its significance upon binding, the 
fluorescence melting profiles will be presented as the percentage change in fluorescence (AF52onm (%)) vs 
temperature and the melting temperatures (Tm) will be determined as the first derivative. Tm values of 
each aptamer for all three TDC with both MUCI/Y peptides are presented in the table shown in appendix 
2.9. The results from the analysis of the S ll  series, without the addition of the peptides are shown in 
figure 5.8. The truncation of the S l l a  aptamer to S l l b  (central variable region) reduces the Tm from 
35°C to 21°C, resulting in a loss of thermostability of the aptamer by more than 10°C. The control 
scrambled version of S l lb  (Sllb-smd) has the same Tm as SI lb (21 °C), whilst the Sllb-PEG appears to 
possibly induce another stem structure resulting in a second Tm at 40°C. The other possibility could be 
that the solution may contain a mixture of S 11 b-PEG with two different structural conformations, one of 
which melts at 21°C and the other at 40°C. Figure 5.8B shows that truncation of the S l l a  aptamer to 
S l l c  (stem-loop region) has led to an aptamer with two Tm (20°C and 45°C) where the second Tm 
increases the thermostability of the aptamer by 10°C from 35°C to 45°C. S l l c  (Tm 20°C and 45°C) also
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appears to be more stable than the S l l b  (21°C). The control scrambled version o f S l l c  (S Ilc-sm d) 
reverts back to a single T m of 47°C appearing to be overall more stable than S l l b ,  whilst the pegylated 
S l l c  (S llc -P E G ) further increases the second T m by 5°C from 45°C to 50°C. Like the unmodified 
aptamer S l l b  and S 1 lc , the S 1 lc-PEG  (Tm 20°C and 50°C) appears to be more stable than the S 1 lb-PEG  
(Tm 20°C and 40°C).
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Figure 5.8. Therm al denaturation of S l l  series. (A) Fluorescence melting profiles o f S l l a  with 
the SI lb  versions (B) Fluorescence melting profiles of SI la  with the SI lc  versions.
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The effect of the MUCI/Y peptides added to the SI la aptamer is shown in figure 5.9. The addition of the 
10 mer peptide increases the Tm of the aptamer from 35°C to 43°C, whilst the addition of the 20mer 
peptide reduces the Tm by 5°C down to 30°C.
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Figure 5.9. Therm al denaturation of S l la .  Comparison of the fluorescence melting profiles of 
S l l a  with the 10 mer and 20 mer peptide.
Figure 5.10 shows the fluorescence melting profile of the truncated aptamers (Sl lb and Sl lc)  with the 
MUCI/Y peptides. The addition of the 10 mer peptide to SI lb causes a change in the melting profile as 
two Tm are observed (7°C and 20°C) although the there is no significant difference in the later Tm from 
that of free Sl lb  (21°C), whilst the 20 mer peptide reduces the Tm to 16°C (figure 5.10A). The addition 
of the 10 mer and the 20 mer peptides to SI lc causes the melting profile to change to provide a single Tm 
of 26°C and 16°C respectively from Sl l c  (20°C and 45°C). If the later Tm of S l l c  (45°C) is considered, 
then the addition of the lOmer peptide has decreased thermostability of the aptamer by ca. 20°C, whilst 
the 20 mer has caused a 30°C decrease (figure 5.10B). Thus, the MUCI/Y peptides have the greatest 
effect on the melting temperature of the SI lc aptamer compared to the SI la and Sl lb.
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Figure 5.10. Therm al denaturation of S l lb  and S llc . (A) Comparison of the fluorescence 
melting profiles of S l lb  with the 10 mer and 20 mer peptide. (B) Comparison of the fluorescence 
melting profiles of SI lc with the 10 mer and 20 mer peptide.
The thermal denaturation of the scrambled versions of the Sl lb  and S l l c  (Sllb-smd and SI lc-smd 
respectively) used as controls with the MUCI/Y peptides is shown in figure 5.11. The SI lb-smd has very 
similar Tm values as Sl lb.  Addition of the 10 mer produces a second Tm (20°C and 35°C) and the 20 mer 
decreases the Tm to 16°C from 21°C (Sllb-smd free) (figure 5.11A). Contrary to Sl lc,  the addition of the
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MUCI/Y peptides to SI lc-smd has less of an effect on the Tm, where the 10 mer and 20 mer decreased 
the Tm to 42°C and 36°C from an original Tm of 47°C (figure 5.1 IB). The SI lc-smd control aptamer 
appears to be more thermostable than the SI lc aptamer.
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Figure 5.11. Thermal denaturation of S llb-sm d and Sllc-sm d. (A) Comparison of the 
fluorescence melting profiles of Sllb-smd with the 10 mer and 20 mer peptide. (B) Comparison of the 
fluorescence melting profiles of SI lc-smd with the 10 mer and 20 mer peptide.
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Although the pegylated aptamers Sllb-PEG and Sllc-PEG have shown increased thermostability 
compared to the unmodified aptamers, the thermostability is not extensively retained upon the addition of 
the MUCI/Y aptamers. Comparable Tm values of Sllb-PEG (23°C and 19°C), shown in figure 5.12A, 
with S l lb  (20°C and 16°C) and likewise of Sllc-PEG (35°C and 19°C), shown in figure 5.12B, with 
S l l c  (26°C and 16°C) upon the addition of the 10 mer and 20 mer peptide respectively, suggests that the 
pegylation of the aptamers has not affected the ability of the aptamers to bind to the MUC1 A" peptides.
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Figure 5.12. Therm al denaturation of S llb -P E G  and S llc-P E G . (A) Comparison of the 
fluorescence melting profiles of Sllb-PEG with the 10 mer and 20 mer peptide. (B) Comparison of the 
fluorescence melting profiles of SI lc-PEG with the 10 mer and 20 mer peptide.
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Plots of the S51a series with the control aptamers (S2.2 (MUC1) and SP68) without the addition of 
peptides is shown in figure 5.13 and 5.14 respectively, for comparing the effect of truncation on aptamers 
with the full length aptamer and the effect of pegylation with the unmodified versions. The S51a full 
length aptamer has two Tm (30°C and 52°C) and the truncation of the aptamer to S51b led to the loss of 
the higher Tm and decreased the lower Tm to 18°C. The Tm of S51b-PEG is comparable to that of the 
unmodified aptamer, suggesting that the attachment of the large polymer has not effected the primary 
conformation of the aptamer. The MUC1 control aptamer has a lower thermostability than the S51a by 
12°C in both Tm (18°C and 40°C) (figure 5.13).
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Figure 5.13. Therm al denaturation of S51 series. Fluorescence melting profiles of S51a, the 
truncated S5lb versions and the control MUC1 aptamer.
The truncated loop region (S51c) of S51a has maintained the two Tm though with a 12°C reduction in the 
first Tm to 18°C. The Tm of S5lc-PEG (20°C and 61°C) is slightly higher than the unmodified aptamer 
and moreover, the second Tm of S51c-PEG at 61°C is also higher than S51a at 52°C. The SP68 control 
aptamer has a single Tm of 25°C, overall relatively lower than the tm of the S5 lc aptamers, although more 
comparable with the SI lb and S51 b aptamers (figure 5.14).
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Figure 5.14. Therm al denaturation of S51 series. Fluorescence melting profiles of S51a, the 
truncated S51c versions and the control SP68 aptamer.
The effect of the MUCI/Y peptides added to the S51a aptamer is shown in figure 5.15. The addition of 
the lOmer peptide retains the two Tm values of S51a (30°C and 52°C), although the thermostability is 
reduced by 10°C and 16°C respectively. The addition of the 20mer peptide appears to affect the 
conformation, whereby only a single Tm is observed at 29°C, comparable to the first Tm of 30°C.
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Figure 5.15. Therm al denaturation of S51a. Comparison of the fluorescence melting profiles of 
S51a with the 10 mer and 20 mer peptide.
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Figure 5.16 shows the fluorescence melting profile of S51b (variable region) and S51c (loop region) with 
the MUCI/Y peptides. This truncated aptamer, S51b has a single Tm (18°C) that is significantly lower 
than that of the first Tm of S51a (30°C). The addition of the 10 mer and 20 mer peptide increases the 
thermostability slightly to 25°C and 21°C respectively (figure 5.16A). The S51c (loop region) retains the 
two Tm (18°C and 55°C) as present in S51a (30°C and 52°C). However, the first Tm is reduced by 12°C. 
Conversely, upon the addition of the 10 mer and 20 mer peptides, only a single Tm is observed at 37°C 
and 30°C respectively, thus appearing that the primary Tm value of S51c (18°C) has increased by 19°C 
and 12°C respectively (figure 5.16B).
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Figure 5.16. Therm al denaturation o f  S51b and S51c. (A) Comparison of the fluorescence 
melting profiles of S51b with the 10 mer and 20 mer peptide. (B) Comparison of the fluorescence 
melting profiles of S5lc with the 10 mer and 20 mer peptides.
CHAPTER FIVE 139
QUALITATIVE MUC1 / ¥  APTAMER CHARACTERISATION 
The S51b-PEG shows comparable Tm (19°C) values with the unmodified S51b (18°C) even with the 
addition of the 20 mer peptide resulting in a Tm of 23°C (S51b-PEG) compared to 25°C (S51b). The 
S51b-PEG (33°C) has an 8°C higher stability with the 10 mer peptide than the S51b (25°C) (figure 5.17).
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Figure 5.17. Therm al denaturation of S51b-PEG. Comparison of the fluorescence melting 
profiles of S51b-PEG with the 10 mer and 20 mer peptides.
S51c-PEG has been able to maintain the two Tm (20°C and 61°C) of the unmodified S51c (18°C and 
55°C), even with the addition of the 10 mer peptide (36°C and 48°C) and 20mer peptide (20°C and 50°C). 
The S5 lc-PEG has slightly increased thermostability compared to the S51c and, although the stability is 
reduced to some extent with the addition of the MUCI/Y peptides, the Tm values are still comparable to 
that of the unmodified S51c (figure 5.18).
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Figure 5.18. Therm al denaturation of S51c-PEG. Comparison of the fluorescence melting 
profiles of S5lc-PEG with the 10 mer and 20 mer peptides.
The MUC1 aptamer has two Tm (18°C and 40°C) which goes to a single Tm on the addition of the 10 mer 
(29°C) and 20 mer (22°C) peptides. This trend of initially two Tm values and changing to only one Tm was 
also observed with the S l l c  (20°C and 40°C); 10 mer (26°C) and 20 mer (16°C) and with S51c (18°C and 
55°C); 10 mer (37°C) and 20 mer (30°C) (figure 5.19).
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Fig 5.19 Therm al denaturation of M U C l. Comparison of the fluorescence melting profiles of 
MUCl with the 10 mer and 20 mer peptides.
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The SP68 has a Tm of 25°C, whereby significant changes ate not observed upon the addition of the 10 
mer peptide (27°C) or the 20 mer peptide (29°C). SP68 has mainly retained its thermostability upon the 
addition of the MUCI/Y peptides (figure 5.20).
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Figure 5.20. Therm al denaturation of SP68. Comparison of the fluorescence melting profiles of 
SP68 with the 10 mer and 20 mer peptides.
Plots of the S75a series without the addition of the MUCI/Y peptides is shown in figure 5.20. The full 
length S75a has three Tm (20°C, 35°C and 59°C) and the S75b (variable region) has a single Tm of 19°C 
comparable to the first Tm of S75a. The control aptamer, S75b-smd has two Tm (20°C and 47°C) of which 
the first Tm value is the same as the first Tm of S75a, and the second Tm (47°C) is between the second and 
third Tm values of S75a. The Tm of S75b-PEG (20°C and 40°C) is more comparable with the values of 
S75b-smd than the unmodified S75b, whereby a second Tm at 40°C is introduced (figure 5.20A). S75c 
(loop region) has Tm of 22°C, 43°C and 63°C, retaining the three Tm values of the full length S75a with 
slightly greater thermostability. The S75c-PEG has similar Tm values (21°C, 35°C and 63°C) to the 
unpegylated S75c with the exception of the second Tm values which is lower by 8°C (figure 5.2IB).
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Figure 5.21. Therm al denaturation of S75 series. (A) Fluorescence melting profiles of S75a with 
the S57b versions (B) Fluorescence melting profiles of S75a with the S75c versions.
The effect of the MUC1/Y peptides added to the S75a aptamer is shown in figure 5.22. The addition of 
the 10 mer peptide appears have caused a loss in the third Tm at 59°C and exhibit to Tm of 20°C and 43°C, 
whilst the addition of the 20 mer peptide only displays a single Tm of 28°C, 8°C higher than the first Tm 
of the free S75a and with the 10 mer peptide.
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Figure 5.22. Therm al denaturation of S75a. Comparison of the fluorescence melting profiles of 
S75a with the 10 mer and 20 mer peptide.
Figure 5.23 shows the fluorescence melting profile of S75b (variable region) and S75c (loop region) with 
the MUC1/Y peptides. The thermostability of S75b remains unchanged compared to the free aptamer 
upon the addition of the lOmer peptide at a Tm of 19°C. However, the addition of the 20 mer peptide 
increases the thermostability by 4°C to 23°C (figure 5.23A). The addition of the MUC1/Y peptides 
appears to reduce the thermostability and change the conformation of S75c, as only two Tm (20°C and 
30°C) are observed with the addition of the 10 mer peptide and only a single Tm (22°C) with the 20 mer 
peptide compared to the Tm values of the free S75c (22°C, 43°C and 63°C) (figure 5.23B).
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Figure 5.23. Therm al denaturation of S75b and S75c. (A) Comparison of the fluorescence 
melting profiles of S75b with the 10 mer and 20 mer peptide. (B) Comparison of the fluorescence 
melting profiles of S75c with the 10 mer and 20 mer peptides.
The control aptamer S75b-smd which is the scrambled version of the S75b has two Tm (20°C and 47°C) 
as opposed to single Tm like the S75b (19°C), although upon the addition of the MUC1/Y peptides, S75b- 
smd only remains with a single Tm of 22°C and 24°C for the 10 mer and 20 mer peptide respectively. The
CHAPTER FIVE 145
QUALITATIVE MUC1/Y APTAMER CHARACTERISATION 
Tm values following the addition of the MUC1/Y peptides are comparable with the Tm of S75b at 19°C 
and 23°C upon the addition of the 10 mer and 20 mer peptide respectively (figure 5.24.).
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Figure 5.24. Therm al denaturation of S75b-smd. Comparison of the fluorescence melting 
profiles of S75b-smd with the 10 mer and 20 mer peptide.
The S75b-PEG has two Tm (20°C and 40°C) of which the first Tm is comparable to the single Tm of 
unmodified S75b (19°C). The addition of the 10 mer peptide still retains the two Tm (19°C and 34°C) but 
with slightly reduced thermostability, whilst the addition of the 20mer peptide changes the conformation 
of S75b-PEG resulting in a single Tm of (28°C) (figure 5.25A). The Tm values of S75c-PEG (21°C, 35°C 
and 63°C) are similar to the unmodified S75c aptamer (22°C, 43°C and 63°C) with the exception that the 
second Tm is lowered by 8°C. The addition of the MUC1/Y peptides appears to bring about a 
conformational change in the aptamer, whereby only a single Tm at 39°C and 22°C for the 10 mer and 20 
mer peptides respectively is exhibited. Overall, the addition of the peptide reduces the thermostability of 
the original aptamer conformation (figure 5.25B).
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Figure 5.25. Therm al denaturation of S75b-PEG. Comparison of the fluorescence melting 
profiles of S75b-PEG with the 10 mer and 20 mer peptide.
This thermal DNA denaturation technique has been an insightful method to ascertain the potential 
conformational changes that may occur at particular temperatures, upon binding to the peptides and from 
any structural modifications. From the three different series of aptamers, including the control aptamers, 
single, double and triple melting points for an aptamer were observed on occasion. This could be 
attributed to a number of factors which includes the possibility that there is a mixture of conformations of 
the aptamer in solution. Alternatively, there maybe just one conformation which contains one, two or
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three short stems which have different Tm values. The fluorescence melting curves obtained from all the 
aptamers has evidently shown that once the aptamer denatures in the presence of the peptide, re-folding 
of the aptamer back to its natural conformation was inhibited. In the case of the MUCl/Y peptides, the 
length of the peptide played a significant role as the 20 mer peptide was able to denature the aptamer to a 
greater extent than the 10 mer peptide prior to the first TDC. Thus, greater reduced thermostability of the 
aptamer was observed with the 20 mer peptide than the 10 mer peptide during the first TDC (table 5.0). 
This was exhibited by the progressive decrease in the fluorescence of the SYBR Green dye through each 
TDC. As this trend was also observed with the control aptamers, this could be a possible indication, that 
as the scrambled and selected aptamers possess identical base composition and charge, once 
unstructured, can interact similarly with the peptides. In the case of all three aptamer series, the truncated 
b versions (central variable region) of the full length aptamer presented reduced Tm, whilst the truncated 
c versions (stem-loop region) showed greater stability than the b version and comparable or higher Tm 
values to the full length aptamers. This is expected, as the truncated c versions contained the main 
structural features of the aptamers and their truncations were based on these features. The scrambled 
control aptamer SI lb-smd had the same Tm as SI lb, whilst SI lc-smd had greater Tm than the full length 
SI la. S75b-smd showed greater thermostability than the S75b. All the pegylated aptamers exhibited 
greater thermostability than the unmodified aptamers except for S51b-PEG which had a similar Tm to the 
unmodified S51b. This typically indicates that the pegylation of the aptamers aids in improving the 
thermostability of the aptamers. The pegylated aptamers retain their increased thermostability compared 
to the unmodified aptamers upon the addition of the MUCl/Y peptides. In addition, all the pegylated 
aptamers with the exception of the S51b-PEG possess two or more melting temperatures, of which one is 
greater than 37°C. This implies that at physiological temperature, the pegylation of the aptamers would 
assist in the maintenance of the natural aptamer conformation. Furthermore, upon the pegylated aptamer 
binding to the target peptides the aptamer is still able to adopt an open structure, further strengthening the 
affinity of the aptamer for the peptides. Thus, pegylated aptamers would be the most applicable when 
considered for studies involving physiological temperatures as initially the original structure of the 
aptamer is stabilised and the large polymer also does not demonstrate any form of interference in the 
binding of the aptamers with the MUCl/Y peptides. The control non-MUCl/Y aptamers (MUC1 and
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SP68) shows comparable Tm values to the MUCl/Y aptamers, however, SP68 appears to be the only 
aptamer which shows least effect on the conformation of the aptamer upon the addition of the peptides. 
This is an indication that SP68 may not have a significant affinity and specificity for the MUCl/Y 
peptides and should be expected, as this aptamer has been selected for a non-MUCl related target (table 
5.0).
APTAMER MELTING TEMPERATU1EtE
Free Aptamer Aptamer + 10 mer Aptamer + 20 mer
S l la 35°C 43°C 30°C
S llb 21°C 7°C;20°C 16°C
Sllb -sm d 21°C 20°C;35°C 16°C
S llb -P E G 20°C;40°C 23°C 19°C
S l lc 20°C;45°C 26°C 16°C
S llc-sm d 47°C 42°C 36°C
S llc-P E G 20°C;51°C 35°C 19°C
S51a 30°C; 52°C 20°C; 36°C 29°C
S51b 18°C 25°C 21°C
S51b-PEG 19°C 33°C 23°C
S51c 18°C;55°C 37°C 30°C
S51c-PEG 20°C; 61°C 36°C; 48°C 20°C;50°C
S75a 20°C; 35°C; 59°C 20°C; 43°C 28°C
S75b 19°C 19°C 23°C
S75b-smd 20°C;47°C 22°C 24°C
S75b-PEG 20°C; 40°C 19°C; 34°C 28°C
S75c 22°C; 43°C; 63°C 20°C;30°C 22°C
S75c-PEG 21 °C; 35°C; 63°C 39°C 22°C
MUC1 18°C; 40°C 29°C 22°C
SP68 25°C 27°C 29°C
Table 5.0. M elting tem peratures of the M U C l/Y  aptam ers. Melting temperature of the first 
TDC is shown for each aptamer before the addition of the peptides and with the each peptide.
5.7 CONCLUSION
The three qualitative characterisation techniques (EMSA, affinity column chromatography and DNA 
thermal denaturation) performed have revealed numerous aspects of the MUCl/Y aptamers behaviour 
towards their target peptides. Whilst the EMSA at first hand does not show any obvious complex 
formation of the aptamer with the peptides, the EMSA results do indicate for all the aptamers analysed 
that upon heating of the aptamer and peptide together, even for a period as short as 5 minutes, the peptide
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is capable of binding to the denatured aptamer and inhibiting the renaturation of the aptamer. On the 
EMSA analysis this was indicated by the disappearance of the aptamer band, as the EtBr was unable to 
intercalate with an open DNA structure. This was further emphasised by the fluorescence thermal 
denaturation studies, whereby a progressive decrease in the fluorescence was observed with each thermal 
denaturation cycle. Both the EMSA and the fluorescence thermal denaturation studies demonstrated that 
the conjugation of the aptamers to a large polymer PEG did not affect the binding of the aptamers to the 
peptides prior to denaturation and during denaturation.
The results obtained from the fluorescence thermal denaturation studies have provided greater 
clarification of the outcomes obtained from the affinity column chromatography studies. As an overall 
trend for all three series, it appears that the conformation the aptamer has prior to the interaction with the 
peptides is different to the conformation the aptamer adopts upon binding to the peptides and the latter 
potentially determines the affinity of the aptamer. As an example, upon binding to the 10 mer peptide, 
SI lb has a Tm of 7°C and 20°C, SI lb-smd has a Tm of 20°C and 35°C, and SI lb-PEG has a Tm of 20°C 
and 40°C, with a 10 mer affinity column binding of 32 %, 27% and 20.5% respectively. This trend 
implies that as the second Tm of each aptamer increases, greater secondary structure of the aptamer is 
present and combined with the low affinity column binding results, this further suggests that a more open 
conformation of the aptamer yields greater affinity of the aptamer for the target peptide. However, this 
trend is not consistent with all the aptamers. As an example, upon binding to the 20 mer peptide, SI lb 
has a Tm of 16°C, SI lb-smd has a Tm of 16°C, and SI lb-PEG has a Tm of 19°C, with a 20 mer affinity 
column binding of 21 %, 20% and 47% respectively. In this case SI lb-PEG has a low Tm (19°C) yet the 
binding in the affinity column to the 20 mer peptide was 47%. This suggests that only an open 
conformation is not the main determinant for the binding of the aptamer to the peptides, but also the 
overall conformation of the aptamer plays a significant role in the binding and thus indicating structural 
specificity of the aptamers for their target upon binding. However, differences in aptamer Tm that are 
below room temperature are of no relevant significance with respect to the binding, as these would be 
mute point unless experiments were performed at 4°C, and would of course not be useful in the design of 
a therapeutic that needs to function at physiological temperatures. Thus, differences between SI lb, for
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example (Tm of 16°C) and SI lb-PEG (Tm of 19°C) would not actually portray any specific binding, as 
both aptamers would be unstructured at a physiological temperature. On the other hand, the pegylated 
aptamer has been shown to have a higher affinity for the peptide. Thus, though the selection has been 
performed with different methodologies and consensus sequences have been obtained, which are clearly 
important for binding, it appears that the binding of the selected aptamers to the MUCl/Y peptides is not 
based on a key-lock mode of binding, where the aptamer retains a fixed secondary structure, but it is 
more based on the aptamers and peptides adopting complementary structures that lead to optimal 
binding. Furthermore, of the two control aptamers, MUC1 displayed comparable Tm values to the 
MUCl/Y aptamers whilst the SP68 exhibited the least change in conformation upon the addition of the 
peptides. Likewise, if however scrambled peptides (10 mer and 20 mer) were to be used, there is a high 
probability that the aptamers may interact with the scrambled peptides as with the unscrambled peptides. 
This could be a result of the aptamers being more structural specific to the peptides than sequence 
specific. Thus, if the structure of the scrambled peptides remained unaffected, then significant 
differences in the denaturation of the aptamers may not be observed.
Therefore to conclude the overall findings from the combination of all three techniques, it appears that 
the conformation which the aptamer adopts upon binding to the peptide then further determines its 
affinity for the target. Typically if the conformation is resulting in a more open structure, then the affinity 
for the target appears to be greater and the interaction between the aptamer and peptide can be 
irreversible.
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6 .0  INTRODUCTION
The qualitative analysis of series SI 1, S51 and S75 aptamers all indicated affinity for the MUCl/Y 10 
mer and 20 mer peptides to varying degrees, depending upon the conformation they adopt, which is 
influenced by temperature. As the MUCl/Y peptide sequences are identical to the sequence present in 
the MUCl/Y protein21. expressed on many carcinoma cells lines, it was essential to determine whether 
the selected aptamers exhibit any form of binding to the full protein expressed on tumour cells. In 
addition, the aptamers possess different melting temperatures, and some aptamers were found to have Tm 
similar to that of the physiological temperature 37°C, whilst others have Tm values significantly higher or 
lower than 37°C. Therefore, it was also crucial to analyse whether there was a correlation in Tm value 
with the aptamer binding. To assess the binding of the aptamers, fluorescence activated cell sorting 
(FACs) technique was employed, which entails incubation of the fluorescently labelled aptamers with the 
cell lines of interest, followed by separation and analysis of these cells based on their size and 
fluorescence. Changes in the shift pattern of the histograms indicate whether binding of the aptamers to 
the MUCl/Y protein expressed on the cells has taken place when compared to the cytometric profile of 
the control cells (no aptamer). From the ten different cancer cell lines screened for MUC1 and MUCl/Y 
positive cell lines, three MUC1 positive MCF-7 (human breast carcinoma), DU145 (human prostate 
carcinoma) and CALU-6 (human lung carcinoma) and one MUC1 negative A498 (human kidney 
carcinoma) cell lines were used to conduct FACs analyses. Alongside the cell binding studies, cell 
internalisation of the aptamers on the same four cell lines was also investigated using fluorescence 
microscopy analysis.
6.1 APTAMER CELLULAR BINDING USING FACs
Each Cy3 fluorescently labelled aptamer of the SI 1 series (SI lb, SI lb-smd, SI lb-PEG, SI lc, SI lc-smd, 
and Sllc-PEG), the S51 series (S51b, S51b-PEG, S51c, and S51c-PEG), the S75 series (S75b, S75b- 
smd, S75b-PEG, S75c and S75c-PEG) and the control aptamer SP68 (selected against a non-MUCl 
tumour target peptide) were incubated with MCF-7, DU145, CALU-6 and A498 cell lines in PBS at 37°C 
for 1 hour. Upon incubation, the cells were washed with PBS, centrifuged, resuspended in PBS and
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analysed. Histograms of the S ll series analysed with the four carcinoma cell lines, clearly demonstrate 
that aptamer binding in the MUCl/Y positive cell lines (MCF-7, DU 145 and CALU-6) has taken place, 
as shown by a shift in the cytometric profiles to the right of the control cell population (figure 6.0). MCF- 
7 cell line showed significant binding to SI lb and Sllc,  but only marginally superior to that of their 
respective scrambled versions (SI lb-smd and Sllc-smd). SI lb-PEG demonstrated equal or slightly 
greater binding than SI lb, whilst Sllc-PEG had much lower binding than Sl lc  (figure 6.0, 1A-B). A 
similar binding trend was observed with the DU145 cell line but to a lesser extent than with the MCF-7 
cell line. The SI lb and Sl lc aptamers have comparable level of binding to their respective scrambled 
versions (SI lb-smd and Sllc-smd), whilst the SI lb-PEG shows slightly greater binding than the 
unmodified SI lb. On the other hand, the Sllc-PEG has shown similar or slightly less binding than the 
Sl lc (figure 6.0, 2A-B). CALU-6 cell line has shown as strong binding as the MCF-7 cell line with the 
S ll aptamer series. The scrambled SI lb-smd has a reduced affinity than SI lb whereas the SI lb-PEG 
has a similar binding profile to the unmodified aptamer. SI lc-smd has an almost identical binding to the 
aptamer Sl lc  and theSllc-PEG has lower binding than the unmodified aptamer. However, this decrease 
in binding is to a lesser extent to that observed with the MCF-7 cell line (figure 6.0, 3A-B). No binding 
of the SI 1 aptamer series was observed in the A498 MUCl/Y negative cell line with the exception of the 
Sllc-smd aptamer where some binding maybe observed when compared to the other S ll aptamers 
(figure 6.0, 4A-B).
The FACs analyses of the S ll aptamer series revealed that these MUCl/Y selected aptamers have 
specificity for their target protein expressed on the carcinoma cells, as binding was observed with the 
MUCl/Y positive cell lines and not on the MUCl/Y negative cell line. Furthermore, the pegylation of 
the aptamers have shown to alter the conformation of the aptamer, which is marked by the difference in 
the Tm value from the unmodified aptamer. Thus, the alteration in the aptamer structure clearly correlates 
to the changes in the binding to the protein expressed by the cells, as in the case of SI lb-PEG, where the 
increased thermal stabilisation of the aptamer from 45°C to 51°C leads to a reduction in binding. This is 
consistent with observations from the Tm study, where lower Tm values correlated with increased binding.
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However, the increase in thermal stability of the SI lb-PEG from 21°C to 40°C has led to no significant 
change in binding.
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SI lb-smd (Xu = 21°) 
Sllb-PEG (Tn = 2(fC; 4(PC)
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Figure 6.0. FACs histograms of S l l  aptamer series. (A) SI lb version (B) S llc  version. (1) 
MCF-7 cell line, (2) DU 145 cell line, (3) CALU-6 cell line and (4) A498 cell line.
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Figure 6.1 shows the FACs analysis of the S51 series and the control aptamer SP68. Considerable level 
of binding has been observed of the S51 aptamer series with the MCF-7 cell line. The aptamers S5 lb- 
PEG and S5lc-PEG have shown to retain their binding potential and are equal to their respective 
unmodified aptamers S51b and S51c. The control aptamer, SP68 has also shown binding and has a 
cytometric profile which is comparable to that of the Sllb-PEG (figure 6.1, 1A-B), although this was 
expected as this aptamer was also selected against another tumour target (non-MUCl). The S51 aptamer 
series, however, has shown only minor binding to the DU145 cell lines, where again the S5lb-PEG and 
S5lc-PEG display comparable binding with the unmodified aptamers S51b and S51c respectively. 
Furthermore, the control aptamer SP68 has similar binding to the S51b aptamer (figure 6.1, 2A-B), as 
expected. The CALU-6 cell line showed variability in the binding to the different aptamers of the S51 
series. S5lb-PEG and S5lc-PEG showed lower binding when compared to the unmodified aptamers 
S51b and S51c respectively. Moreover, although SP68 has shown binding, it is to a less extent than the 
S51b aptamer (figure 6.1, 3A-B). This series of aptamers have shown negligible level of binding and the 
shift like appearance of the cytometric profiles are likely to be attributed to the increase in the cell 
population and thus explaining the broadness of the peak. Additionally, the SP68 does not show any 
significant binding (figure 6.1, 4A-B).
Analysis of the S51 aptamer series has demonstrated that the greatest binding of the pegylated and 
unpegylated aptamers was observed with the MCF-7 cell line. The modified aptamers S5lb-PEG (Tm: 
19°C) and S5lc-PEG (Tm: 20°C; 61°C) share similar Tm values with their respective unmodified 
aptamers S51b (Tm: 18°C) and S51c (Tm: 18°C; 55°C) along with exhibiting similar binding profiles with 
the DU145 cell line. Contrary to this, the aptamers S5lb-PEG and S5lc-PEG exhibit reduced binding 
than the unmodified aptamers in the CALU-6 cell line. This would indicate one of three possibilities; 1) 
the adoption of a slightly different conformation of the pegylated aptamers at 37°C, 2) the structural 
conformation of the MUCl/Y protein expressed varies slightly in each cell line, or 3) that the PEG offers 
a varying level of steric hindrance, which may be different depending on the cell line and the other 
expressed cell surface determinants. The latter two options appear to be more plausible, as if only the 
thermal stability, hence the conformation of the aptamer, was the determinant of the binding, then similar
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cytometric profile changes with the unmodified aptamers would be have been observed, especially in the 
case of the S51b and S5 lb-PEG where there is only a 1°C difference in the Tm value.
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Figure 6.1. FACs histograms of S51 aptamer series and control aptamer SP68 . (A) S51b
version (B) S51c version. (1) MCF-7 cell line, (2) DU145 cell line, (3) CALU-6 cell line and (4) A498 
cell line.
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FACs analysis of the S75 aptamer series with four different cell lines is shown in figure 6.2. The S75b 
aptamer versions all show considerable binding to the MCF-7 cell line, although the S75b-PEG shows 
fractionally less binding compared to the unmodified aptamer. The S75c aptamer versions appear to 
display lower binding than the S75b aptamer versions. Again, the S75c-PEG has shown less binding than 
the unmodified aptamer S75c (figure 6.2, 1A-B). With the DU145 cell line, only limited binding was 
observed with the S75b and S75b-smd, whilst no binding was detected with the S75b-PEG, S75c and 
S75c-PEG (figure 6.2, 2A-B). A similar trend that was observed with MCF-7 cell line was also observed 
with the CALU-6 cell line, where the S75b aptamer versions all displayed significant binding, whilst the 
S75c exhibits binding but to a lesser extent. Furthermore, the S75c-PEG had an even lower binding than 
the unmodified aptamer (figure 6.2, 3A-B). No binding of the S75 aptamer series was observed in the 
MUC1 /Y negative A498 cell line (figure 6.2,4A-B).
The most substantial binding from the FACs results is obtained with the MCF-7 and the CALU-6 cell 
lines. Furthermore, the S75b-PEG (Tm: 20°C; 40°C) shows equal binding to the unmodified aptamer 
S75b (Tm: 19°C). This suggests that the adopted conformation as a result of conjugating the aptamer to a 
large polymer, indicated by the change in Tm value, has not by and large affected the binding potential of 
the aptamer. However, this does not appear to be so in the case of the S75c-PEG (Tm: 21 °C; 35°C; 63°C) 
where a noticeable reduction in the binding is observed compared to the unmodified S75c (Tm: 22°C; 
43°C; 63°C). Hence, a change in the aptamer structure which has led to the change in the second Tm 
value of the aptamer, from 43 °C to 35°C, has resulted in the reduction of the aptamer binding.
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Figure 6.2. FACs histograms of S75 aptamer series. (A) S75b version (B) S75c version. (1) 
MCF-7 cell line, (2) DU 145 cell line, (3) CALU-6 cell line and (4) A498 cell line.
FACs analysis of all three aptamer series has revealed their specificity for the MUCl/Y protein 
expressed on the MUCl/Y positive MCF-7, DU145 and CALU-6 cell lines, as evidenced by the lack of 
binding to the MUCl/Y negative A498 cell line. Varying degrees of binding affinity were observed for
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each aptamer in the different cell lines, whereby MCF-7 and CALU-6 showed the greatest binding, 
whilst the DU145 showed the least. The substantially reduced binding observed in the DU145 cells may 
indicate lower expression levels of the MUCl/Y protein on this cell line. Moreover, with respect to the 
MCF-7 and CALU-6 cell lines, the ‘c’ versions (loop region) of S51 and S75 aptamer series showed 
lower binding than the ‘b’ version (central variable region). This is likely to indicate that the open 
structure (low duplex formation) of the ‘b’ version aptamers as opposed to the loop region (higher duplex 
content) is preferred for binding to the intact protein on the cells as was also demonstrated by the DNA 
thermal denaturation studies with the short peptides. Additionally another point to take into consideration 
is that the Tm values obtained were of the aptamers which were unmodified or modified with PEG. 
However, the aptamers analysed by FACs have an additional modification, a Cy3 fluorophore, whose 
effect, if any, on the aptamer conformation is unknown.
6.2 APTAMER CELLULAR INTERNALISATION WITH FLUORESCENCE MICROSCOPY 
Each Cy3 fluorescently labelled aptamer of the SI 1 series (SI lb, SI lb-smd, SI lb-PEG, S llc, SI lc-smd, 
and Sllc-PEG), the S51 series (S51b, S51b-PEG, S51c, and S51c-PEG), the S75 series (S75b, S75b- 
smd, S75b-PEG, S75c and S75c-PEG) and the control aptamers SP68 (selected against a non-MUCl 
tumour target peptide) and S2.2 (selected against MUC1) were incubated with MCF-7, DU145, CALU-6 
and A498 cell lines in serum-free cell media for 15 minutes, 1 hour and 3 hours at 37°C. Following 
incubation, the cells were washed and fixed with paraformaldehyde and the nucleus of the cells was 
stained with Hoeschst 33258. Cellular internalisation of the SI lb in MUCl/Y positive MCF-7 cells at 
incubation times 15 minutes, 1 hour and 3 hours is shown in figure 6.3, where the control is the cells only 
and the nucleus is stained in blue. Incubation of the cells with SI lb at 15 min is comparable to the 
control, and cellular binding has not taken place during this short incubation period. However, incubation 
at 1 hr has shown aptamer binding mainly on the cell surface, indicated by a speckled red pattern on the 
outer edge of the nucleus. Moreover, incubation with SI lb for 3 hr has allowed aptamer internalisation 
to take place and, as seen in many cells, the aptamer appears to have entered the nucleus (indicated by the 
yellow arrow).
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Figure 6.3. Cellular internalisation of S l lb  in MCF-7cells. MCF-7 cells treated with Cy3- 
labelled SI lb at 15 minutes, 1 hr and 3 hr in serum free media at 37°C.
As all the aptamers exhibited similar fluorescence patterns at 15 minutes and 1 hour in each cell line, for 
the simplicity of comparison and discussion, only images of the 3 hour aptamer incubation will be 
presented, analysed and discussed. The fluorescence binding and internalisation of the Sllb/c, S51b/c 
and S75b/c aptamer series and the control aptamers in MCF-7 cells is shown in figure 6.4. A high uptake 
of the aptamers Sllb, S51c, S75b, S75c and SP68 was observed, whilst very little uptake was observed 
with the 3 scrambled aptamers (SIlb-smd, Sllc-smd and S75b-smd) and the MUC1 aptamer. However, 
with the exception of the Sllc-PEG, the other pegylated aptamers showed extensive uptake compared to 
their unmodified sequences.
The aptamers studied for fluorescence binding and cellular internalisation in MCF-7 cell line were also 
studied using the DU145 cell line (figure 6.5). A relatively high uptake of S llc, S51c, S75b and S75c, 
mainly the loop region aptamers, was observed, whilst the central variable region aptamers S llb  and 
S51b, the 3 scrambled aptamers, and the control aptamers SP68 and MUC1, all show considerably low 
aptamer binding and uptake. Sllb-PEG, S5lb-PEG, S5lc-PEG and S75b-PEG show binding and 
internalisation that is comparable to that of the unmodified aptamers and not as extensive as with the 
MCF-7 cell line. Sllc-PEG and S75c-PEG shows lower uptake than the unmodified aptamers S llc  and 
S75c.
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Figure 6.4. Cellular internalisation in MCF-7 cells. MCF-7 cells treated with Cy3-labelled
MUCl/Y aptamer, scrambled aptamers and control aptamers in serum free media at 37°C for 3 hr.
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Figure 6.5. Cellular internalisation in DU145 cells. DU145 cells treated with Cy3-labelled
MUCl/Y aptamer, scrambled aptamers and control aptamers in serum free media at 37°C for 3 hr.
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The aptamers studied using the CALU-6 cell line are shown in figure 6.6. Aptamers Sllb/c, S51b, 
S75b/c, SI lc-smd, S75b-smd and SP68 all show significantly high uptake into the cells whilst very little 
uptake was observed with the SI lb-smd, S51c and MUC1 aptamers. With the exception of the S5lb- 
PEG, the other five pegylated aptamers all exhibited very high uptake in the cells. The uptake of the 
aptamers in the CALU-6 cell line has demonstrated an atypical pattern to the norm that is usually 
observed in a speckled manner within the cytoplasm. With this particular cell line the uptake of the 
aptamer appears to be more in an aggregated form.
The fluorescent binding and cellular internalisation of the aptamers using the MUCl/Y negative A498 
cell line is shown in figure 6.7. The MUCl/Y aptamers, including the pegylated and scrambled aptamers 
all showed no significant binding to the A498 cells. However, noticeable uptake of aptamers MUC1 and 
SP68 was displayed in the cytoplasm.
The fluorescence binding and internalisation studies using fluorescence microscopy has shown that the 
MUCl/Y aptamers have specificity to their target protein, as this was clearly indicated by the lack of 
binding observed in the MUCl/Y negative cell line. The low binding and therefore no internalisation of 
the MUC1 aptamer in the MUCl/Y positive cell line possibly indicates that the expression of the MUC1 
protein was not as significant to be detected as was the MUCl/Y protein. The SP68 aptamer displayed 
substantial binding in the all three MUCl/Y positive cell lines, however, the SP68 also showed binding 
and internalisation in the MUCl/Y negative A498 cell line. This could suggest that the protein SP68 was 
selected against, also a known tumour marker, is likely to also be expressed in these cell lines. From the 
six unmodified MUCl/Y aptamers, S75b and S75c are the two aptamers which have consistently shown 
high binding and internalisation in all three positive cell lines. Furthermore, typically it has been 
observed that if binding of the unmodified aptamer is observed, then greater binding and uptake of the 
pegylated aptamer for the same cell line is obtained. This indicates that the large polymer does not affect 
the binding of the aptamer to the target protein nor does it cause non -specific binding, but helps 
facilitate internalisation of the aptamer once bound.
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Figure 6.6. Cellular internalisation in CALU-6 cells. CALU-6 cells treated with Cy3-labelled 
MUCl/Y aptamer, scrambled aptamers and control aptamers in serum free media at 37°C for 3 hr.
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Figure 6.7. Cellular internalisation in A498 cells. A498 cells treated with Cy3-labelled
MUCl/Y aptamer, scrambled aptamers and control aptamers in serum free media at 37°C for 3 hr.
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6.3 CONCLUSION
The results obtained from the FACs analysis and the fluorescence microscopy studies both draw a 
parallel with regards to the MUCl/Y aptamers, showing greatest binding to the MUCl/Y protein 
expressed on the MCF-7 (human breast carcinoma) and the CALU-6 (human lung carcinoma) cell lines. 
Moreover, both techniques have shown that the expression of MUCl/Y on the DU145 (human prostate 
carcinoma) cell line is not substantial, thus extensive binding with the aptamers was not observed. As 
there has been no antibody available against the MUCl/Y protein, either polyclonal or monoclonal, 
aptamers can also be used to test for the presence of MUCl/Y on the cell surface using FACS, and thus 
identify MUCl/Y positive cell lines. However, contradictory results were obtained with regards to the 
pegylated aptamers, where in the FACs analysis they were shown to have reduced binding compared to 
their respected unmodified aptamers. However, the analysis of the fluorescence confocal microscopy 
studies shows that PEG enhances the uptake of the aptamers. This could be attributed to the difference in 
aptamer incubation periods with the cell lines, where for FACs analysis the aptamers were incubated for 
1 hour and for confocal microscopy studies aptamers were incubated for 3 hours. Furthermore, it is 
possible that although PEG has a slight inhibitory effect in initial binding, possibly due to steric 
hindrance, once bound it facilitates aptamer internalisation into the cell. Another contrast in the findings 
between the two techniques was with respect to the control scrambled aptamers. FACs analysis indicates 
that the scrambled aptamers share comparable affinity for the protein as the non-scrambled aptamers, 
whereas the confocal microscopy studies show very little uptake of the scrambled aptamers even with the 
3 hour of incubation. This discrepancy could be attributed to the different condition used in both 
techniques during the incubation period. The aptamers were incubated with the cells in PBS for the FACs 
analysis whilst for the fluorescence microscopy experiments the aptamers were incubated with the cells 
in serum free media. In any case, this differentiation is desirable, as demonstrates greater specificity of 
the selected aptamers over their scrambled counterparts.
The fluorescence microscopy provides confidence that the MUCl/Y aptamers have specificity and 
affinity for their target protein and, in addition, the pegylation of the aptamers enhances their binding and
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internalisation further. Whilst all six aptamers have shown binding affinity and specificity, the S75b and 
S75c aptamers appear to be more promising as their binding has remained consistent in the three 
MUC1/Y positive cell lines.
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7.0 CONCLUSIONS
There are many proteins, growth factors, hormones, antibodies and small molecules which are involved 
either at different stages of cancer development or during the progression of the malignancy. However, 
involvement of any of these molecules in cell proliferation, initiation of excessive cellular division or cell 
signalling, indicate their potential as tumour biomarkers. Molecules involved in cell signalling are vital 
as, through mutations, the normal function is bypassed, allowing cell proliferation to occur infinitely and 
inhibiting apoptosis, which can result in greater expression of particular proteins. Hence, over-expression 
of proteins predominantly found in malignant tissues, as opposed to the expression of the proteins 
present in normal tissues of the same organ, are crucially important and of great interest as potential 
molecular tumour targeting biomarkers. MUC1/Y is such a protein. The MUC1/Y transmembrane 
protein, a splice variant of the MUC1 glycoprotein, has been found to be prevalent in many epithelial 
carcinomas and, unlike MUC1, this protein does not possess the variable tandem repeat region. This has 
resulted in the absence of the carbohydrate structures which are characteristically present in MUC1, 
causing substantial deficiency in the polarisation of the protein, permitting the MUC1/Y to be greatly 
overexpressed in the cell surface. Furthermore, the loss of the adhesive properties from the absence of 
the carbohydrate structures has also contributed to the aggressive nature of the tumours expressing this 
protein, by enhancing their ability to invade into the lymph vessels and metastasise to the other organs. 
Therefore, the development of low toxicity molecules with the ability to bind to MUC1/Y with 
substantial affinity and specificity, which could potentially result in tumour cell death through interfering 
with the cell signalling pathways, is a viable approach for target cancer therapy.
Following this rationale, MUC1/Y was selected as a potential therapeutic target and as a tumour 
biomarker for the diagnosis of many epithelial tumours. As MUC1/Y is a transmembrane protein, and 
due to the complexities involved in its isolation and purification, the whole protein was not employed for 
the selection of the aptamers. Instead two short synthetic peptides were designed to be used as targets for 
the selection of MUC1/Y aptamers. The MUC1/Y peptides consist of 10 and 20 amino acids, referred to 
as lOmer peptide and 20mer peptide respectively. The lOmer peptide sequence (TEKNAFNSSL) was 
selected on the basis of 5 amino acids before the splice site of the MUC1 and 5 amino acids after the
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splice site of the protein which generates the MUC1/Y from the MUC1 extracellular domain protein 
sequence. The 20mer peptide sequence (SVPSSTEKNAFNSSLEDPST) is an extension to the lOmer 
peptide of 5 additional amino acids either side. The purpose of the MUC1/Y peptides was to mimic the 
splice site present in the MUC1/Y protein, which is a specific portion of the amino acid sequence that 
differentiates the MUC1/Y isoform from the MUC1 protein and its other splice variants.
Taking into consideration the traditional SELEX system, involving numerous rounds of selection and 
amplification, an alternative approach for generating aptamers to potentially any target was considered. 
SimpLex, a novel one round selection method developed to obtain aptamers against the MUC1/Y 
peptides entailed immobilisation of the biotinylated peptides to the streptavidin coated PCR tubes to 
which the single stranded combinatorial library was incubated with the target peptides. The bound 
aptamers were separated according to their binding strength to the target peptides via either a salt 
gradient or a heat gradient elution. Forty sequences were obtained from both methods and peptides, of 
which only three aptamer sequences (SI la, S51a, S75a) were considered for further investigation. These 
three sequences were chosen to be taken further on the basis that they were also obtained from a repeat 
selection employing the traditional affinity chromatography system. Additionally, another six sequences 
were designed from the parent sequences which consisted of two different constructs. The first construct 
involved the removal of the hybridising primer sequences leaving only the central variable region (SI lb, 
S51b, and S75b) and the second construct entailed the sequence forming the stem-loop conformation 
obtained from the predicted secondary structures (Sllc, S51c, and S75c). SimpLex has shown potential 
to generate aptamers by acquiring binding oligonucleotides of the same sequences as those obtained from 
the traditional selection system. Hence, SimpLex presents a possible novel alternative to the SELEX 
process, eliminating numerous successive rounds of selection and PCR amplification cycles over a period 
of several days, with the additional advantage of using low amounts of target and combinatorial library. 
Furthermore, when compared to other single step selection methods such as the MonoLex and ASExp of 
which both aim to remove the repetition of successive rounds of selection, both processes appear to be 
far more time consuming than the SimpLex method. The MonoLex system involves incubating the 
combinatorial library with the target attached in an affinity capillary column. The unbound
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oligonucleotides are washed away with numerous buffer washes, followed by physical segmentation of 
the column, where the bound sequences are removed via desorption for PCR amplification and 
sequencing. In this system the opportunity to obtain sequence homology is quite limited 199. The ASExp 
system entailed PCR amplification of the ssDNA library to generate a dsDNA library, which was 
incubated with the target causing denaturation of the dsDNA upon the ssDNA-target complex formation. 
Separation of the bound sequences from the unbound was performed using magnetic beads attached with 
random ssDNA, resulting in a complex of the bound sequence-target-magnetic bead, which was PCR 
amplified for sequencing. The entire process approximately takes ten hours to complete 206. Thus, the 
SimpLex offers a practical yet much simpler, fast and less laborious process for isolating the greater 
binding sequences from the low binders.
The unmodified aptamers are subjected to rapid renal clearance which prevents the aptamers from 
reaching the biomarker and achieving an adequate therapeutic response. Thus the aptamers are required 
to be modified so as to surpass the minimum molecular weight cut off for glomerular filtration of 30 kDa. 
This limitation was addressed by chemically modifying the potential aptamers through a process of 
pegylation, which entailed conjugating the truncated aptamers to a 32 kDa molecular weight polymer, 
polyethylene glycol (PEG). Several different parameters for aptamer conjugation were investigated 
before the optimised condition was obtained to provide a high yielding aptamer pegylation reaction of 
79%. The optimal reaction conditions are; 15: 85 (v/v) mixture of 53.4 mM sodium carbonate buffer (pH 
10) and DMF, at 60C for 2 hours. These pegylation conditions significantly varied from those described 
in literature where Kang et al 226 utilised pegylation conditions of 100 mM sodium carbonate buffer (pH 
8.5), 5 molar excess of PEG, in equal volume of acetonitrile with a reaction time of 1 hour. This 
pegylation method has also been described by Healy et al 221 with the difference of 2.5 molar excess of 
PEG. Sainathan et al 238 employed different conditions to some extent for pegylation which included PBS 
(pH 8.2), 5 molar excess of PEG, at 25°C for 30 minutes. These described methods, however did not 
indicate the percentage yield of the pegylated product obtained and were unsuccessful in achieving 
significant pegylation of the MUC1/Y DNA sequences. The presence of pegylated aptamers was 
confirmed by anion exchange HPLC analysis, native and agarose gel electrophoresis.
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The pegylated sequences were characterised alongside the unmodified sequences for any changes in the 
affinity or specificity of the potential aptamers for their target peptides upon conjugation. With the aim 
of the selected aptamer to be investigated further as therapeutic agents, it was vital that the potential 
aptamer was pegylated. Therefore, to avoid inaccurate conclusions with respect to which aptamer may 
have the greatest potential for therapeutic development, the selected oligonucleotides were screened 
using qualitative techniques in parallel with the pegylated potential aptamers. This allowed the 
concluding of which aptamer retained its activity subsequent to pegylation and which would be the most 
suited candidate to be taken for further studies.
The qualitative techniques employed to assess the individual aptamer affinity and specificity for the 
MUC1/Y 10 mer and 20 mer peptides were EMSA, affinity chromatography and DNA thermal 
denaturation. The full length, truncated and pegylated aptamers analysed by EMSA all exhibited 
marginal band shifts in the native PAGE when incubated with the 10 mer and 20 mer peptides as 
compared to the band of the free aptamer. This was due to the MUC1/Y peptides having a low molecular 
weight ( 1 - 2  kDa), and not significantly altering the electrophoretic properties of the aptamer to result in 
a retardation within the gel and produce a visible band shift. With respect to many of the sequences, such 
as the S51a, a marginal retardation was observed with the S5la-20 mer mixture whilst the S51a-10 mer 
mixture was running slightly faster than the free S51a oligonucleotide. On the other hand, the reverse 
was observed with the SI la, where SI la-10 mer mixture migrated slightly ahead and the SI la-20 mer 
mixture was fractionally retarded than the free SI la oligonucleotide. Typically, it is expected that upon 
aptamer-peptide complex formation a slower mobility of the complex is observed compared to that of the 
free aptamer. However, this is not always the case, as upon the aptamer binding to the target, the change 
in conformation of the aptamer can affect its migration through the gel. For example, if an aptamer is 
induced to have a greater secondary structure upon binding to the peptide, then this may lead to the 
aptamer-peptide complex having a swifter mobility than the free aptamer, whilst if an aptamer is induced 
to adopt an open structure upon binding, then the aptamer-peptide complex may be slightly retarded in 
the gel. Furthermore, the heating of the aptamers in the presence of the MUC1/Y peptides to 95°C for 5 
minutes appeared to interfere with the reformation of the aptamers secondary structure. This effect was
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indicated in the gel by the disappearance of the aptamer bands after staining with EtBr, an intercalating 
dye, and this was observed for all the aptamers analysed including the control aptamers. Thus, suggesting 
that non-specific aptamer binding to the target when fully denatured (presence of no secondary structure) 
is likely to take place, particularly as the control aptamers are of the same base composition as the 
selected ones. Therefore, due to this lack of sensitivity, the EMSA technique cannot to be used to deduce 
which aptamer retains to a greater extend its secondary conformation. In addition, this technique cannot 
be used to conclude with certainty that the marginal band shifts observed were a result of the aptamer- 
peptide complex formation, as this can also be attributed to the possible discrepancies of the technique. 
Nonetheless, upon heating of the aptamers, their stabilisation in the unstructured conformation by the 
peptides was also observed in the thermal denaturation studies.
DNA thermal denaturation studies of the aptamers have shown substantial decreases in fluorescence 
during the second and third thermal denaturation cycles of the aptamer in the presence of the MUC1/Y 
peptides. This effect indicated that binding to the peptides had occurred and the peptides possessed the 
ability to inhibit the renaturation of the aptamers, causing the potential aptamers to remain unstructured. 
It was also observed that the 20 mer peptide had a greater effect on stabilising the unstructured aptamer 
conformation than the 10 mer peptide. However, as the aim is to utilise the aptamer as a therapeutic 
agent, it was more relevant to consider the binding of the MUC1/Y peptides with the aptamer prior to any 
heating, as the highest temperature the aptamer would be subjected to in in vivo would be the 
physiological temperature of 37°C. For all three series (SI 1, S51 and S75) it was observed that 
truncation of the full length aptamers to the central variable region (b series) resulted in significant 
decrease in the thermostability, whilst truncation to the loop region (c series) resulted in either change in 
conformation (SI lc) or slightly enhanced thermostability (S51c and S75c). The pegylation of the b series 
aptamers has resulted in a change in conformation and enhanced thermostability (Sllb-PEG and S75b- 
PEG) with the exception of S51b-PEG, which showed no notable difference. The pegylation of the c 
series oligonucleotide has resulted in a slight increase in the thermostability of SI lc-PEG and S51c-PEG, 
whilst the S75c-PEG showed a slight decrease. The Sllb-smd exhibited a similar melting profile and 
temperature as the SI lb (21 °C), which could be explained by the predicted m-fold secondary structure
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showing identical number of GC (2) and AT (1) base pairs in the single stem conformation of both 
oligonucleotide. However, the Sllc-smd (47°C) and S75b-smd (20°C; 47°C) showed a change in the 
melting profile and temperature compared to Sllc  (21 °C; 45°C) and S75b (19°C) respectively. 
According to the predicted structure for Sllc, the aptamer possess two stems separated by a small bulge 
between the stems containing 3 GC and 4 AT base pairs, thus, possibly resulting in two different Tm 
values. Whereas the SI lb-smd has a single straight stem conformation consisting of 4 GC and 1 AT base 
pairs and as the stem is largely composed of GC base pairs, this is perhaps the reason for a single Tm 
value being observed. The S75b has a short single stem comprised of 1 GC and 2 AT base pairs 
providing a single Tm value, whilst the S75b-smd forms a stem of 3 GC and 2 AT base pairs resulting in 
two different Tm values. The varying thermostability of the free aptamers observed from the different 
modifications performed suggests that each aptamer possesses its own individual characteristics. 
However, upon the addition of the 20 mer peptide, with the exception of S51c-PEG, all potential 
aptamers have displayed a Tm value of below 37°C. Conversely, this is not the case with the 10 mer 
peptide, where Tm values above 37°C are detected along with greater stabilisation of many of the 
aptamers. This shows that the length of the peptide makes a remarkable difference in the conformation 
the aptamer adopts and its thermostability. This investigation has shown that a secondary structure is 
preferred for the initial binding. However, upon binding, if the aptamer adopts a more labile 
conformation, this further increases the affinity of the aptamer for its target, presumably as a change in 
structure occurs upon binding. If an aptamer lacks sufficient secondary structure, it was observed that 
specificity is lost. This was also displayed by the analysis of the aptamers through affinity 
chromatography.
The affinity column chromatography technique results showed no elution of the bound aptamers even at 
salt concentrations as high as 1.6 M NaCl, even though different amount of aptamers were retained by 
the column. This was characteristic of a tight binding of the aptamer, though the lack of specificity may 
be due to the low melting temperatures of the aptamers. Thus, it is likely that during this study, the 
aptamers were largely in an unstructured conformation at ambient temperature, which resulted in a loss 
of specificity, indicated by the binding of the control aptamers to the MUC1 /Y peptides to some extent.
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However, in accordance with the thermal denaturation studies, the pegylated oligonucleotides displayed 
increased binding for both the 10 mer and 20 mer peptides, which further suggests that an initial 
secondary structure conformation of the aptamer is vital for increased affinity. A point to note with 
respect to the results obtained from the affinity column chromatography technique is that they may vary 
from the results obtained via the EMSA and the thermal denaturation studies due to the difference in the 
incubation condition. The EMSA and the thermal denaturation techniques involved incubation of the 
potential aptamer with the peptides free in solution, whereas the affinity column chromatography method 
required the potential aptamers to be incubated with the peptides in a stationary phase. The qualitative 
characterisation methods described here are not conventional methods which can be found typically in 
literature to assess the binding of the aptamers to the selected target, thus comparison to previous work 
cannot be made. These characterisation techniques are subjected to providing inaccurate results due to 
the inconsistencies associated with the nature of the techniques. To accurately determine the 
biomolecular interactions of the aptamer with the target and obtain real-time kinetic analysis such as rate 
constants and binding affinities, surface plasmon resonance (SPR) spectroscopy should be employed 239. 
SPR further allows the opportunity to explore the effects of different salt concentrations on the binding 
along with the possibility to gain a better understanding of the aptamer-target complex formation and the 
stability of the complex via competition and displacement experiments 24°.
Although the qualitative characterisation techniques show variability in the affinity and specificity of the 
potential aptamers for their target peptides, which was much dependent upon the conditions employed in 
the individual studies, the subsequent cell binding and internalisation studies have shown greater clarity 
of the prospective aptamers with respect to their specificity and affinity for the full, intact, MUC1/Y 
protein expressed on the cell surface. Cell binding studies using FACs analysis has shown significant 
binding of all the potential aptamers to the MUC1/Y positive MCF-7 and CALU-6 cell lines, whilst 
reduced binding to the MUC1/Y positive DU 145 cell line. No binding of the potential aptamers was 
observed in the MUC1/Y negative A498 cell line. The Sllb-smd (Tm: 21°C) has the same Tm value as 
SI lb (Tm: 21°C) but showed a marginal reduction in the binding at the FACS analysis, whilst SI lc-smd 
(Tm: 47°C) has a different conformation to the Sl lc  (Tm: 21°C; 45°C) and also exhibited a small decrease
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in binding with the MCF-7 cell line. The Sllb-PEG displayed similar binding to the unmodified SI lb 
whilst the Sllc-PEG exhibited a decrease in binding compared to Sllc  with the MCF-7 cell line. 
However, the SI 1 series sequences displayed comparable binding to each other within the series with the 
DU145 and CALU-6 cell lines. The S51 series oligonucleotides demonstrates similar binding to each 
other in the MCF-7 and DU145 cell lines, which could be attributed to their comparable Tm values. 
However, this was not the case with the CALU-6 cell line where S51b-PEG (Tm: 19°C) and S51c-PEG 
(Tm: 20°C; 61°C) have shown reduced binding compared to the unmodified oligonucleotide S51b (Tm: 
18°C) and S51c (Tm: 20°C; 61 °C). Hence, the variation in binding observed for the same 
oligonucleotides in different MUC1/Y positive cell lines further indicates that the actual expression of 
the MUC1/Y protein also dictates the binding potential of the prospective aptamers. In addition, the SP68 
oligonucleotide has shown comparable binding to the S51 series aptamers, although this is expected, as 
the SP68 was selected against a different tumour marker, which is likely to be expressed on the surface of 
these malignant cells. The series S75b oligonucleotides show comparable binding to each other in all 
three MUC1/Y positive cell lines even though the S75b-smd (Tm: 20°C; 47°C) and the S75b-PEG (Tm: 
20°C; 40°C) have different Tm values and conformations to the S75b aptamer (Tm: 19°C). In contrast, the 
S75c-PEG (Tm: 21 °C; 35°C; 63°C) has shown slightly lower binding in the MCF-7 and CALU-6 cell 
lines compared to the unmodified S75b oligonucleotide (Tm: 22°C; 43°C; 63°C). The positive shift in the 
histograms of the SI lb and S75b oligonucleotides are comparable to those observed by the anti-MUCl 
aptamer in an individual study 235 with the MCF-7 cell line. Hence, supporting the hypothesis of the 
oligonucleotides generated against the MUC1/Y peptides may be capable of recognising the peptide 
epitope which would be present within the full protein expressed on the cell surface.
A similar trend to that observed in the FACs analysis is also observed with the fluorescence microscopy 
studies, where greater binding and internalisation of the potential aptamers was detected with the MCF-7 
and CALU-6 cell lines than the DU145 cell line, whilst no binding was obtained with the A498 cell line. 
Nonetheless, substantial differences were observed with individual prospective aptamers, as the 
scrambled oligonucleotides; SP68 and MUC1 showed very little binding, if any, with the three MUC1/Y
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positive cell lines. The pegylated oligonucleotides displayed far greater binding and internalisation than 
the unmodified oligonucleotides, without resulting in any non-specific binding. The fluorescent signal for 
cellular binding and internalisation of the potential MUC1/Y oligonucleotides with the MCF-7 cell line is 
shown to be similar to the MUC1 aptamer, whilst the pegylated sequences have presented fluorescent 
signals that are alike, produced by the multi-walled carbon nanotubes (MWNT) -  MUC1 aptamer 
complex. However, in the same study, the MUC1 aptamer has shown very little uptake by the CALU-6 
cell indicating the cell line to be MUC1 negative 241. Conversely, this was not the case for the potential 
MUC1/Y aptamers, as considerable cellular binding and internalisation was observed suggesting that the 
CALU-6 cell line is MUC1 positive. This discrepancy in cellular binding and internalisation of the same 
cell line but of a different batch is observed often, thus inconsistency in the protein expression levels can 
be expected and should be not presumed that aptamer binding has not taken place.
The differences in binding outcomes presented by the two techniques, FACs and fluorescence 
microscopy can be attributed to the different conditions utilised during the incubation of the aptamers 
with the cells. In the FACs technique the aptamers were incubated with the cells in PBS, whilst for the 
fluorescence microscopy the aptamers were incubated in serum free media. Thus, it is evident from the 
different biophysical and in vitro cell binding studies performed that the affinity and specificity of the 
each oligonucleotide varies depending upon the conditions employed in the implementation of the 
technique. On this basis the results obtained from the fluorescence microscopy studies can be considered 
to be the most realistic, as the serum free media used in this technique is the closest in mimicking the 
physiological conditions. Therefore, as the pegylated oligonucleotide did not show any reduced binding 
or adverse effect on the specificity of the aptamers towards the MUC1/Y protein, but rather enhanced the 
existing properties of the aptamers, it would appear feasible to take the pegylated oligonucleotide further 
for characterisation studies to determine which of the six pegylated oligonucleotides would be the best 
candidates for clinical development.
Finally a point to note, although the experimental results from the FACs analysis and fluorescence 
microscopy studies are encouraging, the varied and less definitive outcomes obtained from the qualitative
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characterisation studies cannot be ignored. The disparity between the results obtained the in vitro 
internalisation and qualitative studies could indicate a potential failure within the selection method. This 
is further indicated by the lack of sequence consensus obtained from the SimpLex selection method. The 
following could propose to be significant validations for the inefficient outcome obtained from the 
selection method; physiological conditions (buffer and temperature), negative and counter selection were 
not incorporated during the SimpLex selection. In addition, SimpLex only consisted of sequencing 10 
clones from each of the two methods (salt and temperature gradient) and the two target peptides (10 mer 
and 20 mer), where this low number of sequences cloned is not sufficient to increase the possibility of 
achieving sequence homology or to validate a new selection method. For rectification of the SimpLex 
protocol to achieve an improved and more accurate end result for future targets, the following should be 
taken into consideration; cell media should be employed as the physiological solution in which the 
oligonucleotide library is incubated with the target, at a physiological temperature of 37°C. The cell 
media solution can be considered to be comparable to the physiological fluid, as this media is also 
utilised to grow cells. This change alone should aid in eliminating unstructured low binding sequences at 
37°C and enrich the pool of oligonucleotide sequences with a stable conformation under correct buffer 
conditions. Negative and counter selections should be performed, for example, the oligonucleotide 
library should be subjected to the support medium and to molecules similar to that of the target 
respectively, in order to remove non-specific sequences and increase the stringency of the selection. In 
the case of aptamer selection against the MUC1/Y targets, the library should be incubated with the 
streptavidin coated tubes to performing a negative selection and to the MUC1 peptides for perform 
counter selection. Furthermore, to increase the probability of obtaining sequence homology, typically 100
'> A ri 0 4 0
individual clones should be sequenced for each method and peptide ’ .
7.1 FUTURE WORK
The qualitative characterisation and the in vitro cell binding studies have given a good insight as to how 
the binding potential of the aptamer is altered depending upon the conditions utilised in the investigation. 
The results obtained in this investigation are preliminary, but leave great scope for aptamer development
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as a potential cancer therapeutic agent. This work also provides a good foundation for future work which 
would entail performing quantitative biophysical binding studies using conditions which are closely 
related to the physiological. This could include using cell media as the solution in which the aptamer and 
peptide are incubated in, rather than the use of binding solution or buffers. In addition, all the studies 
should be performed in a controlled environment with a temperature of 37°C, as it was obvious from the 
current studies that a lot of the aptamers presented melting temperatures below this value and would be 
potentially unstructured at physiological temperatures. Incorporation of these conditions during aptamer 
characterisation studies will ensure the natural conformation of the aptamer at 37°C is adopted and hence 
reduce the potential variability that was observed in these studies in the aptamers’ affinity and specificity 
for their target. Furthermore, with respect to the biophysical characterisation studies in particular, the 
thermal denaturation experiment where a 1:1000 aptamer: peptide ratio was used and could be repeated 
using lower ratios of peptide to aptamer, to determine the minimum concentration of peptide required to 
inhibit the renaturation of the aptamer and reduce non-specific binding.
Following aptamer characterisation studies cell cytotoxicity of the pegylated aptamers would ascertain 
the aptamers’ potential as a therapeutic agent and provide an indication of which aptamers are able to 
result in cell apoptosis. Results from this study would also aid in narrowing down the potential 
therapeutic candidates from six to two.
Upon selecting the pegylated aptamer to be taken forward for further investigation, it would be 
informative to deduce the structure of the aptamer free in solution and the conformation it adopts upon 
binding to the peptide. Structural analysis of the aptamer can be performed using nuclear magnetic 
resonance (NMR) and x-ray crystallography techniques. The NMR studies would aid in the resolving the 
three-dimensional structure of the peptide, aptamer and the peptide-aptamer complex at atomic 
resolution. As the NMR structural studies are performed in solution, the experimental conditions can be 
generated to mimic physiological fluid, whereby the most precise structure of the peptide, aptamer and 
complex can be obtained under physiological conditions. The NMR data can provide insights to the 
dynamic properties of the individual molecular structures and identify nucleotides involved in Watson-
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crick base pairing. The studies can also provide structural, thermodynamic and kinetic aspects of the 
interactions present between the aptamer and the peptide. Furthermore, structural changes under the 
influence of potassium and sodium ion under varied concentrations can be explored 244,245. Alternatively, 
X-ray crystallography studies can be an addition in gaining a better understanding of the chemical bonds, 
along with identifying the types of interaction that are present within the aptamer folding, peptide and the 
peptide-aptamer complex. X-ray studies aid in deducing the structure of the molecular complex by 
assessing the position of the atoms 246. The structural folding and binding data would allow further 
optimisation of the aptamer sequence by removing bases which are not necessarily involved in the 
binding to the peptides
Aside from aptamer modification for improved affinity, the aptamer could be further functionalised with 
a different form of PEG, such as a four arm peg. If four aptamer molecules could be attached to one 
single polymer of PEG, then this would have the potential to significantly improve the efficacy of the 
aptamer for in vivo investigations.
Finally, as the MUC1/Y aptamers have shown binding specificity for the MUC1/Y protein, other than 
being employed as a direct therapeutic agent, they could be adapted for use as drug delivery agents. This 
typically involves activating a liposome that has encapsulated a therapeutic drug, by attaching a ligand, 
such as an aptamer, on its surface, which is capable of binding to a specific epitope present on the target 
site. The aptamer would bring an added advantage by increasing the therapeutic response due to 
delivering the drug directly to the target site, preventing the drug from being released in any healthy
247organs
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APPENDIX
CHAPTER 3 .0
The forty aptamer sequences identifying the unknown variable region from the 1.5 M NaCl concentration 
and the 95°C samples for both MUC1/Y lOmer and 20mer peptides.
Aptamer sequences selected against the lOmer peptide at 1.5 M NaCl
Name of 
Sequence
Forward hybridising 
primer
Variable region Reverse hybridising 
primer
S ll GGGAGACAAGAATAAACGCTCAA GGCAACATACTGTAAAGCTCAGGAC TTCGACAGGAGGCTCACAACAGGC
S12
GGGAGACAAGAATAAACGCTCAA CTAAAGTGCCTCACGCTGTTAACTC TTCGACAGGAGGCTCACAACAGGC
S13 GGGAGACAAGAATAAACGCTCAA TTATCACCTTAACTTCGTCGGACG TTCGACAGGAGGCTCACAACAGGC
S15 GGGAGACAAGAATAAACGCTCAA TTACTTGCTCAACACACGCCAGGAG TTCGACAGGAGGCTCACAACAGGC
S18
GGGAGACAAGAATAAACGCTCAA CGCCTAGTAAGATTTGACGGACCCC TTCGACAGGAGGCTCACAACAGGC
S75 GGGAGACAAGAATAAACGCTCAA CTGGTATCTATATGAAGGTTGTAGC TTCGACAGGAGGCTCACAACAGGC
S76
GGGAGACAAGAATAAACGCTCAA AAACCGAATAGAATCGCCTGACGGG TTCGACAGGAGGCTCACAACAGGC
S85 GGGAGACAAGAATAAACGCTCAA GATCTATCCTAACCCCGGTAGCGCC TTCGACAGGAGGCTCACAACAGGC
S86 GGGAGACAAGAATAAACGCTCAA CACTATGGCCACTCGACAGGAGGCT TTCGACAGGAGGCTCACAACAGGC
S87
GGGAGACAAGAATAAACGCTCAA GGCATTTTGTCCCTTGTTTGAACAA TTCGACAGGAGGCTCACAACAGGC
Aptamer sequences selected against the lOmer peptide at 95°C
Name of 
Sequence
Forward hybridising 
primer
Variable region Reverse hybridising 
primer
S37
GGGAGACAAGAATAAACGCTCAA TAACCCGACATCAACGCAATCTCAC TTCGACAGGAGGCTCACAACAGGC
S38 GGGAGACAAGAATAAACGCTCAA TCTCCCCGTGGGGTATGGGTGGAAA TTCGACAGGAGGCTCACAACAGGC
S51 GGGAGACAAGAATAAACGCTCAA AGATAAAAAGGCTGTCTGAAAATT TTCGACAGGAGGCTCACAACAGGC
S52
GGGAGACAAGAATAAACGCTCAA ATTAACTTCCAAGCTCTTGGACTAT TTCGACAGGAGGCTCACAACAGGC
S56 GGGAGACAAGAATAAACGCTCAA CCATCGGCGTCTAATACGTCA TTCGACAGGAGGCTCACAACAGGC
S58 GGGAGACAAGAATAAACGCTCAA GTAAGTTCTTAGTGCTGCCCTTTCA TTCGACAGGAGGCTCACAACAGGC
S101
GGGAGACAAGAATAAACGCTCAA TCACATAATAACCCGCAGCTAAAGT TT CGACAGGAGGCTCACAACAGGC
S102 GGGAGACAAGAATAAACGCTCAA AAATTTTATGGAGTTCTTTGGATAA TTCGACAGGAGGCTCACAACAGGC
S114
GGGAGACAAGAATAAACGCTCAA ACTTCACAAACGGTGCGGAATCCGA TTCGACAGGAGGCTCACAACAGGC
S116 GGGAGACAAGAATAAACGCTCAA ATCCTGTTATCTCCTTCTGCT TTCGACAGGAGGCTCACAACAGGC
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Aptamer sequences selected against the 20mer peptide at 1.5 M NaCl
Name of 
Sequence
Forward hybridising 
primer
Variable region Reverse hybridising 
primer
S6 GGGAGACAAGAATAAACGCTCAA GCCAAGCATGCGTCACATGGCTGTG TTCGACAGGAGGCTCACAACAGGC
S8 GGGAGACAAGAATAAACGCTCAA TGAGTGGCACATGGCAGTACGTAGG TTCGACAGGAGGCTCACAACAGGC
S9 GGGAGACAAGAATAAACGCTCAA CGCCACCACCAGTCATAGCCCAGTA TTCGACAGGAGGCTCACAACAGGC
S10 GGGAGACAAGAATAAACGCTCAA TCGCTGACCATAGGTTCCTTAACTA TTCGACAGGAGGCTCACAACAGGC
S31 GGGAGACAAGAATAAACGCTCAA AATAACCTCAGCAGATCCAACGGGA TTCGACAGGAGGCTCACAACAGGC
S32 GGGAGACAAGAATAAACGCTCAA CGGCCCGTACGGCCA TTCGACAGGAGGCTCACAACAGGC
S33 GGGAGACAAGAATAAACGCTCAA TGGATAAACACCATTCACGGTAGGC TTCGACAGGAGGCTCACAACAGGC
S35 GGGAGACAAGAATAAACGCTCAA CTAATGCCCATATTCCAAGACACCG TTCGACAGGAGGCTCACAACAGGC
S36 GGGAGACAAGAATAAACGCTCAA TCAGCAATAGCCATCCATACTGGC TTCGACAGGAGGCTCACAACAGGC
S78 GGGAGACAAGAATAAACGCTCAA GCGCACGACTA TTCGACAGGAGGCTCACAACAGGC
Aptamer sequences selected against the 20mer peptide at 95°C
Name of 
Sequence
Forward hybridising 
primer
Variable region Reverse hybridising 
primer
S41 GGGAGACAAGAATAAACGCTCAA TCCATCTATAAATTCAAACAACATT TTCGACAGGAGGCTCACAACAGGC
S44 GGGAGACAAGAATAAACGCTCAA TGGCCGGGCGTTCCCCGTACAGAAC TTCGACAGGAGGCTCACAACAGGC
S46 GGGAGACAAGAATAAACGCTCAA ACAACACGCTAAAACGGACTGTTCT TTCGACAGGAGGCTCACAACAGGC
S47
GGGAGACAAGAATAAACGCTCAA TGAGGCTTCAAACTCTTATGTTCAG TTCGACAGGAGGCTCACAACAGGC
S49 GGGAGACAAGAATAAACGCTCAA GTAAAATTTAATTACATTTAATA TTCGACAGGAGGCTCACAACAGGC
S88 GGGAGACAAGAATAAACGCTCAA TCGGTAAAATACGACAGCCCGCAAA TTCGACAGGAGGCTCACAACAGGC
S89 GGGAGACAAGAATAAACGCTCAA TTGTCCCATACCGCATGCGTCTAGA TTCGACAGGAGGCTCACAACAGGC
S90 GGGAGACAAGAATAAACGCTCAA TGCTAACTTTAACAAACTCACCATTTC TTCGACAGGAGGCTCACAACAGGC
S105 GGGAGACAAGAATAAACGCTCAA GAAGTTGTAGCACCATTGGCACGG TTCGACAGGAGGCTCACAACAGGC
S106 GGGAGACAAGAATAAACGCTCAA TACACTTAAAAAGTAATTATGGGCG TTCGACAGGAGGCTCACAACAGGC
Appendix 1.0. Forty aptamer sequences from the SimpLex selection method. Sequences 
obtained from the 1.5 M NaCl concentration and 95°C samples for both MUC1/Y lOmer and 20mer 
peptides.
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CHAPTER 5 .0
Sequences and predicted structures of the control aptamers obtained from the m-fold programme.
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Appendix 2.0. The predicted secondary structures for the control aptam ers. S1 lb-smd o f
25nt ( a t g c c a a a t c g g c a c g a c t g a g a a t ) .  Sllc-smd o f  26nt ( c c g t a t g c g g g c t a t a a t a g c a c g a a ) .  S75b- 
smd o f  25nt ( t a g t t a a c g c c t a g g g t g t t t a t a g ) .  SP68 o f  25nt ( c g t c a g t a t t t t g g g a t g c c c g g g t ) .  S2.2 
(MUC1) o f  25nt ( g c a g t t g a t c c t t t g g a t a c c c t g g ) .
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Analysis of aptamer-peptide mixtures by EMSA.
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Appendix 2.1. Analysis of the S75a-peptide mixture. 14% native PAGE: (1) free 10 mer 
peptide (2) S75a + 10 mer at 95°C, (3) 25 bp ladder, (4) S75a + 10 mer, (5) free S75a, (6) S75a + 20 mer, 
(7) S75a + 20 mer at 95°C, (8) free 20mer peptide.
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Appendix 2.2. Analysis of the S51b and S51c-peptide mixture. 18% native PAGE: S51b:
(1) S51b + 10 mer at 95°C, (2) S51b + 20 mer at 95°C, (3) 25 bp ladder, (4) S51b + 10 mer, (5) free 
S51b, (6) S51b + 20 mer, S51c: (7) S51c + 10 mer, (8) free S51c, (9) S51c + 20 mer, (10) S51c + 10 mer 
at 95°C, (11) S51c + 20 m er at 95°C.
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Appendix 2.3. Analysis of the S75b and S75b-smd-peptide mixture. 18% native PAGE: 
S75b: (1) S75b + 1 0  mer at 95°C, (2) S75b + 20 mer at 95°C, (3) 25 bp ladder, (4) S75b + 1 0  mer, (5) 
free S75b, (6) S75b + 20 mer, S75b-smb: (7) S75b-smd + 10 mer, (8) free S75b-smd, (9) S75b-smd + 20 
mer, (10) S75b-smd + 10 mer at 95°C, (11) S75b-smd + 20 mer at 95°C. Smd = scrambled aptamer.
bp ,v*
100
75
50
25
Appendix 2.4. Analysis of the S75c-peptide mixture. 18% native PAGE: (1) free 10 mer 
peptide (2) S75c + 10 mer at 95°C, (3) 25 bp ladder, (4) S75c + 10 mer, (5) free S75c, (6) S75c + 20 mer, 
(7) S75c + 20 mer at 95°C, (8) free 20mer peptide.
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Appendix 2.5. Analysis of the SP68 and M U Cl-peptide mixture. 18% native PAGE: 
SP68: (1) SP68 + 10 m er at 95°C, (2) SP68 + 20 mer at 95°C, (3) 25 bp ladder, (4) SP68 + 10 mer, (5) 
free SP68, (6) SP68 + 20 mer, MUC1: (7) MUC1 + 10 mer, (8) free MUC1, (9) MUC1 + 20 mer, (10) 
MUC1 + 10 mer at 95°C, (11) MUC1+ 20 mer at 95°C.
EtBr Stain BaClI Stain
(A) (B)
2 4^ » 7 V 9 Wbp 1 z  ^  ^  j  m  rnr 1 2 3  4 5  6 3 7  8 9 10
w m m ^
Appendix 2.6. Analysis of the pegylated S51b and S51c-peptide mixture. 7 % native 
PAGE: S51b-PEG: (1) S51b-PEG + 10 mer at 95°C, (2) S51b-PEG + 20 mer at 95°C, (3) 25 bp ladder, 
(4) S51 b-PEG + 10 mer, (5) free S51b, (6) S51b-PEG + 20 mer, S51c-PEG: (7) S51c-PEG + 10 mer, (8) 
free S51c, (9) S51c-PEG + 20 mer, (10) S51-PEG c + 10 mer at 95°C, (11) S51c-PEG + 20 mer at 95°C.
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Appendix 2.7. Analysis of the pegylated S75b and S75c-peptide mixture. 7 % native 
PAGE: S75b-PEG: (1) S75b-PEG + 10 mer at 95°C, (2) S75b-PEG + 20 mer at 95°C, (3) 25 bp ladder, 
(4) S75b-PEG + 10 mer, (5) free S75b, (6) S75b-PEG + 20 mer, S75c-PEG: (7) S75c-PEG + 10 mer, (8) 
free S75c, (9) S75c-PEG + 20 mer, (10) S75-PEG c + 10 mer at 95°C, (11) S75c-PEG + 20 mer at 95°C.
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Analysis of aptamer-peptide interaction by affinity column chromatography.
Aptamer-
Peptide
0.2M
(% )
0.4M
(% )
0.6M
(% )
0.8M
(% )
1.0M
(% )
1.2M
(% )
1.4M
(% )
1.6M
(% )
Bound 
aptame 
r (% )
S lla -1 0  mer 74.1 
(± 1.3)
0 0 0 0 0 0 0 25.9 
(± 1.3)
SI la-20 mer 70.7
(±5.4)
0 0 0 0 0 0 0 29.3
(±5.4)
S llb -1 0  mer 68.4 
(± 1.7)
0 0 0 0 0 0 0 31.6 
(± 1.7)
SI lb-20 mer 78.5
(±4.1)
0 0 0 0 0 0 0 21.5
(±4.1)
SI lb-sm d- 10 
mer
72.9 0 0 0 0 0 0 0 27.1
SI lb-sm d- 20 
mer
80.0 0 0 0 0 0 0 0 20.0
Sllb-P E G - 
10 mer
79.5 0 0 0 0 0 0 0 20.5
Sllb-P E G - 
20 mer
52.6 0 0 0 0 0 0 0 47.5
S llc -1 0  mer 60.9
(±3.5)
0 0 0 0 0 0 0 39.1
(±3.5)
S llc -2 0  mer 64.6
(±2.5)
0 0 0 0 0 0 0 35.4
(±2.5)
S llc-sm d - 10 
mer
71.9
(±4.5)
0 0 0 0 0 0 0 28.1
(±4.5)
S llc-sm d- 20 
mer
75.0 
(± 12.4)
0 0 0 0 0 0 0 25.0 
(± 12.4)
Sllc-P E G - 
10 mer
22.3 0 0 0 0 0 0 0 77.7
Sllc-P E G - 
20 mer
16.8 0 0 0 0 0 0 0 83.2
S51a-10 mer 50.0
(±23.1)
0 0 0 0 0 0 0 50.0
(±23.1)
S51a-20 mer 54.8
(±9.9)
0 0 0 0 0 0 0 45.2
(±9.9)
S51b-10 mer 70.5
(±6.2)
0 0 0 0 0 0 0 29.5
(±6.2)
S51b-20 mer 75.5
(±2.7)
0 0 0 0 0 0 0 24.5
(±2.7)
S51b-PEG - 
10 mer
20.2 0 0 0 0 0 0 0 79.8
S51b-PEG - 
20 mer
40.2 0 0 0 0 0 0 0 59.8
S51c-10 mer 66.2
(±11.6)
0 0 0 0 0 0 0 33.8
(±11.6)
S51c-20 mer 74.3
(±3.4)
0 0 0 0 0 0 0 25.7
(±3.4)
S51c-PEG- 
10 mer
10.7 0 0 0 0 0 0 0 89.3
S51c-PEG - 
20 mer
23.8 0 0 0 0 0 0 0 76.2
SP68-10 mer 73.6
(±11.8)
0 0 0 0 0 0 0 26.4
(±11.8)
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SP68-20 mer 74.6
(±4.3)
0 0 0 0 0 0 0 25.4
(±4.3)
S75a-10 mer 69.5
(±3.1)
0 0 0 0 0 0 0 30.5
(±3.1)
S75a-20 mer 68.6
(±5.9)
0 0 0 0 0 0 0 31.4
(±5.9)
S75b-10 mer 66.8
(±5.5)
0 0 0 0 0 0 0 33.3
(±5.5)
S75b-20 mer 75.3
(±9.8)
0 0 0 0 0 0 0 24.7
(±9.8)
S75b-smd - 
10 mer
71.1 
(± 10.8)
0 0 0 0 0 0 0 28.9 
(± 10.8)
S75b-smd - 
20 mer
78.4
(±8.0)
0 0 0 0 0 0 0 21.6
(±8.0)
S75b-PEG - 
10 mer
59.0 0 0 0 0 0 0 0 41.0
S75b-PEG - 
20 mer
62.8 0 0 0 0 0 0 0 37.2
S75c-10 mer 74.6
(±6.8)
0 0 0 0 0 . 0 0 25.4
(±6.8)
S75c-20 mer 71.2
(±6.1)
0 0 0 0 0 0 0 28.8
(±6.1)
S75c-PEG- 
10 mer
45.6 0 0 0 0 0 0 0 54.4
S75c-PEG- 
20 mer
44.8 0 0 0 0 0 0 0 55.2
Appendix 2.8. A ptam er binding with affinity chrom atography. The percentages of each 
aptamer eluted and bound for both MUC1/Y peptides (10 mer and 20mer). Values are expressed as mean 
% (n =3), with the exception of the pegylated and SI lb-smd (n = 1).
Analysis of aptamer-peptide mixtures by DNA thermal denaturation.
Aptamer Thermal Denaturation Cycles
Cycle 1 Cycle 2 Cycle 3
S lla 35°C 35°C 35°C
S lla  lOmer 43°C 23°C 13°C
S lla  20mer 30°C 12°C < 5°C
S llb 21°C 21°C 21°C
S llb  lOmer 7°C; 20°C 10°C 7°C
S llb  20mer 16°C < 3°C < 3°C
SI lb-smd 21°C 21°C 21°C
SI lb-smd lOmer 20°C; 35°C 17°C 12°C
Sllb-sm d 20mer 16°C 10°C 8°C
Sllb-PEG 20°C; 40°C 20°C; 40°C 20°C; 40°C
Sllb-PEG lOmer 23°C 15°C 14°C
Sllb-PEG  20mer 19°C 10°C 9°C
S llc 20°C; 45°C 20°C; 45°C 20°C; 45°C
S llc  lOmer 26°C 10°C; 22°C 15°C;24°C
S llc  20mer 16°C 5°C 7°C
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Sllc-smd 47°C 47°C 47°C
Sllc-smd lOmer 42°C 23 °C 20°C
Sllc-smd 20mer 36°C 13°C < 3°C
Sllc-PEG 20°C; 51°C 20°C; 51°C 20°C; 51°C
Sllc-PEG lOmer 35°C 20°C 12°C
Sllc-PEG 20mer 19°C 13°C 5°C
S51a 30°C; 52°C 30°C;52°C 30°C; 52°C
S51a lOmer 20°C;36°C 17°C 15°C
S51a 20mer 29°C <5°C <5°C
S51b 18°C 18°C 18°C
S51b lOmer 25°C 7°C 10°C
S51b 20mer 21 °C 12°C <5°C
S51b-PEG 19°C 19°C 19°C
S51b-PEG lOmer 33°C 10°C <5°C
S51b-PEG 20mer 23°C 24°C 21°C
S51c 18°C; 55°C 18°C; 55°C 18°C; 55°C
S51c lOmer 37°C 21°C 11°C
S51c 20mer 30°C <5°C <5°C
S51c-PEG 20°C; 61°C 20°C; 61°C 20°C; 61°C
S51c-PEG_10mer 36°C; 48°C 11°C 10°C
S51c-PEG 20mer 20°C;50°C 15°C <5°C
MUC1 18°C; 40°C 18°C; 40°C 18°C; 40°C
MUC1 lOmer 29°C 16°C 12°C
MUC1 20mer 22°C 8°C 8°C
SP68 25°C 25°C 25°C
SP68 lOmer 2TC 8°C 7°C
SP68 20mer 29°C 7°C 6°C
S75a 20°C; 35°C; 59°C 20°C; 35°C; 59°C 20°C; 35°C; 59°C
S75a lOmer 20°C; 43°C 8°C; 25°C 10°C
S75a 20mer 28°C 10°C; 25°C; 59°C 8°C
S75b 19°C 19°C 19°C
S75b lOmer 19°C 7°C <3°C
S75b 20mer 23°C <5°C <5°C
S75b-smd 20°C; 47°C 20°C; 47°C 20°C; 47°C
S75b-smd lOmer 22°C 16°C 12°C; 27°C
S75b-smd 20mer 24°C 9°C 5°C; 22°C
S75b-PEG 20°C; 40°C 20°C; 40°C 20°C; 40°C
S75b-PEG lOmer 19°C; 34°C 15°C 10°C; 28°C
S75b-PEG 20mer 28°C 20°C <5°C
S75c 22°C; 43°C; 63°C 22°C; 43°C; 63°C 22°C; 43°C; 63°C
S75c lOmer 20°C; 30°C 14°C;24°C 10°C; 25°C; 37°C
S75c 20mer 22°C 13°C <3°C
S75c-PEG 21°C; 35°C; 63°C 21 °C; 35°C; 63°C 21°C; 35°C; 63°C
S75c-PEG lOmer 39°C 19°C 10°C; 22°C
S75c-PEG 20mer 22°C 16°C <5°C
Appendix 2.9. Melting tem peratures of the MUC1/Y aptam ers. Melting temperatures of 
each aptamer for all three TDC with both MUC1/Y peptides (10 mer and 20mer).
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